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Abstract 
Background: Inflammation is the natural reaction of the body to an antigen. In 
some conditions, this reaction continues even after the elimination of the antigen, 
entering a chronic stage; it targets normal cells of the body and causes extensive 
damage. Rheumatoid arthritis (RA) is such a condition. It associates with 
significant metabolic alterations that lead to changes in body composition and 
especially body fat (BF) increases. In the general population, increased body fat 
(i.e. obesity) associates with a number of health disorders such as systemic low 
grade inflammation and a significantly increased risk for cardiovascular disease 
(CVD). Both effects of obesity could have detrimental effects in RA. Increased 
inflammation could worsen disease activity while obesity could further increase 
the already high CVD risk in RA. However, obesity in RA has attracted minimal 
scientific attention.  
Aims: The present project aimed to: 1) assess whether the existing measures of 
adiposity are able to identify the changes in body composition of RA patients, 2) if 
necessary develop RA-specific measures of adiposity, 3) investigate the 
association of obesity with disease characteristics and CVD profile of the patients, 
4) and identify factors that might affect body weight and composition in these 
patients. 
Methods: A total of 1167 volunteers were assessed. Of them 43 suffered from 
osteoarthritis and 82 were healthy controls. These, together with 516 RA patients 
were used in the first study. Their body mass index (BMI), BF, and disease 
characteristics were assessed. In the second, third, fourth and fifth studies a 
separate set of 400 RA patients was assessed. In addition to the above 
assessments, their cardiovascular profile and more detailed disease 
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characteristics were obtained. For the final study, 126 RA patients were assessed 
for all the above and also data on their physical activity levels and their diet were 
collected.  
Results: Assessments of adiposity for the general population are not valid for RA 
patients. Thus, we proposed RA-specific measures of adiposity. These are able to 
better identify RA patients with increased BF. We were also able to find 
associations between obesity and disease activity. Both underweight and obese 
RA patients had more active disease compared to normal-weight patients. Obese 
patients had significantly worse CVD profile compared to normal-weight. The 
newly devised measures of adiposity were able to identify those at increased risk. 
However, not all obese individuals were unhealthy and not all normal-weight 
healthy. Among our patients we were able to identify subtypes of obesity with 
distinct phenotypic characteristics that warrant special attention. Finally, we were 
able to identify factors that influence body weight and composition. Cigarette 
smoking protected against obesity while its cessation associated with increased 
adiposity. Physical activity was also found to be protective against obesity while 
diet or inflammation of the disease failed to produce any significant results. 
Conclusions:  Obesity is a significant threat to the health of RA patients. The 
measures of adiposity developed herein should be used to identify obese RA 
patients. Physical activity seems like the sole mode for effective weight 
management in this population. Health and exercise professionals should actively 
encourage their patients to exercise as much as they can. This study has created 
more questions than it answered; further research in the association of obesity 
and inflammation, as well as in ways to treat it, is essential.   
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Chapter 1: Introduction 
Inflammation [from Latin: inflammatio i.e. to set on fire (Onions et al., 1996)] is the 
normal response of the immune system to antigens, such as pathogens, damaged 
cells, or irritants (Stedman, 2005). It is a complex biological reaction of the 
vascularised connective tissue that leads to accumulation of fluid and leukocytes 
in extravascular tissue and can be divided into acute and chronic patterns.  
Acute inflammation is the immediate and early response to an infectious 
agent; it is of short duration, usually lasting minutes, hours or a few days. Since 
the two major defence components against microbes -_namely antibodies and 
leukocytes – are normally carried in the bloodstream, acute inflammation has 
three major components: a) alterations in the vascular calibre that lead to an 
increase in blood flow, b) structural changes in the microvasculature that permit 
plasma proteins and leukocytes to leave the circulation, and c) emigration of the 
leukocytes from the microcirculation and their accumulation in the infected or 
damaged tissue (Cotran et al., 1999). These alterations are the causes of the five 
cardinal signs of inflammation as identified by Celsus (30BC-32AD) and R.L.K. 
Virchow (1821-1902): pain (dolor), heat (calor), redness (rubor), swelling (tumour) 
and loss of function (functio laesa) (Stedman, 2005).  
Acute inflammation may have one of four outcomes: 1) Complete 
resolution: If the infectious agent is successfully neutralised, inflammation should 
end with restoration of the site of the inflammation to its normal condition. This is 
characterised by neutralisation or spontaneous decay of the chemical mediators, 
normalisation of vascular permeability, cessation of leukocytic infiltration, death of 
neutrophils, removal of oedema and necrotic debris from the site 2) Abscess 
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formation: This commonly occurs during infections with pyogenic organisms, such 
as bacteria. 3) Fibrosis: Healing by connective tissue replacement usually occurs 
after extensive damage of a tissue, when the inflammatory process takes place in 
tissue that cannot regenerate, or when there is abundant fibrin exudation. 4) 
Progression to chronic inflammation: Transition from acute to chronic 
inflammation occurs when the former cannot be resolved due to the persistence of 
the infectious agent or to some interference in the process of healing (Cotran et 
al., 1999). 
Chronic inflammation is of longer duration characterised by the presence of 
lymphocytes and macrophages, proliferation of blood vessels, fibrosis and tissue 
necrosis in and around the affected tissue.  During its course, active inflammation, 
tissue destruction and repair processes occur simultaneously. Although it may 
follow acute inflammation, the chronic stage offen begins insidiously, as a low-
grade, initially asymptomatic response. This latter type of chronic inflammation is 
the cause of some common diseases such as atherosclerosis, tuberculosis, lung 
diseases and rheumatoid arthritis (RA). Chronic inflammation is the result of 
persistent infections, prolonged exposure to toxic agents, or autoimmunity (Cotran 
et al., 1999). 
Both patterns of inflammation aim to destroy, dilute or fend off the harmful 
agents but also they initiate the process of healing in the damaged tissues. 
Inflammation, fundamentally a protective response, is tightly controlled by the 
immune system as uncontrolled inflammation can be harmful or even fatal. Life-
threatening allergies, common chronic inflammatory and autoimmune diseases 
are such examples (Cotran et al., 1999). 
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 Arthritis (i.e. the inflammation of the joints) is a group of conditions that 
cause damage to the joints. Several different types of arthritides exist, and they 
are often categorised as non-inflammatory and inflammatory, mostly due to their 
pathophysiology. Even though “inflammation” is inherent in the definition of any 
type of arthritis, this classification is widely used in the medical profession and 
thus will be used in this thesis as well. Osteoarthritis is the commonest non-
inflammatory arthritis; it is most usually caused by mechanical joint damage from 
age or an injury (Altman et al., 1986). On the other hand, RA is the commonest 
inflammatory arthritis and will be used in this project as a model for the study of 
obesity in chronic inflammation. RA is a chronic, progressive, autoimmune, 
inflammatory disease. It mainly affects synovial joints, producing symmetrical 
arthritis and is characterised by joint pain and stiffness. If left untreated, it leads to 
irreversible joint damage and deformity, and ultimately disability (Emery et al., 
2002). Even though not fatal per se, patients with RA have reduced life 
expectancy compared to the general population (Erhardt et al., 1989) mainly due 
to increased prevalence of cardiovascular disease (CVD) (Kitas and Erb, 2003). 
The exact cause for this remains unknown, however genetic predisposition 
(Gonzalez-Gay et al., 2007), classical CVD risk factors (Panoulas et al., 2007) 
and inflammation related to the disease (Gonzalez et al., 2008) all contribute. 
Interestingly, RA also associates with altered body composition. The chronic 
inflammation of the disease and especially the activation of the nuclear factor 
kappa-beta (NF-κβ) pathway (discussed in detail in Chapter 2.1.6.3) trigger the 
degradation of lean tissue mass and especially muscle mass (Roubenoff et al., 
1994). Indeed, RA patients have reduced muscle mass in the presence of 
unchanged body weight (Roubenoff et al., 1994). In combination with their 
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sedentary lifestyle, this leads to increased accumulation of body fat 
(Stavropoulos-Kalinoglou et al., 2007) and could potentially have detrimental 
effects on both the disease itself and on the overall health of a patient. 
Increased adiposity - or obesity - is a well established risk factor for the 
development of CVD in the general population and is suggested to be the 
underlying cause of the metabolic syndrome – a constellation of classical CVD 
risk factors (such as hypertension, hypercholesterolaemia, and 
hyperinsulinaemia) that results in a two to three-fold increase in CVD risk (Bray 
and Bellanger, 2006). Moreover, it is now recognised that adipose tissue is not 
merely an energy storage depot but it is an active endocrine/paracrine organ that 
secretes a number of bioactive molecules known as adipokines (Mohamed-Ali et 
al., 1998). Adipokines have several different functions such as regulation of 
energy intake and expenditure (Houseknecht et al., 1998, Chandran et al., 2003); 
however, most of them are also implicated in regulation of inflammation 
(Mohamed-Ali et al., 1998). As a general rule, increased adiposity associates with 
heightened production of pro-inflammatory molecules, whereas reduced adiposity 
associates with decreased concentration of such molecules and increased 
concentration of anti-inflammatory ones (Ramos et al., 2003). The close 
associations of obesity both with CVD risk and inflammation as well as the body 
composition changes of the RA patients render the concomitant study of the two 
conditions highly significant. 
In the following pages, the author presents the current knowledge on the 
aetiology, pathophysiology, epidemiology and treatment of RA. Thereafter, the 
basic concepts of obesity are discussed, focusing mostly on the functions of 
adipose tissue as a secretory organ. Also, existing evidence on the associations 
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of RA with obesity are reviewed. The several questions that arise from this review 
form the basis of the various studies of the present project. The hypotheses, 
methods and findings of the studies are presented and discussed in the relevant 
chapters. Finally, the clinical applications and future recommendations for practice 
and research are discussed in the general discussion.  
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Chapter 2: Literature Review 
(Parts of this chapter have been published in the journal Immunology, Endocrine 
& Metabolic Agents - Medicinal Chemistry (2008), 8, 259-74) 
2.1 Rheumatoid Arthritis  
2.1.1 Historical Concepts and Definition 
RA was first described in 1800 as a new form of gout under the designation 
“primary asthenic gout”. The author identified several distinctive characteristics of 
the disease, including predominance in women, a chronic course, involvement of 
many joints from the onset and a decline in general health (Landré Beauvais, 
2001). The term Rheumatoid Arthritis was later introduced to characterise this 
disease. Rheumatoid (from Greek: ρεύμα [rhevma] meaning the flow; and suffix –
oid meaning similar to, alike) signifies the chronic cyclic nature of the disease 
which is characterised by periods of increased activity (flares) and others of 
remission. Arthritis (from Greek: άρθρωση [arthrosi] meaning joint; and suffix –itis 
meaning inflammation) is literally the inflammation of the joints (Onions et al., 
1996). Thus, RA is a systemic chronic inflammatory disorder of cyclic nature that 
affects mainly synovial joints (Hunder, 2005). 
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2.1.2 Clinical Manifestations 
RA affects any joint where cartilage overlies bone and with a joint cavity lined by a 
synovial membrane that contains synovial fluid. The changes to the synovium (i.e. 
oedema, increased vascularity and hyperplasia), the primary site of inflammation 
in RA, are important to the course of the disease  (Buch and Emery, 2002).  
RA usually initiates its course of articular symptoms over a period of 
several weeks to months, however in almost a third of all RA patients disease 
onset is rapid, occurring over a few days or weeks. At the initial stages of the 
disease the majority of patients present with oligoarthritis (i.e. less than six joints 
affected) often asymmetric; monoarthritis is very rare  (Hunder, 2005). Stiffness 
following prolonged periods of rest (i.e. sleep) is also noted as are signs of 
fatigue. 
 As the disease progresses the majority of the patients develops 
polyarthritis and experience unexplained flares and remissions. Even though the 
course of the disease differs between individuals, most RA patients develop 
destructive arthritis which can be disabling (Scott et al., 2000). Among patients 
with long-standing disease (i.e. >10 years) only 17% are free from any disability 
while 16% are completely disabled (Sherrer et al., 1986). As early as 1949 
(Steinbrocker et al.), this difference in disease outcomes was known and a 
classification of the functional limitations of the disease was proposed (Table 1). 
This classification is important in the planning of future health needs and 
treatment. More worryingly though, survival rates of RA patients are significantly 
lower compared to that of controls (Wolfe et al., 1994). All these have a significant 
impact both on the patient and their families as well as the society in general as 
the costs incurred by RA are significant (Cooper, 2000). 
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 Table 1: Functional classification of Rheumatoid Arthritis (adopted from 
Steinbrocker et al., 1949) 
Class Description 
I No limitations 
II Function is adequate for normal activities despite joint discomfort or limitation of motion 
III Function is inadequate for most self care and vocational activities 
IV Patient is largely or wholly unable to manage self-care and may 
be restricted to a wheelchair or bed 
 
2.1.3 Diagnosis and Treatment 
Early and effective interventions can minimise the destructive course of RA 
(O'Dell, 2002), thus prompt identification of individuals with RA is essential. 
Unfortunately, the differential diagnosis of polyarthritis is extensive and includes 
conditions such as inflammatory bowel disease, psoriatic arthritis, acute rheumatic 
fever, human-immunodeficiency-virus infection, gout, hyper- and hypothyroidism, 
systemic lupus erythematosus, osteoarthritis, malignancy and several other. Thus 
a careful examination of patients history, persistence of symptoms, laboratory and 
radiographic features are essential to establish an accurate diagnosis (Hunder, 
2005). In 1987, the American Rheumatism Association (now known as American 
College of Rheumatology - ARC) devised a number of criteria for the identification 
of patients with RA. The full list of these criteria is presented in Table 2. At least 
four of the seven criteria have to be present for a patient to be diagnosed with RA 
(criteria 1-4 for at least six weeks). These criteria can distinguish RA from other 
forms of arthritis with a specificity of 89% and a sensitivity of 94% (Arnett et al., 
1988). 
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Table 2: The 1987 American College of Rheumatology revised criteria for the 
classification of rheumatoid arthritis (adopted form Arnett et al., 1988) 
Criterion Description 
1. Morning 
Stiffness 
Morning stiffness in and around the joints, lasting at least 
one hour before maximal improvement 
2. Arthritis of 3 or 
more joint 
areas 
At least three joint areas (out of 14 possible; right or left 
proximal interphalangeal , metacarpophalangeal, wrist, 
elbow, ankle, metatarsophalangeal joints) simultaneously 
have had soft tissue swelling or fluid (not bony overgrowth 
alone) as observed by a physician  
3. Arthritis of hand 
joints 
At least one area swollen (as defined in criterion two) in a 
wrist, metacarpophalangeal, or proximal interphalangeal 
joint 
4. Symmetric 
arthritis 
Simultaneous involvement (as in criterion two) of the same 
joint areas on both sides of the body (bilateral involvement 
of interphalangeal, metacarpophalangeal, or metatarso-
phalangeal joints without absolute symmetry is acceptable) 
5. Rheumatoid 
nodules 
Subcutaneous nodules over bony prominences or extensor 
surfaces, or in juxta-articular regions as observed by a 
physician 
6. Serum 
rheumatoid 
factor 
Demonstration of abnormal amounts of serum rheumatoid 
factor by any method for which the result has been positive 
in <5% of normal control subjects 
7. Radiographic 
changes 
Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must 
include erosions or unequivocal body decalcification 
localised in, or most marked adjacent to, the involved joints 
(osteoarthritis changes alone do not qualify) 
 
 Unfortunately, to date, there is no known cure for RA. However, several 
different medical approaches are used to treat it. Their main aims are to relieve 
symptoms (i.e. joint pain, swelling and stiffness) or to decelerate the progression 
of joint damage. The choice of medication depends on the severity of the disease 
and its symptoms as well as the response of the patient to them. The most 
commonly used medicines are described below.  
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Analgesics: More commonly known as painkillers, they aim at pain relief 
rather than reduction of inflammation. The most commonly prescribed analgesic is 
paracetamol. Codeine is another analgesic, which is sometimes prescribed as a 
combined medicine with paracetamol. This is known as co-codamol.  
Non-steroidal anti-inflammatory drugs (NSAIDs): Several different types of 
NSAIDs exist. Ibuprofen and aspirin are those most commonly used. Diclofenac, 
fenoprofen and flurbiprofen are also frequently prescribed. A new type of NSAIDs, 
called COX-2 (cyclooxigenase-2) inhibitors is also available. Like analgesics, 
NSAIDs help to relieve pain while they can also reduce stiffness and 
inflammation. However, they don’t affect disease progression. They act by 
blocking the action of the enzyme cyclo-oxygenase. This enzyme, and especially 
its second form (i.e. COX-2), produces prostaglandins which are involved in the 
inflammatory cascade of RA (McWhorter, 1988). When taken in high doses, or 
over a long period of time, NSAIDs can cause complications, such as digestive 
problems, stomach bleeding, kidney and liver damage, tinnitus (ringing in the 
ears) and high blood pressure. COX-2 inhibitors are generally less harmful to the 
stomach, however they might increase CVD risk (Mukherjee et al., 2001). 
Corticosteroids: Drugs such as prednisone and methylprednisolone are 
used to reduce pain and inflammation and can also reduce joint damage (Pisetsky 
and St Clair, 2001). They are usually used when NSAIDs fail to provide relief 
(Verhoeven et al., 1998). They are prescribed on a short term basis, most often 
during a flare-up. Relief is rapid and the effect can last from a few weeks to 
several months depending on the severity of the disease. Such drugs act directly 
on the immune system and lower its response to the antigen (Vane and Botting, 
1987). However, this has a significant impact on the ability of the body to fend off 
 24
harmful agents such as viruses and bacteria (Doran et al., 2002a). Other side-
effects of corticosteroids include weight gain, osteoporosis, easy bruising, muscle 
weakness, and thinning of the skin. They can also worsen diabetes and glaucoma 
and increase risk for CVD (Panoulas et al., 2008b). 
Disease modifying anti-rheumatic drugs (DMARDs): DMARDs are the 
second line of defence against RA. They were initially prescribed when the above 
options failed to produce sufficient results; nowadays however they are used 
earlier and earlier in the course of the disease. While NSAIDs focus on reduction 
of symptoms, DMARDs aim to reduce the destructive effect of inflammation on the 
joints. A drawback of these drugs is that it may take several months before their 
action is noticed, thus early intervention is imperative. Depending on the specific 
medicine the mechanism of action differs; however, all focus on limitation of the 
damage caused by inflammation to the bones, tendons, ligaments and cartilage of 
the joint (Kremer, 2001). The most commonly prescribed DMARDs at present 
include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide and can 
be prescribed either alone or in combination with each other; older drugs, such as 
gold injections and penicillamine are now rarely used.  
Biologics: Tumour necrosis factor alpha (TNFα) blockers are a more recent 
type of DMARD that act faster compared to other DMARDs. The most commonly 
prescribed such medications include infliximab, etanercept and adalimumab. 
TNFα blockers can usually reduce symptoms within a few weeks and can also 
slow down or even halt the progression of RA. They bind TNFα in the joint as well 
as the circulation and prevent its interaction with the cells it targets. This leads to 
significant reductions in circulating TNFα and most importantly to rapid relief of 
symptoms as well as minimising the effects of RA on the joints (Louie et al., 
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2003). However, TNFα blockers may have serious side-effects. They can cause 
heart failure, infection and lymphoma amongst others (Fleischmann et al., 2004). 
Interleukin (IL)-1 and -6 blockers are also available. Anakinra blocks the biologic 
activity of naturally occurring IL-1, improving inflammation and cartilage 
degradation associated with RA, by competitively inhibiting the binding of IL-1 to 
the IL-1 type receptor. Even though it is safer compared to TNFα blockers, it is not 
as effective in preventing joint damage (Fleishmann, 2002). MRA is an anti-IL-6 
receptor monoclonal antibody that acts by blocking the activity of IL-6. It has been 
shown to effectively reduce inflammation and minimise joint damage in RA 
patients. However, it is a very new drug and its long-term side effects have not yet 
been extensively studied (Choy et al., 2002, Nishimoto et al., 2004). 
Surgery: In severe cases of RA, arthroplasty (reconstruction or 
replacement of the affected joint) or osteotomy (shortening or lengthening of the 
bone) is sometimes required. Its main aim is to restore movement and function of 
the joint (Coventry, 1973). Most commonly operated joints are the hips and knees. 
In the hands most surgeries aim to repair damaged tendons (Clayton, 1965).  
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2.1.4 Epidemiology 
Several studies in various countries have investigated the prevalence and 
incidence of RA and a considerable variation between different populations has 
been found (Table 3). However, in Northern Europe and North America a 
prevalence of 0.5-1% with an annual incidence of 20-50 new cases per 100.000 
inhabitants is usually reported (Alamanos and Drosos, 2005). These values seem 
to have decreased compared to older ones (Guillemin et al., 1994, Shichikawa et 
al., 1999, Doran et al., 2002b) however it is not clear whether this is a true 
reduction or merely a reflection of different methods used to identify RA patients 
(Alamanos and Drosos, 2005).  
 RA has also been shown to reduce life expectancy by 3-10 years 
depending on severity of the disease and age at onset (Erhardt et al., 1989). The 
increases in life expectancy recorded in the general population over the past 
decades are not reflected in RA patients (Glennas et al., 2000, Buch and Emery, 
2002). The causes of death do not differ significantly between RA patients and the 
general population, but they occur at a younger age (Alamanos and Drosos, 
2005). The main cause of death in RA is CVD which is both more prevalent and 
more likely to lead to death in these patients than in the general population 
(Glennas et al., 2000, Kitas and Erb, 2003). 
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Table 3: Prevalence and incidence of Rheumatoid Arthritis in different countries 
(adopted form Alamanos and Drosos, 2005) 
Population Prevalence rates Incidence rates
USA  
(general population) 0.9–1.1  0.02–0.07  
North America 
USA  
(native-Americans)  5.3–6.0  0.09–0.89  
England  0.8–1.10  0.02–0.04  
Finland  0.8  0.03–0.04  
Sweden  0.5–0.9   
Norway  0.4–0.5  0.02–0.03  
Netherlands  0.9  0.05  
Denmark  0.9   
North Europe  
Ireland  0.5   
Spain  0.5   
France  0.6  0.01  
Italy  0.3   
Greece  0.3–0.7  0.02  
South Europe  
Yugoslavia  0.2   
Argentina  0.2   
Brazil  0.5   South America 
Colombia  0.1   
Japan  0.3  0.04–0.09  
China  0.2–0.3   
Taiwan   0.3  
Indonesia  0.2–0.3   
Philippines  0.2   
Asia  
Pakistan  0.1   
Egypt  0.2   
Israel  0.3   
Oman  0.4   Middle East  
Turkey  0.5   
Africa   0–0.3   
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2.1.5 Aetiology and Risk Factors 
The aetiology of RA is not clear. It is believed that RA is triggered when an 
immunogenetically susceptible host is exposed to an antigen. In this manner, an 
acute inflammatory reaction is initiated. In contrast to the normal course of 
inflammation, when the antigen has been repelled, this reaction is not terminated. 
Instead, it recognises some of the tissues in the joints as foreign and attacks them 
(autoimmune reaction). It is this chronic uncontrolled phase of the inflammation 
that ultimately destroys the joints. The antigen(s) that triggers the initial 
inflammation has not been positively recognised; however, several potential risk 
factors have been identified and are discussed below. 
2.1.5.1 Genetic Susceptibility  
Studies have found high rates of concordance between monozygotic twins 
(Jarvinen and Aho, 1994) and first-degree relatives of RA patients (Cotran et al., 
1999) suggesting a definite genetic predisposition to RA. However, the failure to 
demonstrate Mendelian inheritance patterns indicates interplay of multiple genetic 
factors (Ollier and MacGregor, 1995, Buch and Emery, 2002).   
 The most consistent genetic association of RA is with the human leukocyte 
antigen (HLA) alleles (Cotran et al., 1999, Buch and Emery, 2002). HLA is a part 
of the major histocompatibility complex (MHC) of genes, located in chromosome 
six. Its main function is to encode molecules (Class I and II) responsible for 
presenting T-cells (a lymphocyte sub-type of the immune system capable of 
destroying virally infected cells) with viral or other peptides. The majority of 
individuals who develop RA (65%-80%) have the HLA-DR4 or DR1 allele or both. 
All the DR alleles associated with RA share a common region of four amino acids 
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located in the antigen-binding cleft of the DR molecule adjacent to the T-cell 
receptor (Cotran et al., 1999). This is referred to as “the shared” or “the 
rheumatoid epitope” (Alamanos and Drosos, 2005) and is presumably the specific 
binding site of the antigen that initiates the inflammation of the joints (Cotran et al., 
1999). Differences in genes of various proteins implicated in the course of RA (i.e. 
cytokines) have also been studied; however, their results were not consistent 
between different populations (Hajeer et al., 2000, Martinez et al., 2000). This 
indicates that, in addition to HLA, the development and progression of RA is 
influenced by a complex genetic profile. 
2.1.5.2 Age and Gender 
Even though RA is not age or gender specific, differences between age groups 
and genders exist. Most epidemiological studies suggest an age of disease onset 
during or after the fifth decade of life (Guillemin et al., 1994, Shichikawa et al., 
1999, Alamanos and Drosos, 2005). However, no age is immune to RA as even 
young children can suffer from it (Hunder, 2005). Females are two-three times 
more likely to develop RA compared to males (Gabriel et al., 1999, Symmons et 
al., 2002, Alamanos and Drosos, 2005).  
2.1.5.3 Hormones 
The above mentioned gender difference as well as the observations that 
pregnancy has an ameliorating effect on RA and that RA patients are more likely 
to be nulliparous before disease onset compared to the general population 
suggest an influence of hormonal factors in the occurrence and progression of the 
disease (Hazes, 1991, Buch and Emery, 2002). Overall, androgens have an 
immunosuppressive role whereas oestrogens are known to stimulate the immune 
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system. In pregnant women corticotrophin-releasing hormone directly stimulates 
production of dehydroepiandrosterone, the major androgen in women, by foetal 
adrenal cells (Smith et al., 1998) and could be the reason for disease remission 
during pregnancy. In a similar way, oral contraceptives reduce disease severity 
(van Zeben et al., 1990) or could even protect against its development (Hazes 
and van Zeben, 1991, Koepsell et al., 1994). 
 Moreover, during pregnancy, alloantibodies developed against the paternal 
HLA are found in maternal circulation (Combe et al., 1985). These alloantibodies 
block the function of HLA-DR epitopes and could thus down-regulate the disease 
(Moynier et al., 1987, Kim et al., 2003). However, the positive effects of pregnancy 
on RA revert in the post-partum period (Alamanos and Drosos, 2005). 
2.1.5.4 Infectious Agents 
Several different infectious agents (e.g. retroviruses, parvoviruses, mycobacteria, 
Borrelia, Mycoplasma) have been studied as possible “initiators” of RA, however 
Epstein-Barr virus is currently the most investigated such agent (Krause et al., 
1996, Schaeverbeke et al., 1997, Hunder, 2005). This virus shares some 
homologous HLA-DRβ chain epitopes with type-2 collagen. Joint cartilage is rich 
in this type of collagen and autoimmunity to it can be demonstrated in most RA 
patients. It is thus suggested that initial infection with Epstein-Barr virus causes a 
normal immunological reaction. Due to the similarities of the virus with type-2 
collagen, the reaction crosses over to affect joint cartilage (Cotran et al., 1999). 
 A similar hypothesis exists for Mycobacterium tuberculosis. This bacterium 
produces a number of heat shock proteins (proteins produced by cells of all 
species in response to stress) which have up to 65% sequence homology with 
human heat shock proteins (Kaufmann, 1990). It is suggested that antibodies and 
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T-cells recognise epitopes shared by such proteins of both the infectious agent 
and the host, facilitating cross-reactivity and triggering an autoimmune response 
(Buch and Emery, 2002). 
2.1.5.5 Other Risk Factors 
 Smoking has also been implicated in the initiation of the disease. Its effects 
appear to be dose depended and heavy smoking associates with increased risk 
for seropositive (i.e. abnormal rheumatoid factor) disease (Wilson and Goldsmith, 
1999). Furthermore, smoking has been suggested to affect severity and outcome 
of RA (Harrison, 2002, Manfredsdottir et al., 2006) but findings in other studies are 
not consistent (Finckh et al., 2007). 
 Diet is yet another potential risk factor for the development of RA. Recent 
studies have indicated that consumption of fish, olive oil and vegetables could 
protect against initiation of RA (Cleland et al., 2003). Similarly, the increased 
intake of such food and a concomitant reduction in fat intake can decrease 
disease severity (Cleland and James, 2002). The protective role of fish and 
vegetable consumption has been attributed to the effect of omega-3 long chain 
polyunsaturated fatty acids and other anti-oxidants against the oxidative stress 
associated with rheumatoid arthritis (Alamanos and Drosos, 2005). 
Finally, ethnicity can affect the development of RA. Genetic variations in 
the rheumatoid epitope and its associations with the progression of the disease 
have been found in different populations (Drosos et al., 1992, Drosos and 
Moutsopoulos, 1995, Gorman et al., 2004). This variation in combination with 
environmental and lifestyle factors (e.g. diet) are most probably responsible for 
the geographic variation of the disease (Alamanos and Drosos, 2005). 
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2.1.6 Pathogenesis  
Even though our understanding of the aetiology of RA is limited, the pathogenesis 
of this disease is much clearer. As described previously, an antigen with 
characteristics similar to a normal cell in the joint triggers an autoimmune reaction 
which is responsible for the chronic destructive nature of RA.  
MHC class II molecules, carrying the antigen, cause naive T cells to divide 
and differentiate. Activated T cells release a number of bioactive molecules called 
cytokines. Angiogenic cytokines, such as vascular endothelial growth factor, are 
responsible for the growth of new blood vessels (Colville-Nash and Scott, 1992, 
Fearon et al., 2003) as well as rendering them hyper-permeable (Ferrara et al., 
1991, Malemud, 2007). The adhesion of leukocytes (i.e. T cells; mainly CD4+ 
helper T cells, B-cells, macrophages) to the endothelium is initially controlled by 
E-selectin, an adhesion molecule that forms low-affinity bonds with the leukocytes 
and causes them to slow down and roll along the blood vessel wall (Ospelt and 
Gay, 2008). Migration of these cells to the site of inflammation is then facilitated 
by other adhesion molecules, such as intercellular adhesion molecules and 
vascular cell adhesion molecules (Malik and Lo, 1996). Cytokines, such as TNFα, 
IL-1, IL-6, and IL-8, are again implicated in this process by inducing the expression 
of adhesion molecules on endothelial cells and leukocytes (Mojcik and Shevach, 
1997, Nassonov et al., 2000). The main noticeable structural changes are 
oedema, increased vascularity and hyperplasia of the synovium which manifest 
clinically as joint swelling and pain (Buch and Emery, 2002). 
As the disease progresses, neovascularisation and migration of leukocytes 
in the synovium continues; hyperplasia of the synovium becomes even more 
apparent (Henderson et al., 1988). Ultimately, the hypertrophied synovium 
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becomes invasive at the site of the joint where the synovium attaches to the bone 
or cartilage. This causes the formation of a distinctive tissue, called “pannus” 
where a large concentration of matrix metalloproteinases is observed (Ospelt and 
Gay, 2008). These molecules are involved in the destruction of extracellular 
matrix and are responsible for the joint erosions observed in RA (Buch and 
Emery, 2002, Ospelt and Gay, 2008). Cytokines, especially TNFα and IL-1 are 
known to induce their production.  
2.1.6.1 Cytokines 
The pathogenesis of RA as described above is a complicated procedure involving 
several different mechanisms. However, in every step of it the involvement of 
cytokines is apparent. Cytokines are a category of soluble proteins that serve as 
chemical messengers between cells. They are produced de novo in response to 
an immune stimulus by a wide variety of cells and can have autocrine, paracrine 
and endocrine effects. Different cell types can produce the same cytokine or a 
single cytokine can act on several different cells (i.e. pleiotropy). Several different 
cytokines can have a similar effect (i.e. redundancy) and they can be produced in 
a cascade (i.e. stimulate their target cell to produce more cytokines). Finally, 
cytokines can act synergistically (together with each other) or antagonistically 
(against each other) (Ashman and Papadimitriou, 1995). Cytokines are involved in 
several processes including cell growth and differentiation, inflammation, tissue 
repair and remodelling, and are thus critical to the development and functioning of 
both the innate and humoral immune responses (Buch and Emery, 2002).  
In the rheumatoid synovium the cytokines most often encountered are 
TNFα, IL-1 and IL-6. Synergistically, TNFα and IL-1 promote a pro-inflammatory 
profile which induces the functions previously described, namely: T- and B-cell 
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recruitment and activation, angiogenesis, chemotaxis, vessel permeability and 
matrix metalloproteinase production (Klimiuk et al., 1997). TNFα is responsible to 
a greater extent for the proliferative and inflammatory aspects of the disease, 
whereas IL-1 is for its destructive aspects (Buch and Emery, 2002). IL-6 seems to 
be implicated more in the systemic effects of RA (discussed in the following 
section). The sources, functions and effects of cytokines implicated in RA are 
presented in Table 4. 
Table 4: Sources, functions and effects of selected cytokines 
Cytokine Producing Cell Target   Cell Function Main Effects 
Th cells co-stimulation 
B cells maturation and proliferation 
natural killer 
cells activation  IL-1 
monocytes 
macrophages  
B cells  
dendritic cells 
various 
inflammation, 
acute phase 
response, fever 
damage to 
proteoglycans in the 
cartilage   
activated B 
cells 
differentiation into 
plasma cells 
plasma cells antibody secretion 
stem cells differentiation 
IL-6 
monocytes 
macrophages 
Th2 cells 
stromal cells 
various acute phase response 
production of acute 
phase reactants 
macrophages
adhesion 
molecules and 
cytokine 
expression 
TNFa 
macrophages 
mast cells 
natural killer 
cells 
tumour cells cell death 
bone and cartilage 
resorption 
MHC class II expression 
chemotaxis 
increase production of  
IL-1 and IL-6 
activation of adhesion 
molecules 
activation of T and B 
cells 
muscle degradation 
IL: interleukin; TNF: Tumour Necrosis Factor. Th: T helper 
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2.1.6.2 Systemic Effects of Cytokines 
The effects of cytokines are not limited within the synovium. The local 
inflammation of RA soon triggers a systemic response of the innate immune 
system (i.e. antigen-nonspecific defence mechanisms that a host is born with), the 
acute phase response. This response provides an early defence and enables the 
body to recognize foreign substances early in the infection process prior to the full 
activation and implementation of the immune responses (Baumann and Gauldie, 
1994). It is characterized by leukocytosis, fever, alterations in the metabolism of 
many organs as well as changes in the plasma concentrations of various acute-
phase proteins (Gabay and Kushner, 1999). 
Blood-borne cytokines, and especially IL-6 (Smith and McDonald, 1992), 
that leave the synovium reach the liver and stimulate hepatocytes to synthesize 
and secrete acute phase proteins; i.e. soluble pattern-recognition receptors that 
bind onto the pathogen and present it to the respective leukocytes (Cotran et al., 
1999). Acute phase proteins have been defined as any protein whose plasma 
concentrations increases or decreases by at least 25% during an acute 
inflammatory disorder (Morley and Kushner, 1982). Acute phase response is 
normally terminated when the pathogen is eliminated. Mechanisms, involving 
production of anti-inflammatory cytokines (e.g. IL-10) by Kupffer cells (fixed 
macrophages located in the liver), suppress the expression of IL-6 in the liver and 
terminate the inflammatory cascade (Suffredini et al., 1999). However, in chronic 
or recurring inflammation acute phase response is constantly activated increasing 
significantly the levels of acute phase proteins in the blood. 
An important acute phase protein, for RA, is C-reactive protein (CRP). Its 
levels, normally below 1mg/L of whole blood, can rise 10.000-fold following 
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infection within very short periods of time (Pepys and Hirschfield, 2003). CRP is a 
prominent indicator of disease activity in RA as well as other conditions. Increased 
levels of it indicate uncontrolled disease or a flare while reduced levels indicate 
disease remission (Crockson et al., 1978). However, most RA patients constantly 
exhibit CRP levels well above the “accepted” values (i.e. <8mg/L) (Kushner, 
1991). Apart from its association with disease activity, CRP has been identified as 
an independent risk factor for the development of CVD (Ridker et al., 2002, de 
Ferranti and Rifai, 2007), and inflammation overall is thought to affect the function 
and health of several different organs and tissues in the body. 
2.1.6.3 Transcription Factors 
The way cytokines influence all these functions is by affecting gene transcription. 
In the process of transcription, RNA is produced from the DNA and this 
conversion is an essential element in gene expression. The central role of 
transcription in the process of gene expression means that it regulates the 
expression of genes in particular cell types or in response to a particular stimuli, 
such as cytokines (Okamoto et al., 2008). To date two such factors have been 
implicated in the pathogenesis of RA; the nuclear factor kappa beta (NF-κB) and 
the activator protein one (AP-1). 
 
NF-κB 
NF-κB proteins are a family of ubiquitously expressed transcription factors that 
play an essential role in most immune and inflammatory responses. The NF-κB 
proteins are retained in an inactive form in the cytoplasm through their interaction 
with inhibitor of NF-κB proteins (Okamoto et al., 2008). Stimulation by cytokines, 
such as TNFα and IL-1, phosphorylates the inhibitor proteins and leads to their 
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ubiquitination and subsequent proteosomal degradation. This enables NF-κB to 
translocate to the nucleus and stimulate the transcription of genes. Among the 
numerous genes that NF-κB influences are those of cytokines (TNFα, IL-1, IL-6), 
adhesion molecules, matrix metalloproteinases and others that control apoptosis 
and cell proliferation (Makarov, 2001). The NF-κB proteins are highly expressed 
and activated in the RA synovium (Miagkov et al., 1998).  
The increased cellularity of the synovium is a result of the increased 
recruitment of leukocytes. However, it is also mediated by deficient or even 
impaired apoptosis resulting from the up-regulation of anti-apoptotic molecules by  
NF-κB (Perlman et al., 2001, Schedel et al., 2002). Apart from this association 
with the inhibition of programmed cell death, NF-kB also has an important role in 
the development and homeostasis of the immune, hepatic, and nervous systems 
(Okamoto et al., 2008).  
 
AP-1 
AP-1 transduces extracellular signals to immune cells, resulting in changes in the 
expression of specific target genes with an AP-1 binding sites in their promoter or 
enhancer regions. Even though the knowledge around this transcription factor is 
relatively limited, several mechanisms by which it may affect the severity of 
inflammation have been proposed. AP-1 has been suggested to activate cytokine 
production (in co-operation with other transcription factors), regulate differentiation 
of naive T cells into Th-1 or Th-2 cells or interact and suppress the glucocorticoid 
receptors (Okamoto et al., 2008).  
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2.1.7 Extra-articular Manifestations 
A common feature of RA is the presence of extra-articular manifestations with 
almost 15% of RA patients suffering from such conditions (excluding CVD) 
(Turesson and Jacobsson, 2004). Extra-articular manifestations usually present in 
patients with high disease activity and increased markers of inflammation, such as 
CRP (Turesson et al., 2003) and associate with increased morbidity and mortality 
(Turesson et al., 1999). All the known extra-articular manifestations are listed in 
Table 5, however only those relevant to this project are discussed below.  
 
Table 5: Systemic Manifestations of Rheumatoid Arthritis 
Organ System Systemic Manifestation 
Cardiovascular Coronary artery disease, myocardial infraction, pericarditis 
Muscle Rheumatoid cachexia 
Blood Anaemia, thrombocytosis, Felty's syndrome, large 
granulocytic leukaemia, non-Hodgkin's lymphoma 
Pulmonary Pleural effusion, nodules, interstitial lung disease 
Vascular Vasculitis  
Nervous  Neuropathy 
Bone Osteopenia and osteoporosis 
Ocular Keratoconjunctivitis sicca, scleritis, episcleritis, peripheral 
ulcerative keratitis 
Salivary glands Secondary Sjögren's syndrome with dry eyes and mouth 
Skin Cutaneous vasculitis, nodules 
2.1.7.1 Cardiovascular Disease 
RA is associated with an estimated 70% excess mortality rate (Pham et al., 2006) 
that can be ascribed to cardiovascular causes in up to 50% of cases (del Rincon 
et al., 2001).  In this population a 3-fold increased adjusted risk of myocardial 
infraction has been reported, particularly in subjects with long-standing disease 
(Solomon et al., 2003). The exact causes for that remain unclear; however, 
classical CVD risk factors (i.e. hypertension, dyslipidaemia, insulin resistance), the 
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inflammation related to RA and antirheumatic medication have been shown to 
affect cardiac health of these patients. 
 Hypertension is highly prevalent in RA but often remains undiagnosed  
(Panoulas et al., 2007). Genetic factors, inflammation and commonly used 
therapies are known to affect it (Panoulas et al., 2007, Panoulas et al., 2008a, 
Panoulas et al., 2008b, Panoulas et al., 2008c). Dyslipidaemia is also common in 
RA and associates with disease activity; it manifests as low total and high density 
lipoprotein (HDL), in the presence of high triglyceride levels (Quyyumi, 2006). This 
pattern produces a more dense, easily oxidisable, and intensely atherogenic low-
density lipoprotein particle (Sattar et al., 2003). Hyperinsulinaemia and insulin 
resistance are also observed in RA (Paolisso et al., 1991). The potential 
mechanisms again include use of glucocorticoids but also the direct effects of 
cytokines, such as TNFα, on impeding insulin-mediated glucose uptake in skeletal 
muscle and on lipolysis (Sattar et al., 2003).  
 Inflammation however, is currently considered to be the unifying 
mechanism that explains cardiovascular risk in RA (Quyyumi, 2006). 
Atherosclerosis is a chronic inflammatory process of the vascular bed mediated 
by mononuclear cell infiltration fibrosis, elaboration of cytokines, increased cellular 
adhesion, and plaque destabilization. This leads to a low-grade systemic 
inflammatory response that is an indicator of increased future risk of 
atherothrombotic events (Ross, 1999). In RA, inflammation of the synovium leads 
to a far greater elevation of circulating cytokines (i.e. IL-1, IL-6 and TNFα) and 
markers of inflammation (i.e. CRP). Elevated levels of circulating cytokines do not 
simply reflect increased risk, but, through their pleiotropic effects, directly 
exacerbate vascular disease (Sattar et al., 2003). As indicated previously, 
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cytokines can affect glucose handling in the skeletal muscle, and lipid metabolism 
in the adipose tissue leading to insulin resistance and dyslipidaemia respectively. 
They also stimulate production of plasminogen activator inhibitor-1 and fibrinogen 
by the liver, enhancing a prothrombotic state and activating the vascular 
endothelium (Quyyumi, 2006). The latter has been shown to increase arterial 
stiffness (a measure of subclinical vascular disease that predicts future CVD) and 
lead to endothelial dysfunction (the first step in the process of 
atherosclerosis)(Yasmin et al., 2004). Indeed, RA patients exhibit increased 
arterial stiffness (Maki-Petaja et al., 2006) and endothelial dysfunction (Hurlimann 
et al., 2002, Raza et al., 2006) compared to controls. 
 Control of inflammation with medication can have both beneficial and 
deleterious effects on CVD risk of RA patients. Corticosteroids exacerbate 
dyslipidaemia, blood pressure and insulin resistance (del Rincon et al., 2004, 
Quyyumi, 2006, Panoulas et al., 2008b); despite reducing inflammation, patients 
treated with high doses of them have greater incidence of carotid plaque and 
arterial stiffness (del Rincon et al., 2004). Similarly, nonsteroidal-antiinflammatory-
agents may exacerbate hypertension, and COX-2 antagonists are associated with 
increased risk of myocardial infraction (Quyyumi, 2006). In contrast, DMARDs 
may be protective against cardiovascular risk by reducing risk for myocardial 
infraction by almost 70% (Choi et al., 2002). Finally, anti-TNFα treatment has 
been shown to improve arterial stiffness and endothelial function (Maki-Petaja et 
al., 2006). However, whether this translates into true reduction in cardiovascular 
risk remains unknown (Quyyumi, 2006) although early results appear promising 
(Dixon et al., 2007). 
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2.1.7.2 Rheumatoid Cachexia 
RA also has a significant impact on body composition. Almost 2/3 of RA patients 
experience involuntary wasting of muscle mass accompanied by stable or slightly 
decreased total body weight (Roubenoff et al., 1994). This condition is termed 
“rheumatoid cachexia”. It differs from the age-related sarcopenia, a qualitative and 
quantitative decline in skeletal muscle mass, as muscle wasting in rheumatoid 
arthritis occurs at a younger age and at an accelerated rate (Roubenoff et al., 
1994, Walsmith and Roubenoff, 2002). It also differs from cachexia, a condition of 
rapid muscle degradation accompanied by rapid weight loss, due to the small 
changes in body weight of RA patients (Rall and Roubenoff, 2004). Thus, 
rheumatoid cachexia is a distinct condition observed solely in RA. 
The exact mechanisms underlying the development of rheumatoid 
cachexia are not yet clear. However, inflammation of the disease as well as the 
inactive lifestyle of most RA patients are thought to play a central role in its 
development (Metsios et al., 2006). TNFα, initially named “cachectin”, has been 
recognised as a potent enhancer of muscle degradation and in conjunction with 
IL-1 they have been shown to enhance proteinolysis (Zamir et al., 1992). They 
activate the NF-κB transcription pathway which in turn acts on proteinolytic genes 
and increases conjugation of ubiquitin (a regulatory protein that labels other 
proteins for proteosomal degradation) to muscle proteins (Lecker et al., 1999). 
These proteins are then catalysed to small peptides and disposed by the body  
(Kisselev et al., 1998). TNFα also reduces insulin action in the muscle 
(Hotamisligil et al., 1994); this results in limited transportation through muscle-cell 
membrane of amino acids essential for proteinosynthesis (Rall and Roubenoff, 
2004). Control of inflammation with medication has been shown to reduce muscle 
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catabolism; however it can not reverse rheumatoid cachexia on its own (Metsios 
et al., 2007). 
In order for the above negative effects of inflammation to be reversed, 
adequate stimuli for muscle growth need to be present. Physical activity, even at 
very low intensity, is the best such stimulus. Low-intensity aerobic exercise is 
known to acutely and chronically improve insulin action on the muscle allowing for 
greater amino-acid delivery which can then be used to synthesise protein (Fujita 
et al., 2007). Resistance exercise initiates muscle reconstruction mechanisms, 
mainly through activation of the “mammalian target of rapamycin” signalling 
pathway (Kubica et al., 2005). Contrary to common belief, RA patients are able to 
exercise at the required intensities without aggravating their disease and to elicit 
beneficial changes in their body composition; however very few of them chose to 
do so (Metsios et al., 2008c). In order for the exercise-induced muscle synthesis 
to occur, diet needs to provide adequate supply of amino-acids (Hebuterne et al., 
2001). However, diet on its own is not enough to reverse rheumatoid cachexia 
(Marcora et al., 2005a). 
The loss of muscle mass in RA patients results in movement limitations 
and is partly responsible for the functional disability of these patients (Munro and 
Capell, 1997, Westhovens et al., 1997). Rheumatoid cachexia may also be 
implicated in the cardiovascular risk of RA patients. As noted previously, muscle 
wasting is accompanied by very little change in total body weight; this indicates 
increased quantity of body fat (BF) (Stavropoulos-Kalinoglou et al., 2007). In the 
general population, increased BF has been proposed as the underlying cause of 
classical risk factors as well as the metabolic syndrome (a constellation of risk 
factors and central adiposity which increases the risk for CVD 2-3 fold) (Grundy et 
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al., 2004). Moreover, adipose tissue is a potent producer of cytokines, especially 
TNFα and IL-6, and in the general population increases in this tissue associate 
with increased levels of circulating cytokines (Pi-Sunyer, 2006). Thus, increases in 
BF might also affect disease activity of RA patients. The potential associations 
between adiposity of RA patients with CVD risk and disease activity form the main 
questions of the present project and are discussed later in the literature review 
following an introduction to the basic concepts of obesity.  
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2.2 Obesity 
2.2.1 Historical Concepts and Definition 
Obesity (from Latin obēsus = stout, fat, or plump. Ēsus is the past participle of 
edere = to eat) (Onions et al., 1996) is a condition that develops from a chronic 
quantitative imbalance between energy intake and energy expenditure leading to 
accumulation of excessive adipose tissue (i.e. fat) within the body (Bray and 
Bellanger, 2006). According to the guidelines of the World Health Organisation 
(WHO, 2000) individuals with a body mass index (BMI) (i.e. weight divided by 
height squared; discussed in further detail in the following section) of more than 
30kg/m2 are classified as obese. They are a distinct category from those with a 
BMI of 25-30kg/m2 who are characterised as overweight.  
Obesity has been recognised as a medical condition at least since the time 
of Hippocrates. He wrote “Corpulence is not only a disease itself, but the 
harbinger of others”, recognising that obesity is a medical disorder also leading to 
several comorbidities (Haslam and James, 2005). The first attested use of the 
word in English is in 1651, in Matæotechnia Medicinæ Praxeos by Noah Biggs 
(Onions et al., 1996). In the ancient times, obesity was considered a flaw and in 
the Christian religion excessive consumption of food was viewed as a sign of sloth 
and lust (Woodhouse, 2008). In recent years, obese individuals have been the 
target of social discrimination; they are less likely to be hired for a job, they earn 
less and they are less likely to be promoted (Haslam and James, 2005). On the 
same line, the perceived ideal weight has changed during the past century. 
Indicative is the trend in “beauty contests” as the weight of the winners has 
decreased by 12% from 1922 to 1999 (Caballero, 2007).  
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 Even though obesity was present since the early days of human 
civilisation, it is only in the last few decades that it has become a serious problem. 
For the most of human history, mankind was faced with starvation. During the 
industrial revolution it was realised that the efficiency and productivity of the 
workers depended on their body size and strength. Increased energy 
consumption resulted in height and weight increases throughout the 19th century 
in the developed world. However, as populations reached their genetic potential 
for height in the 20th century, weight increased disproportionately, resulting in 
obesity. By the year 2000, the human race reached a negative landmark, the 
number of adults with excess weight (i.e. BMI >25kg/m2) is now higher than that of 
normal-weight (i.e. BMI between 18.5kg/m2 and 25 kg/m2) (Caballero, 2007). 
2.2.2 Assessments 
The assessment of obesity is a complicated procedure as direct measurement of 
the adipose tissue in vivo is virtually impossible. Thus several indirect methods for 
its assessment have been devised. 
2.2.2.1 Body Mass Index 
BMI is the most commonly used method for the assessment of obesity in the 
clinical setting and in epidemiological studies (WHO, 2000). It was developed in 
1871 by Adolph Quetelet, a Belgian statistician and anthropometrist and for that it 
is also known as Quetelet index (Eknoyan, 2008). BMI is a simple mathematical 
calculation based on height and weight; depending on the units used this 
calculation is:  
• System International units: BMI = weight (kg) / height2 (m) 
• Imperial units: BMI = weight (lb) x 703 / height2 (in) 
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BMI is inherent in the definition of obesity as the world health organisation 
(WHO) has used this measure to categorise individuals according to their body 
weight. The categories and the corresponding BMI values are listed in Table 6.  
 
Table 6: Body mass index categories for the general population 
BMI (kg/m2) Category 
<18.5 Underweight 
18.5-25 Normal Weight
25- 30 Overweight 
>30 Obese 
 
These categories, in general, associate with low, medium, and high risk for 
health complications (WHO, 1998, Calle et al., 1999, Haslam and James, 2005, 
Eknoyan, 2008). However, BMI is only a proxy of BF (Wellens et al., 1996) and 
over recent years its validity has been questioned (Manson et al., 1995, Willett et 
al., 1995, Blew et al., 2002, Nevill et al., 2004, Romero-Corral et al., 2006). 
Overweight as defined by BMI of >25, has poor specificity in detecting excess BF 
in males and in the elderly (Wellens et al., 1996) as well as in patients with 
coronary heart disease (Romero-Corral et al., 2006). In specific sub-populations, 
such as Indian-Asian (WHO, 2004), women (Manson et al., 1995, Willett et al., 
1995, Blew et al., 2002), and large size athletes (Nevill et al., 2004), new BMI cut-
off points have been suggested, that optimally reflect  BF and may better predict 
CVD risk.  
The weakness of BMI is that it does not distinguish between lean-body 
mass and fat mass. Consequently people of similar stature and weight, but 
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different muscle content, will have the same BMI but different levels of BF. This 
tends to be more evident in individuals with low BMI levels (Wellens et al., 1996). 
Such limitations of BMI may explain the better cardiovascular outcomes observed 
in overweight and mildly obese patients with established CVD as compared to 
their normal-weight counterparts, who may have proportionately more BF 
(Romero-Corral et al., 2006). Therefore, although it is well established that CVD 
risk increases with advancing BMI levels, (WHO, 1998) global cut-off points may 
be misleading for several populations.  
2.2.2.2 Central Obesity 
Central obesity, also termed "apple-shaped" or intra-abdominal obesity, refers to 
the accumulation of fat in the visceral area (fat deposited between the internal 
organs in the torso). Increased intra-abdominal fat results in an increased waist 
size and associates with negative health outcomes (Yusuf et al., 2005). Even 
though not indicative of total body fat content, assessments of central obesity 
correlate strongly with cardiovascular disease (Hsieh and Yoshinaga, 1995, Rimm 
et al., 1995). Waist circumference and waist-to-hip ratio are the two most widely 
used such assessments. Gender specific cut-off points for both are designed to 
identify individuals at increased risk for CVD (Table 7). 
 
Table 7: Cut-off points for waist circumference and waist-to-hip ratio 
Waist Circumference Waist-to-hip ratio 
Male Female Male Female 
102 cm 88 cm 0.9 0.85 
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Several studies have proposed that, compared to BMI, central obesity 
better identifies individuals at increased risk for CVD (Janssen et al., 2002, 
Janssen et al., 2004) and thus the definition of obesity should be based on it. 
However, its predictive strength can be negatively affected by gender and overall 
body weight. Pear- shaped or obese individuals might have optimal waist 
circumference or waist-to-hip ratio but increased overall body fat (Li et al., 2006). 
More research is necessary to identify the optimal definition of obesity as a 
predictor for CVD in the general population and specific sub-groups (Bray, 2004). 
2.2.2.3 Body Fat Percentage 
BF is an indicator of total body fat content and refers to both essential (i.e. the 
minimum amount of fat necessary for maintenance of life and reproductive 
function) and storage (i.e. the excess amount of fat stored in the various adipose 
depots of the body) fat. In men essential fat is 2-5% whereas in women 10-13% 
(Bray et al., 1998). Storage fat can be accumulated either in subcutaneous (i.e. 
below the skin) or in visceral (i.e. around internal organs in the chest and 
abdomen) adipose tissue. Levels of optimal BF are age and gender specific 
(Figure 1) (Bray et al., 1998). 
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Figure 1: Recommended body fat levels according to gender and age (Adopted 
from: WHO,2000) 
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Estimation of BF is a complicated procedure and several different methods 
have been proposed. Some methods have been based on the assessment of 
body density. Fat is known to have lower density (0.9kg/L) than other organs 
(1.07kg/L) and bones (1.9kg/L) (Visser et al., 1997), thus estimation of average 
body density can reveal BF. Skinfold measurement and hydrostatic or underwater 
weighing are the two most widely used such methods. The former involves 
measurement of different skinfolds of the body (i.e. biceps, triceps, subscapular, 
iliac crest, supraspinale, abdominal, front thigh, median calf) with the use of a 
calliper (ACSM, 2005). The sum of skinfolds is then input in specific equations (for 
details refer to Jackson et al., 1980, Jackson and Pollock, 2004) to estimate body 
density. Then, with the use of yet another equation (Siri, 1961) BF can be 
estimated. This technique however is not considered highly valid especially in 
non-athletic populations as it does not take into account visceral fat (ACSM, 
2005). Hydrostatic weighing, on the other hand, is considered to be a highly valid 
method for assessing BF and until recently it was the “golden standard” against 
which newer methods were validated (Brodie, 1988). Hydrostatic weighing 
involves assessment of body weight in and out of the water. Due to its low 
density, fat is lighter than water and thus it floats. The two weight measurements 
together with lung residual volume and water density are input in a formula that 
calculates again body density (Warner et al., 1986). BF is then calculated again 
with the Siri equation (Siri, 1961). Air displacement plethismography also 
calculates body density and from that BF (Fields et al., 2002). With the 
advancement of technology several other more direct methods for the 
assessment of BF have been developed.  
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Near Infrared Interactance measures the thickness of subcutaneous fat 
over the biceps and, based on equations, BF can be estimated. This method 
assumes that body fat distribution is universal in the body thus might 
underestimate BF of individuals with central obesity (Wagner and Heyward, 
1999).  
Total body potassium assesses the subject’s natural radiation, as 
potassium-40 is measured through the use of scintillation counters. This 
procedure accurately determines the body's total cell mass which in turn can be 
used to estimate fat-free or lean body mass. This method is highly valid and 
reliable; however, the cost of the equipment is a major deterrent for its use.  
Total body nitrogen is a similar technique that measures the amount of 
nitrogen in the body and is a direct indicator of total body protein (Brodie, 1988). 
Nitrogen and protein are closely linked with each other because of a stable 
chemical combination (protein is 16% nitrogen) and because over 98% of the total 
body nitrogen is in the form of protein (Heymsfield et al., 1993). This technique is 
again highly valid but cost of the equipment is also high (Haas et al., 2007).  
Computed tomography is a common medical procedure used to diagnose 
several disorders. It produces high quality images of body tissues and organs 
which can be used to differentiate and measure the amounts of fat and lean body 
tissue, and further distinguish between intra-abdominal and extra-abdominal fat. 
This method is one of the most valid as it literally “photographs” adipose tissue 
(Rogalla et al., 1998). However, the exposure to high amounts of radiation (1 
tomography = 500 chest x-rays) and the cost of the test limit its use in clinical or 
research settings (Wagner and Heyward, 1999). 
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Magnetic resonance imaging is a method with many similarities to 
computed tomography. It also “photographs” adipose tissue and allows for 
estimation of total and regional fat mass  and at the same time it is safer since no 
radiation is involved (Tothill and Stewart, 2002). However, the extreme cost of the 
equipment and its continuous use for other assessments limits its availability for 
research (Wagner and Heyward, 1999). 
Dual energy X-ray absorptiometry (DEXA) is a method initially aimed at 
assessing bone mineral density. However, several studies have found it to be a 
valid and reliable method for assessing BF (Wagner and Heyward, 1999, 
Bolanowski and Nilsson, 2001, Glickman et al., 2004). DEXA differentiates body 
weight into the components of lean soft tissue, fat soft tissue and bone, based on 
the differential attenuation by tissues of two levels of x-rays. The estimation of 
total and regional BF is thus based on a three-compartment model (bones, lean 
and fat mass) making DEXA the current reference method for BF assessment 
(Glickman et al., 2004). Its very low radiation and its relatively low cost (compared 
to CT and MRI) make it also very popular with researchers. However, the long 
assessment time (>15 minutes) does not allow for clinical use. 
Bioelectrical Impedance Analysis (BIA) is a relatively new method used for 
the estimation of BF in different populations. BIA devices emit a low-intensity 
electrical current that passes through the body. Electrodes placed at different sites 
on the body assess the resistance to the current. Due to differing water and 
electrolyte content BF produces a higher resistance compared to fat free mass 
(FFM); thus a high resistance indicates increased BF levels (Bolanowski and 
Nilsson, 2001). Devices with several electrodes are able to send the electrical 
current through different parts of the body and assess segmental body 
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composition (Demura et al., 2005). This method has become popular and widely 
recommended, as it is reliable, objective, practical, relatively inexpensive, and 
does not require highly trained personnel (Demura et al., 1999, Demura et al., 
2004). The validity of this method has been confirmed in various studies (Gray et 
al., 1989, Oppliger et al., 1992, Tanaka et al., 1999, Bolanowski and Nilsson, 
2001, Demura et al., 2004). Especially devices with multiple electrodes using 
single frequency electrical current generate highly reproducible measurements of 
total BF and segmental fat distribution (Demura et al., 2005, Ishiguro et al., 2006). 
Their correlation with the “gold standards” of dual-energy x-ray absorptiometry 
and hydrostatic weighing is 0.90 and 0.80 respectively, with a standard error of 
around 3.0, producing a co-efficient of variation of <10% (Demura et al., 2004). 
This suggests that bioelectrical impedance measurements are valid and suitable 
for body composition studies (Bolanowski and Nilsson, 2001, Demura et al., 2004, 
Demura et al., 2005). Patients are usually happy to undergo such a measurement 
due to its simplicity and similarity to normal weighing. 
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2.2.3 Epidemiology 
Until recently obesity was considered a condition affecting only residents of 
developed countries especially in the United States and Europe. In recent years 
however, obesity has become a world wide problem (WHO, 2000) increasing 
more rapidly in developing countries (Popkin and Gordon-Larsen, 2004).  Its 
global nature was first realised by the WHO in 1997 (WHO, 1998) (Figure 2), and 
by 2000 more than 1.1 billion people worldwide were overweight while more than 
400 million were obese (WHO, 2000). Almost 30.000 deaths per year are 
currently attributed to obesity and with the significant increases in its prevalence it 
is projected that obesity will overtake smoking as the major avoidable cause of 
premature death by 2030 (Haslam et al., 2006). Obesity has also significant 
economic costs as it results in almost 18 million days of absence from work due to 
illness each year; it also associates with increased hospitalisation and medical 
costs (Haslam et al., 2006).  
Specifically in the UK, 23% of men and 25% of women are obese (Rennie 
and Jebb, 2005). When overweight individuals are taken into account, almost 70% 
of males and more than 50% of females show BMI above 25kg/m2 (National Audit 
Office, 2001). Even though obesity increases with age, almost 20% of children 
under the age of 15 and almost 30% of young adults (15-20 years of age) are 
overweight or obese (Department of Health, 2002).  
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Figure 2: Prevalence of obesity in several different countries 
 
Adopted form: Organisation for Economic Co-operation and Development (http://www.oecd.org/home/) 
Percentage of total population (aged 15 and above) classified as obese (BMI> 30kg/m2). Depending on country, data were 
collected and published between 1996 and 2003. 
 
2.2.4 Aetiology 
Obesity is the result of a combination of genetic, behavioural, environmental, 
physiological, social, and cultural factors that affect energy balance and promote 
excessive fat deposition.  
2.2.4.1 Genetic Susceptibility 
Several studies have reported a familial trend of obesity. Children of lean parents 
are less likely to be overweight or obese; whereas those of obese parents are 
more likely to be obese as children or become obese in their adult life (Treuth et 
al., 2003). However, it is not entirely clear whether this is a result of genetics or 
merely of the lifestyle habits of the family. Children of obese individuals tend to 
consume more energy and exercise less compared to those of lean parents 
(Wardle et al., 2001).  
 Nevertheless, in studies of adoptees, the weight class (i.e. underweight, 
normal weight, overweight or obese) of the adopted children in adulthood was 
strongly related to the BMI of their biological parents, but it was unrelated to the 
BMI of their adoptive parents indicating a stronger influence of genetics rather 
than the environment (Stunkard et al., 1986). Similar conclusions were reached in 
a study of homozygotic twins. Following a 100-day overfeeding, twins gained body 
weight ranging from 4.3-13.3kg. The variance in response was significantly lower 
within pairs of twins rather than among pairs. The similarity in response within 
pairs was evident for body weight, percentage of fat, fat mass, and estimated 
subcutaneous fat (Bouchard et al., 1990). In other words, some twin pairs gained 
much more weight than other pairs. The concordance in response between 
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identical twins demonstrates the impact of genetics on weight gain (Pi-Sunyer, 
2002). 
 Up to date 22 genes have been shown to affect body weight (i.e. more than 
five positive studies for each gene), 127 candidate genes have been proposed as 
possible confounders (i.e. less than five positive studies) and several hundred 
mutations of these genes have been identified (Rankinen et al., 2006). However, 
one gene has shown consistent associations with both the development and the 
severity of obesity: the FTO gene (Dina et al., 2007, Frayling et al., 2007, Gerken 
et al., 2007, Scuteri et al., 2007, Fredriksson et al., 2008). This gene associates 
with an almost two-fold increased risk for obesity while carriers of a specific  
mutation weigh an average 3kg more than those carrying different mutations 
(Frayling et al., 2007). Worryingly, the prevalence of the weight-gain prone 
mutation is 45% among Europeans (International HapMap Consortium, 2003). 
Despite its wide prevalence and its strong association with obesity, the FTO gene 
or any other gene (or their combination) indeed, can not explain the steep 
increase in obesity rates of the last decades. Population-wide genetic alterations 
do not occur in the relatively short period of time during which obesity reached 
epidemic proportions (Racette et al., 2003). 
2.2.4.2 Energy Equilibrium 
According to the first law of thermodynamics (i.e. energy can neither be created 
nor destroyed, it can only change forms), the only way to accumulate excess body 
weight is through a positive energy balance. Even the slightest changes in energy 
equilibrium when sustained for a sufficient period of time can result in marked 
changes in body weight (Figure 3). 
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Figure 3: Energy equilibrium (McArdle et al., 2001) 
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When energy intake equals energy expenditure, body weight remains unchanged. 
When intake exceeds expenditure body weight increases whereas when 
expenditure exceeds intake, body weight decreases. 
 
A surplus of only 10 calories per day (i.e. almost two grams of 
carbohydrates or 1 gram of fat) would result in an annual increase of body weight 
by almost 0.5kg. If this imbalance was sustained throughout adulthood, it would 
result in significantly increased body weight by the age of 40-50 (Racette et al., 
2003). However, the control of energy intake and expenditure is a complicated 
procedure. In order to maintain body weight over the years, the two need to match 
within 0.17% per decade (Weigle, 1994). For that level of precision to be 
achieved, tight regulation of energy intake and expenditure is necessary.  
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 Several different mechanisms by which the body maintains energy 
homeostasis have been proposed, however the most potent and widely accepted 
is through leptin (Friedman, 2000). Leptin (from Greek: λεπτός meaning thin) is a 
hormone-like protein that regulates appetite and energy expenditure (Caro et al., 
1996) by reporting nutritional information to the hypothalamus (Friedman, 2000) 
(Figure 4). It is secreted by and in proportion to the adipose tissue mass 
(Considine et al., 1996). An increase in adipocyte size increases levels of 
circulating leptin leading to a reduction in appetite and increase in energy 
expenditure. On the contrary, a reduction in adipocyte size decreases leptin 
concentration resulting in increased appetite and reduced energy expenditure 
(Considine et al., 1996).  Its secretion is also affected by short-term food intake 
(Racette et al., 2003). Increased food intake increases levels of circulating leptin 
while decreased food intake decreases them (Kolaczynski et al., 1996, Racette et 
al., 1997). This mechanism allows for the required tight regulation of energy 
balance; however, obesity is considered a state of leptin resistance. Most obese 
individuals exhibit high levels of leptin while their energy intake remains increased 
and their energy expenditure reduced (Friedman, 2000). Whether leptin 
resistance is genetically controlled or it depends on environmental factors is not 
known, however most researchers suggest a significant influence of continuous 
increased energy intake that renders the hypothalamus “immune” to leptin 
(Racette et al., 2003).  
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Figure 4: Interactions between adipose tissue and leptin in the control of energy 
intake and expenditure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adopted form: Friedman, 2000; p.632. At stable weight (shown as15–20% body 
fat in this figure, which is the typical fat content of a non-obese male subject) the 
amount of circulating leptin elicits a state in which food intake equals energy 
expenditure. Increasing leptin levels result in negative energy balance (energy 
expenditure < food intake), whereas decreasing levels lead to positive energy 
balance (food intake > energy expenditure). These effects maintain constancy of 
fat cell mass within a relatively narrow range. Evidence further suggests that the 
intrinsic sensitivity to leptin is reduced among the obese and that the set point for 
body fat content is thus increased (designated as 30–35% in the bottom panel). 
Most obese individuals have high leptin levels and thus enter a state of negative 
energy balance when weight is reduced and leptin levels fall (Friedman, 2000). 
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2.2.4.3 Energy Intake 
In modern society a large number of eating establishments provide a large variety 
of inexpensive, tasty but most importantly time-saving meals. Food manufacturers 
strive to enhance the appearance, flavour, and portion size of their products and, 
through advertisement, promote over-consumption (Racette et al., 2003). The 
ease of access and omnipresence of such food, which often is of high calorific but 
low nutrient content, leads to the belief that its consumption is safe and healthy, 
diverting people away from cooking and eating at their own place (McCrory et al., 
1999). This has led to a small but significant increase in energy intake over the 
past 20 years. Dietary surveys and food disappearance data indicate an increase 
in caloric intake in Westernised countries of about 200kcal/week (Nielsen et al., 
2002). A large proportion of these excess calories comes from the consumption of 
sweetened beverages and dietary fats which account for almost 25% total daily 
intake among young adults (Rajeshwari et al., 2005, Striegel-Moore et al., 2006). 
At the same time the consumption of “healthy” calories, derived from fruits and 
vegetables, remains below recommended levels (Caballero, 2007).  
 However, the extent to which the above listed changes in eating habits are 
responsible for the obesity epidemic is still under intense debate. The increase in 
daily caloric intake is partly counterbalanced by the increases in height (leading to 
increased energy requirements by the body) observed in the population globally 
over the past decades (Caballero, 2007). Moreover, fat intake over the last 
decades has decreased and its associations with body fat are not consistent 
(Willett and Leibel, 2002). Thus several authors suggest that what has changed in 
terms of energy intake is not the amount of food or type of nutrients but the ease 
of access to it (Racette et al., 2003, Rosmond, 2004, Caballero, 2007).  
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2.2.4.4 Energy Expenditure 
Total daily energy expenditure (TDEE) is composed of three major aspects: 
resting energy expenditure (REE), thermic effect of feeding (TEF) and thermic 
effect of exercise (TEE). REE is the amount of energy required by the body to 
maintain physiological function and accounts for almost 70% of TDEE in 
sedentary individuals (Poehlman, 2002). It is largely dependent on the amount 
FFM (i.e. muscle and organ mass) with active individuals exhibiting both more and 
better quality FFM (Poehlman, 1989, Poehlman et al., 2002). TEF is the amount 
of energy required by the body to process food and store nutrients and depending 
of meals size, it accounts for 10-15% of TDEE (Swaminathan et al., 1985). TEF 
increases linearly with increasing calorific content, but it is relatively independent 
of the type of food (D'Alessio et al., 1988). However, obese individuals are 
suggested to have limited TEF in response to fat ingestion (Swaminathan et al., 
1985). TEE is the most changeable component of TDEE. It accounts for 20-30% 
of TDEE in sedentary individuals but may reach up to >50% in athletes or 
exercising individuals (Poehlman, 1989). In addition to the direct increases in 
TEE, exercise is also known to increase REE over a period of 24-72hours 
resulting in even greater TDEE (Stavropoulos-Kalinglou, 2002). Exercise is also 
an effective means of increasing FFM, thus resulting in long-term REE increases 
as well (Poehlman, 1989). As such exercise is the major contributor to changes in 
TDEE and even small alterations in it might affect positively or negatively energy 
balance (Poehlman et al., 2002).  
In modern society however, industrialisation and the numerous 
technological advances have enabled humans to evolve from hunter-gatherers to 
highly sedentary individuals; they rely entirely on several different machines that 
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perform, once energy-consuming, daily activities. Similarly, changes in the 
educational systems and family structure have led to reductions in physical 
education in schools and to increases in the number of children who stay indoors 
after school (Racette et al., 2003). This promotes sedentary habits such as 
television watching or use of video-games, instead of physical activity (Whitaker et 
al., 1997), which are also accompanied by consumption of snack-like diet (Kubo 
et al., 2008). These changes have coincided with the increases in the prevalence 
of obesity and appear to be the most potent explanation for it. However, obesity is 
most likely a result of a combination between genetic predisposition and lifestyle 
with a relative contribution of 30% and 70% respectively (Pi-Sunyer, 2002).  
2.2.5 Disorders Associated with Obesity 
Obesity predisposes to a large number of different health conditions and also 
associates with increased mortality (Calle et al., 1999). Life expectancy of obese 
individuals is decreased by 6-7 years and due to the large number of such 
individuals in the modern societies, some researchers have suggested that life 
expectancy in several countries could potentially be reduced for the first time in 
more that two centuries (Olshansky et al., 2005). Known complications of obesity 
are listed in Table 8, however only its associations with CVD and inflammation are 
further discussed. 
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Table 8: Disorders associated with obesity (Bray et al., 1998) 
System Condition 
Cardiovascular 
angina (RR= 1.8 both genders) 
myocardial infarction (RR= 1.5 males, 3.2 females) 
congestive heart failure (12% attributable to obesity) 
high blood pressure (RR= 2.6 males, 4.2 females) 
high cholesterol  
deep vein thrombosis and pulmonary embolism  
Endocrine and 
reproductive 
diabetes mellitus (RR= 5.2 males, 12.7 females) 
polycystic ovarian syndrome 
menstrual disorders 
infertility 
complications from pregnancy 
birth defects 
Musculoskeletal 
hyperuricemia / gout: (RR= 2 males, 3 females) 
immobility  
osteoarthritis (RR= 1.9 males, 1.4 females) 
low back pain  
Neurological 
stroke (RR= 1.3 both genders) 
headache  
carpal tunnel syndrome  
dementia  
idiopathic intracranial hypertension  
Cancers 
breast  
esophageal  
colorectal (RR= 3 males, 2.7 females) 
liver  
gallbladder (RR= 1.8 both genders) 
pancreatic  
stomach, prostate  
endometrial, cervical  
ovarian (RR= 1.7 females) 
kidney  
non-Hodgkin's lymphoma  
multiple myeloma  
Gastrointestinal 
gastro-esophageal reflux disease 
fatty liver disease  
cholelithiasis 
hernia  
Respiratory 
obstructive sleep apnea 
obesity hypoventilation syndrome  
asthma 
complications from general anaesthesia  
Psychological 
Depression in women 
low self esteem  
body dysmorphic disorder  
social stigmatization 
suicide (RR=2 both genders) 
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Skin 
stretch marks  
acanthosis nigricans  
lymphedema  
cellulitis  
carbuncles  
intertrigo  
Genitourinary 
erectile dysfunction  
urinary incontinence  
chronic renal failure 
hypogonadism 
stillbirth  
RR= relative risk 
2.2.5.1 Cardiovascular Disease 
CVD is probably the most readily recognisable effect of obesity. Obese individuals 
are at significantly higher risk for developing CVD compared to their lean 
counterparts. The exact links between obesity and CVD are not clear. However, 
the associations between obesity and classical CVD risk factors (i.e. 
hypertension, dyslipidaemia and insulin resistance) are well established. Excess 
adipose tissue releases nonesterified fatty acids in the circulation, which overload 
the liver and muscles with lipids. This increases lipolysis, while reducing glucose 
uptake and utilization by the cells. The resulting increase in circulating glucose 
stimulates insulin production, and eventually leads to insulin resistance (Bray et 
al., 1998). Endothelial function is also impaired causing arterial stiffness and 
hypertension (Zizek et al., 2001). Obesity may also increase CVD risk by reducing 
adiponectin. Adiponectin is a hormone secreted by adipocytes responsible for 
glucose regulation and fatty acid catabolism. Decreased levels of this hormone 
have been associated with insulin resistance and hyperlipidaemia (Ukkola and 
Santaniemi, 2002). Other mechanisms by which adiposity might increase CVD 
risk is the activation of the rennin-angiotensin-aldosterone system, which in turns  
increases sympathetic activity and renal sodium reabsorption leading to 
hypertension (Bray et al., 1998). 
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2.2.5.2 Inflammation 
In recent years adipose tissue has been recognised as a potent endocrine and 
paracrine organ capable of synthesizing and releasing into the bloodstream an 
important variety of peptides and non-peptide compounds that may play a role in 
cardiovascular homeostasis and inflammation (Mohamed-Ali et al., 1998). Among 
others, adipose tissue is a significant source of TNFα, IL-6, leptin and adiponectin 
(Poirier et al., 2006). Increases in BMI result in higher levels of circulating TNFα, 
IL-6, and leptin and lower levels of adiponectin; reductions in BMI have the 
opposite results. In vivo, almost 30% of the total circulating concentrations of IL-6 
originate from adipose tissue (Poirier et al., 2006). This is of importance because 
IL-6 modulates CRP production in the liver (Yudkin et al., 1999), and CRP (which 
is elevated in obesity) may be a marker of a chronic inflammatory state that can 
trigger acute coronary syndrome (Ridker, 2007). 
 The mechanism by which increased adiposity results in inflammation is not 
clear; however adipose hypoxia seems to be the most likely explanation. In order 
to facilitate fat storage, adipocytes have to expand in size, as differentiation of 
pre-adipocytes to adipocytes in this tissue is limited. Enlarged adipocytes show 
consistent low-grade inflammation (Matsuzawa, 2005). Recent studies have 
attributed this to localised tissue hypoxia (Trayhurn and Wood, 2004, Hosogai et 
al., 2007, Ye et al., 2007). Adipose tissue has limited vascularisation and a small 
number of mitochondria (Ailhaud and Hauner, 1998) resulting in its relatively poor 
oxygenisation; enlargement of adipose cells further limits oxygen delivery to them 
(Trayhurn and Wood, 2004). This results in a dysregulation of the expression and 
secretion of pro- and anti- inflammatory cytokines (i.e. increased IL-6 and TNFα 
and decreased adiponectin) (Hosogai et al., 2007, Wang et al., 2007, Ye et al., 
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2007, Trayhurn et al., 2008). Increased levels of pro-inflammatory molecules have 
been implicated in the process of atherosclerosis (Ross, 1999), specifically by 
inducing endothelial dysfunction (Alexander, 1995, Bhagat and Vallance, 1997)- 
the first step of atherosclerosis. 
2.2.5.3 Subgroups of Obesity 
However, not all obese individuals exhibit increased CVD risk or inflammation and 
not all normal-weight individuals are metabolically healthy or free from CVD 
(Karelis et al., 2004). Two distinct subtypes of obesity have been identified 
(Karelis et al., 2004). The first subtype, termed metabolically-obese but normal-
weight (MONW), consists of individuals with normal weight who exhibit increased 
levels of insulin resistance and accumulation of other modifiable CVD risk factors 
(i.e. hypertension, dyslipidaemia) (Ruderman et al., 1981, Ruderman et al., 1982). 
The second subgroup, termed metabolically-healthy but obese (MHO), exhibits 
increased levels of body mass index (BMI) and body fat (BF) but no other 
metabolic complications (Sims, 2001). Significantly, both subtypes associate with 
different inflammatory profiles. MONW exhibit increased levels of inflammation 
compared to other normal-weight individuals (Hyun et al., 2008), while MHO 
exhibit reduced levels of inflammation compared to other obese individuals (Shin 
et al., 2006, Karelis and Rabasa-Lhoret, 2008).  
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2.2.6 Control of Obesity  
The aims of obesity treatment are to achieve and then maintain clinically 
significant weight loss, with the ultimate target of reducing the risk for, or severity 
of, obesity related diseases (Racette et al., 2003). Even a 5% reduction in initial 
body weight has been shown to significantly improve overall health and the risk 
for further complications (Volek et al., 2002, Wilson and Grundy, 2003). However, 
long-term success requires maintenance of a 10% reduction in body weight over a 
period of at least one year. Even though initial weight loss is difficult, its 
maintenance is an even greater challenge both for health professionals and for 
patients themselves; only 1/5 of the patients who achieve initial weight loss 
manage to retain it for the first year and even less for longer periods of time (Wing 
and Hill, 2001). Thus any weight loss regimen should be designed according to 
the individual needs of each patient and utilise all necessary modes of weight 
reduction (Racette et al., 2003).  
2.2.6.1 Diet 
Dieting is probably the most widely utilised mode of weight reduction and forms 
the basis of most weight loss regimens. Diets attempt to provide a balanced 
nutrition focusing on increased nutrient intake (e.g. fibres, vitamins) and reduced 
caloric value of meals (Ayyad and Andersen, 2000). Their success depends highly 
on the total amount of calories they prescribe. Diet can be divided in two large 
categories: very-low-calorie diets (VLCDs, <800kcal/day) and low-calorie-diets 
(LCDs, 800-1500kcal/day). VLCDs are very effective in rapidly reducing weight; 
they result in a 2000kcal/day energy deficit which leads to a weight-loss of almost 
2kg per week (Orzano and Scott, 2004). Despite their short-term benefits, VLCDs 
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are only used in extreme cases of obesity or when rapid weight-loss is required 
(i.e. before an operation). They associate with a number of serious side-effects, 
such as gout, cholelithiasis, and hair loss, and long-term maintenance of weight-
loss is generally poor (Ayyad and Andersen, 2000). LCDs, on the other hand, are 
more commonly used. The modest restriction of energy intake results in 0.5-1kg 
weight loss per week and can be retained for longer periods (Orzano and Scott, 
2004). Such diets can be easily incorporated in the lifestyle of patients increasing 
adherence. In the long-term, a greater and more easily sustainable weight-loss 
compared to VLCDs is achieved (Racette et al., 2003).  
 Both dieting modes have the same drawback. Any energy restriction 
regimen results in a decrease of FFM (Ravussin et al., 1985); the decrease is 
proportional to the energy deficit (Mingrone et al., 2002). As stated previously, 
FFM is major contributor to REE; reductions in the former will decrease the latter. 
Consequently, since REE is the larger component of TDEE, this will result in a 
major decrease in TDEE. For the diet to maintain its effectiveness, energy intake 
needs to be constantly reduced. This might lead to cases of severe undernutrition 
and starvation (Racette et al., 2003) even among the obese (Mingrone et al., 
2002). Thus, in addition to individual design of dieting regimens, an intervention 
that maintains FFM and increases TDEE should be present during weight-loss. 
2.2.6.2 Exercise 
Exercise is the only such intervention. It is known to elicit both direct and indirect 
effects on energy expenditure. It directly increases TEE and indirectly REE 
(Poehlman, 1989, Poehlman, 2002, Poehlman et al., 2002, Stavropoulos-
Kalinglou, 2002). Several studies have investigated the weight reducing potential 
of exercise; however most have failed to notice significant changes in body weight 
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(Miller et al., 1997, Jakicic et al., 1999). The main reason for that is the short 
duration of the interventions (Donnelly et al., 2003) and also their complete 
reliance on BMI to assess obesity (Miller et al., 1997). Exercise in sedentary 
individuals can increase TDEE by an average of 300-500kcal/day resulting in 
almost 1kg weight-loss per month (The Look AHEAD Research Group, 2003). 
Thus, substantial changes in body weight require longer interventions. 
Nevertheless, what most studies have not assessed, are alterations in body 
composition. The reason that total weight does not change significantly is that 
while reducing fat, exercise also increases FFM. Because FFM is heavier that fat 
(McArdle et al., 2001), BMI seems unchanged or even slightly increased, 
especially in individuals who partake in resistance exercise (Nevill et al., 2004). 
Despite the lack of change in BMI, and most likely due to its effect of body 
composition, exercise has been shown to reduce risk for obesity-related diseases 
as well as inflammation in overweight and obese individuals, irrespective of weight 
change (Wood et al., 1988, Ross et al., 2000, Donnelly et al., 2003, Jeffery et al., 
2003).  
  In order for exercise to elicit its beneficial effects on body weight and 
composition, a minimum intensity and duration has to be achieved. For effective 
weight reduction, physical activity should produce a weekly energy expenditure of 
at least 2500kcal. The currently accepted guidelines for weight control, advocate 
at least three exercise sessions per week, of 45-60min duration at an intensity of 
>60% of an individual’s aerobic capacity (ACSM, 2005). However, fitting more 
than three hours of exercise in the very busy week of a modern person is usually 
hard and this can be the decisive factor for someone not to exercise (Lakka and 
Bouchard, 2005). For that reason, prescriptions involving different intensities and 
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durations of exercise have been utilised. Recent findings indicate that very short 
repetitive bouts of intensive exercise or indeed increases in habitual physical 
activity (i.e. the physical activity associated with everyday life and not purposeful 
exercise) are equally effective in producing the required energy expenditure for 
weight loss (Chambliss, 2005). While high intensity sessions are better suited for 
younger individuals and those without any significant medical conditions, 
increases in habitual physical activity are better tolerated by older people and 
those with medical conditions (Lakka and Bouchard, 2005). To further support the 
significance of habitual physical activity, habitually active people are less likely to 
develop obesity compared to their habitually inactive counterparts irrespective of 
participation in other forms of exercise (DiPietro, 1999). Thus, the newest 
interventions for the prevention and treatment of obesity, and related conditions, 
focus on increasing habitual physical activity and maintaining it at a high level 
throughout a person’s life.  
2.2.6.3 Medical Approaches 
Medication for weight-loss is also available. It is usually reserved for individuals 
who have already attempted to lose weight through diet and exercise and have 
failed or when co-existing medical conditions require rapid weight-loss (Racette et 
al., 2003). They are usually used in combination with lifestyle modification and 
seem to have an additive effect, in terms of both weight loss and weight 
maintenance thereafter (Franz et al., 2007). To date, three anti-obesity agents are 
available: Sibutramine, Orlistat and Rimonabant. Sibutramine is a centrally acting 
serotonin-norepinephrine reuptake inhibitor, which acts by inhibiting the reuptake 
of norepinephrine, serotonin and dopamine, thereby inducing satiety (Aronne, 
2007). Orlistat is a pancreatic lipase inhibitor which reduces fat absorption from 
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the intestine through inhibition of the hydrolysis of dietary fat into absorbable free 
fatty acids and monoacylglycerols (Aronne, 2007). Rimonabant is a cannabinoid 
type 1 receptor antagonist, which has been shown to reduce food intake via 
inhibition of the endocannabinoid system, which is known to play a role in the 
central and peripheral regulation of body weight and energy balance (Van Gaal et 
al., 2005) 
Surgery is the final resource for weight-loss. It is reserved solely for 
individuals with very high BMI (>40kg/m2) or those with a BMI of >35kg/m2 in the 
presence of other obesity-related comorbidities such as type-2 diabetes, sleep 
apnea, or heart disease (Brolin, 1996). There are several approaches to bariatric 
surgery, but all procedures are either malabsorptive, or restrictive. Malabsorptive 
procedures, most often referred to as “gastric bypass”, change the way the 
digestive system works. In these procedures the upper portion of the stomach is 
stapled to create a small (10–30 mL) reservoir that attaches directly to the 
jejunum via a Roux-en-Y limb (Deitel and Shikora, 2002). This reduces the 
capacity of the stomach resulting in limited food intake. Also bypassing the 
stomach and upper portions of the small intestine inhibits the absorption of some 
nutrients and calories (Racette et al., 2003). Weight-loss is rapid and patients can 
lose up to 70% of their excess body weight within six months (DeMaria et al., 
2002, Papasavas et al., 2002). More importantly though, results are maintained 
for several years (Mitchell et al., 2001, Mathus-Vliegen, 2006, Pajecki et al., 
2007). Restrictive procedures, usually referred to as “gastric stapling”, involve 
installing a constriction band around the upper portion of the stomach, effectively 
reducing its capacity. Its effectiveness depends on the patient; drastic dietary 
modifications are necessary to avoid complications, rupture of the band or even 
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death. This procedure is also less effective compared to gastric bypass in weight-
reduction thus it is not as common (Racette et al., 2003). In general both 
procedures have severe side-effects. Steatorrhea, vitamin and mineral 
deficiencies, and osteoporosis are common (Sugerman, 2000). Also wound 
infections, incisional hernia, and anastomotic leak with peritonitis may occur and 
could require further surgery for their treatment (Racette et al., 2003). Before a 
patient decides to undergo such surgery the risk and benefits should be clearly 
established; following surgery lifelong supplementation and medical follow-up is 
necessary (Racette et al., 2003).  
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2.3 Obesity in Rheumatoid Arthritis 
Most research in the field of RA has focused on disease prevention and 
treatment, mainly due to the strong associations of RA with joint problems and the 
resulting movement limitations (Kitas and Erb, 2003). The cardiovascular aspect 
of the disease has also attracted some attention with mainly observational studies 
assessing the associations of RA with CVD risk and outcome (Cobb et al., 1953, 
Goodson, 2002, van Doornum et al., 2002, Douglas et al., 2006). Even though the 
exact cause for the increased incidence and severity of CVD in RA is not known, it 
is most likely a combination of genetic predisposition (Gonzalez-Gay et al., 2007), 
modifiable CVD risk factors and the inflammatory burden of the disease 
(Gonzalez et al., 2008). 
 Even though obesity is a significant contributor to CVD in the general 
population (Bray and Bellanger, 2006), it has received limited attention in RA. BMI 
is routinely assessed in most rheumatology clinics and consistently reported in RA 
research. However, it is mainly used as a demographic characteristic of the 
population and it is usually omitted form further analyses or interpretations. In the 
studies that include BMI in their analyses, it is considered as a confounding factor 
against which data should be corrected and not a primary or even a secondary 
outcome that could directly influence aspects of the disease or other conditions. 
Very few studies have addressed obesity as such and these studies are reviewed 
below.  
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2.3.1 Definition and Prevalence 
Most of the studies assessing body weight in RA use the definition of the WHO 
(WHO, 2000) for overweight and obesity. Patients with a BMI between 25-
30kg/m2 are classified as overweight and those with a BMI>30kg/m2 are classified 
as obese. Even though this definition is valid for the general population and can 
identify individuals at increased risk, it has been proven inaccurate for certain 
populations with altered body composition. For example, Asian-Indians exhibit 
increased levels of fat for a given BMI (WHO, 2004), while athletes exhibit 
increased levels of FFM (Nevill et al., 2004).  For the former group new BMI cut-
off points that better identify individuals at increased risk for health complications 
have been established (WHO, 2004), while for the latter group BMI is considered 
an inaccurate measure of CVD risk (Nevill et al., 2004). As discussed earlier 
(Section 2.1.7.2) RA associates with metabolic alterations that lead to reduction in 
FFM without any obvious change in total body weight. Thus, like Asian-Indians, 
RA patients should exhibit reduced FFM for a given BMI and the general BMI cut-
off points might not be able to identify individuals with increased levels of BF. 
However, in all the studies reviewed herein, the general BMI cut-off points have 
been used to assess overweight and obesity. 
 The mean BMI reported in most RA studies (ranging from 26.5-28.2kg/m2) 
(Gordon et al., 2002b, Saravana and Gillott, 2004) is similar to that of the general 
population in the UK (about 27.1kg/m2) (The Information Centre NHS, 2005). 
Prevalence of overweight and obesity, as assessed by the general BMI cut-off 
points, in RA varies according to geographic area. A world-wide study identified 
18% (Naranjo et al., 2008) of RA patients as obese and a UK based study found 
31% (Armstrong et al., 2006). However, in both studies >60% of RA patients 
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exhibited BMI above the desired levels (i.e. 25kg/m2). Results from other studies 
lie within this range indicating that overweight and obesity, even when assessed 
based on the general BMI cut-offs, is highly prevalent among patients with RA 
(Gordon et al., 2002a). 
2.3.2 Obesity as a Risk Factor for the Development of Rheumatoid 
Arthritis 
Due to the long-established close association of obesity with osteoarthritis several 
authors have investigated the potential association of obesity with the risk for the 
development of RA. In the first studies on this matter, obesity in females was 
associated with an odds ratio (OR) for RA of 1.4 [95% confidence intervals (CI) = 
1.0-2.0] (Voigt et al., 1994); in a larger sample including both genders the 
association of obesity with RA was even greater (OR= 3.74, 95% CI: 1.14-12.27) 
(Symmons et al., 1997). Newer studies however, have failed to produce 
consistent results. Obesity has been found not to confer any risk for the 
development of RA whatsoever (Bartfai et al., 2007), and to influence its 
development (OR= 3.45; 1.73-6.87) only in a small proportion of RA patients who 
test negative for anti-cyclic citrullinated peptide (anti-CCP) antibodies (Pedersen 
et al., 2006). Even though the reason for this discrepancy is not discussed by the 
authors it seems that methodological differences and tight standardisation for 
possible confounders in recent studies eliminate the previous positive findings for 
the association of obesity with RA development.  
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2.3.3 Obesity and Disease Activity 
Adipose tissue, initially considered to be simply an energy reservoir, is now 
recognised as a metabolically active tissue. It secretes a number of bioactive 
proteins called adipokines or adipocytokines, including TNFα and IL-6 (Pi-Sunyer, 
2006). Both molecules are implicated in the development and progression of RA 
(Buch and Emery, 2002).This could potentially result in more active disease in 
obese RA patients.  
Studies in patients with early RA, of up to 3 years duration, surprisingly 
suggest that obesity may protect against joint damage (Kaufmann et al., 2003, 
Westhoff et al., 2007, van der Helm-van Mil et al., 2008). On a similar line, 
changes in body weight over 1-year do not correlate with changes in disease 
activity during the same period (Morgan et al., 1997). The protective effect seems 
to be present before the diagnosis of the disease, with overweight or obese RA 
patients exhibiting less joint damage than their normal weight counterparts at the 
time of diagnosis (Westhoff et al., 2007), and to continue during the first few years 
of the disease, with joint damage progressing less rapidly in obese than in normal-
weight RA patients (Kaufmann et al., 2003, Westhoff et al., 2007, van der Helm-
van Mil et al., 2008). However, it is not entirely clear whether this is solely an 
effect of increased weight, for example through increased mechanical loading 
stimulating bone synthesis (Tremollieres et al., 1993), or also a reflection of joint 
damage at the time of first diagnosis. 
In contrast to these observations, studies in unselected (for disease 
duration) RA patients suggest that obesity leads to worse quality of life (Garcia-
Poma et al., 2007) and a narrowing in the joint space of the knees (Hollingworth et 
al., 1982); indicating that its potential protective effects in early RA are diminished 
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or reversed later on in the course of the disease. Interestingly, all studies suggest 
a deleterious effect of low BMI in disease duration and quality of life. Most likely, 
significantly reduced BMI is the result rather than the cause of highly active 
disease over many years (Roubenoff et al., 1994). However, to date no studies 
have investigated the associations of obesity with disease activity and joint 
damage in patients with established RA.  
2.3.4 Obesity and Risk for Cardiovascular Disease 
Obesity is a well established and independent risk factor for CVD (Bray and 
Bellanger, 2006). It is also considered to be the underlying cause of many other 
CVD risk factors such as hypertension, dyslipidaemia, and insulin resistance 
(Grundy et al., 2004) and a potent contributor to the inflammatory state of 
atherosclerosis (Berg and Scherer, 2005). In RA several studies have investigated 
the effects of obesity on CVD risk and their results are conflicting. Obese RA 
patients are likely to exhibit classical CVD risk factors (Armstrong et al., 2006) and 
obesity significantly contributes to the increased 10-year CVD risk event 
probability of RA patients (Kremers et al., 2008) as calculated with the 
Framingham formula (Anderson et al., 1991). However, in patients with low BMI 
(<18.5kg/m2) 10-year CVD risk event probability was even higher (Kremer, 2001). 
In a longitudinal study of RA patients results were different for high but similar for 
low BMI. Patients with a BMI of >30kg/m2 exhibited reduced all-cause mortality 
(Escalante et al., 2005). As BMI decreased, mortality increased and patients with 
a low BMI (<20kg/m2) exhibited significantly increased rates of mortality. On the 
same line are data from the QUEST-RA study, a large multinational study, that 
found no associations between obesity and CVD morbidity (Naranjo et al., 2008).  
 79
 Thus, there is evidence to suggest the presence of reverse epidemiology. 
This refers to paradoxical and counterintuitive epidemiologic associations 
between survival outcomes and traditional CVD risk factors such as obesity 
(Horwich and Fonarow, 2007). In diseases associated with accelerated loss of 
FFM, over-nutrition (a long-term killer) might protect against the significant health 
consequences of reduced FFM while under-nutrition might enhance muscle 
wasting and through it accelerate mortality (Kalantar-Zadeh et al., 2007). 
However, before we jump to conclusions some significant limitations of 
these studies need to be noted. In the study of Escalante and colleagues (2005) 
the protective effect of BMI was present only when the erythrocyte sedimentation 
rate (ESR), an indicator or disease activity, was low. This would suggest a more 
significant influence of disease activity rather than obesity in the CVD of RA 
patients. This could also bias the results as a low disease activity associates with 
higher levels of FFM (Roubenoff et al., 1994). Furthermore, lower disease activity 
is usually achieved through medication. Stable and long exposure to medication, 
that leads to effective control of inflammation, is also associated with reduced 
CVD risk (Kremers et al., 2008). Finally, obesity on its own is a determinant for 
CVD treatment. Obese individuals are more likely to receive medication for CVD 
risk factors modification than their non-obese counterparts (Narbro et al., 2002, 
Chobanian et al., 2003), thus CVD medication should always be included in 
studies investigating the effects of obesity on CVD risk in RA patients as well as in 
the general population. Based on the above, the associations between obesity 
and CVD risk in RA are far from clarified.  
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2.3.5 Control of Obesity 
The control of obesity in RA has received minimal scientific attention. This search 
of the literature was able to identify only two studies aimed at reducing body 
weight of patients with RA. The first used caloric restriction over a period of 12 
weeks, in combination with a protein-rich diet and low-intensity physical activity. 
This intervention resulted in a small weight loss of 2.7kg. However, most of the 
weight loss (1.7kg) came form a reduction in FFM (Heitmann et al., 1994). The 
second study had a similar design (i.e. 12 weeks of caloric restriction with protein 
supplementation) but utilised physical activity of moderate intensity. The results 
indicated a 4.5kg reduction in body weight with only a minimal loss of FFM (>1kg) 
(Engelhart et al., 1996). These findings are in line with recent data of studies 
investigating ways to reverse rheumatoid cachexia. Marcora et al. (2005a) 
investigated the effects of 12 weeks of protein supplementation on lean body 
mass of RA patients. They suggested that increased protein intake is able to 
reverse rheumatoid cachexia and significantly increase lean body mass in such 
patients. However, they were not able to find any changes in body weight or body 
fat. The same group also investigated the effects of a 12-week resistance 
exercise intervention on components of rheumatoid cachexia. Lean body mass 
was again increased as a result of the exercise; interestingly, and even though 
that was not one of the primary objectives of the trial, total body fat was marginally 
(1.1%) but significantly reduced and trunkal fat showed a tendency to reduce 
(Marcora et al., 2005b). 
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2.3.6 Conclusions 
From this short review of the limited literature on obesity in RA, several questions 
arise. First of all, the definition of overweight and obesity used in RA (i.e. that of 
the WHO designed for the general population) might not be accurate for RA 
patients. Secondly, the associations of obesity with disease activity and CVD are 
conflicting and the methodology used in most studies has several potential 
limitations. Also, ways to counteract obesity in RA need to be developed and 
tested, always taking into account the wasting state of these patients. However, in 
order to do that, the potential causes of obesity in RA need to be identified. 
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Chapter 3: Aims and Hypotheses 
The principal aims of the present project were to: 
1. a) Investigate whether BMI and BF differ between patients with RA, 
osteoarthritis (OA), or healthy controls and within RA patients according to 
disease state (e.g. active vs. inactive, early vs. established disease); b) if 
necessary, develop RA specific measures of adiposity; c) assess the 
associations of BMI and BF with RA characteristics in patients with well-
established disease. 
2. Quantify the associations of BMI with classical CVD risk factors in a large 
sample of RA patients. 
3. Identify subgroups of the RA population that exhibit phenotypic characteristics 
different from those expected for their BMI class, and investigate the health 
effects of obesity in these subgroups. 
4. Identify factors that might reduce or increase BMI and BF in RA. 
 
For each of the above aims the following hypotheses were made: 
1. a) RA patients might have increased BF compared to both patients with OA 
and healthy controls of the same BMI; b) Overall BMI, and the prevalence of 
overweight and obesity, in RA patients might also be increased; c) RA patients 
with highly active and/or long-standing disease might exhibit even higher BF 
but not BMI levels. 
2. Most likely, RA specific measures of adiposity will be required. These would 
have to take into account the muscle wasting associated with the disease.  
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3. Due to increased BF, obese individuals are likely to have higher levels of 
inflammation compared to normal-weight individuals. This might also affect 
joint damage. 
4. Increasing BMI and BF are expected to associate with worse CVD profile. 
Most likely, use of CVD medication will further increase this association. 
5. Some normal-weight patients are expected to exhibit increased CVD risk while 
some obese patients reduced. This might also affect their inflammatory status.  
6. The factor most likely to influence BMI and BF of RA patients is inflammation 
and its control through medication. To a lesser extent, physical activity and diet 
might also affect these factors.  
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Chapter 4: Methodology 
4.1 Participants 
For the purposes of this project a total of 1167 volunteers were assessed. Of them 
1042 were RA patients, 43 were patients with OA, and the remaining 82 healthy 
controls. In the first study, data derived from 516 RA patients were compared 
against all 43 OA patients and all 82 controls. In studies two, three, four and five 
data from a different set of 400 patients with RA were used. Data from the 
remaining 126 RA patients were used in the sixth and final study. All RA patients 
met retrospective application of the 1987 American College of Rheumatology 
(ACR) classification criteria for RA (Arnett et al., 1988). Individuals with diagnosed 
OA of the hip (Altman et al., 1991) or knee (Altman et al., 1986) were included in 
the OA groups, and individuals who by self-report did not have any known clinical 
conditions and were taking no medication were included in the healthy control 
group. For the RA and OA groups, consecutive patients attending routine 
rheumatology or orthopaedic outpatient clinics at the Dudley Group of Hospitals 
NHS Trust, UK, were invited to participate. Staff from the same hospital as well as 
the University of Wolverhampton, Walsall Campus, UK, formed the healthy control 
group. All participants were given verbal and written information about the project 
and signed an informed consent according to the declaration of Helsinki (World 
Medical Association, 2000).  Due to the specific requirements of each study, 
further details about the participants are presented in the methods section of the 
respective studies.  
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4.2 Procedures 
Participants were asked to visit the testing venue (Rheumatology Unit of the 
hospital) early in the morning following a 12hour overnight fast. They were also 
instructed to keep their physical activity levels to a minimum on the day prior to 
the assessment. All volunteers were subjected to the same data collection 
procedures overseen by the same trained investigators. Upon arrival, participants’ 
anthropometric characteristics and body composition were assessed. Then, 
participants were asked to rest for 10 minutes on a bed placed in a quiet, 
thermoregulated room (21-23oC) with dimmed lights. Conventional CVD risk 
factors and RA disease characteristics were assessed thereafter. A blood sample 
was also drawn. 
 For the participants of the final study, a physical activity questionnaire was 
completed following the above assessments. Also a food diary was given to the 
patients with instructions on how and when to fill it in. 
4.3 Assessments  
All assessments are described here in full detail. However, they are also 
presented in the studies to help the reader. The information presented in the 
studies is only a summary of the individual assessments. 
4.3.1 Anthropometry and Body Composition 
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body 
composition was assessed by BIA, using a Tanita BC-418 MA Segmental Body 
Composition Analyzer, which incorporates 8 tactile electrodes (Tanita 
Corporation, Tokyo, Japan). This apparatus, measures total body mass (i.e. body 
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weight) to the nearest 0.1kg and assesses body composition in terms of 
percentage BF, fat mass, FFM, and total body water, as well as fat distribution in 
different body segments (abdominal and peripheral fat). The specific device has a 
standard error of <3% when standard procedures are followed (Tanita, 2002). 
These procedures aim at reducing alterations in hydration status. As stated in the 
relative section of the literature review (2.2.2.3, p. 40-41), BIA essentially 
assesses water and electrolyte content of different parts of the body (Bolanowski 
and Nilsson, 2001). Thus, patients were asked to refrain from excessive fluid 
consumption the day before the assessment, and they were instructed to drink 
two pints of water in the morning prior (1-2 hours) to the assessment. After initial 
manual entry of their demographic details, participants stood bare-footed on the 
analyzer and held the handgrips provided until the apparatus printed the results. 
BMI (kg/m2) was calculated on the basis of measured height and weight. Waist 
circumference was measured using a Seca 200 Circumference measuring tape 
(Seca gmbh & co. kg., Hamburg, Germany). Cut-offs for increased waist 
circumference were >102cm for males or >88cm for females (Lean et al., 1995). 
4.3.2 Assessments of Aspects of Rheumatoid Arthritis 
4.3.2.1 Erythrocyte Sedimentation Rate 
ESR is an additional measure of disease activity; however it may reflect longer-
term effects of the disease than CRP. ESR was measured using a Starrsed 
compact (Mechatronics BV, Netherlands). A total of 10ml of undiluted blood, anti-
coagulated with EDTA is inserted in a vertical tube. The sedimentation (in 
millimetres) of the red blood cells within one hour gives the value of ESR. 
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4.3.2.2 C-reactive Protein 
CRP is a measure of acute RA activity closely associated with inflammation. It 
was measured with a Vitros® 5.1 FS chemistry system (Johnson and Johnson 
Inc., Langhorne, PA, USA). This system uses a slide which is a multi-layered 
analytical element coated on a polyester support. A drop of the patient’s serum or 
plasma is deposited on the slide and is evenly distributed by the spreading layer 
to the underlying layers. Measurement is based on an enzymatic heterogeneous, 
sandwich immunoassay format. In this format a derivative of phosphorylcholine is 
covalently bound to polystyrene polymer beads and the presence of calcium 
serves as a capture agent (Park et al., 2004). Monoclonal anti-CRP antibody 
labelled with horseradish peroxidase serves as a signal generator. CRP in the 
blood sample binds to the phosphorylcholine-linked capture beads and the anti-
CRP antibody labelled with horseradish peroxidase to form an insoluble sandwich 
complex in the first incubation. This is subsequently washed with a specific liquid 
which also provides the hydrogen peroxide for the enzyme mediated oxidation of 
leuco-dye. The reflection density of the dye is measured after a second wash 
giving a reflection density directly proportional to the concentration of CRP in the 
sample. 
4.3.2.3 Disease Activity 
The disease activity score 28 (DAS; Appendix 1) was used to assess disease 
activity, being a composite assessment of acute and longer-term disease activity. 
It consists of three components (Prevoo et al., 1995). Initially pain and swelling of 
28 joints of the patients (i.e. shoulders, elbows, wrists, hands and knees) are 
assessed by gently squeezing them. Then the patient grades his/her overall 
health during the last week on a visual analogue scale from zero (best ever 
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health) to 100 (worst ever health). The values from these assessments together 
with current ESR are included in a formula which gives the DAS. 
4.3.2.4 Physical Function 
Physical function is the reflection of chronic disease activity and associates with 
the long-term severity of the disease. It was assessed using the Anglicised 
version of the 40-item Stanford Health Assessment Questionnaire (HAQ; 
Appendix 2) (Kirwan and Reeback, 1986). Participants rate their ability (over the 
past week) to carry out 20 activities within eight aspects of daily living 
(dressing/grooming, rising, eating, walking, hygiene, reach grip and errands/tasks) 
on a four-point scale from ‘without any difficulty’ to ‘unable to do’. For each aspect 
patients also respond whether they receive assistance from people or use specific 
devices. The HAQ is internally consistent (α ≥.89) and has excellent pre- to post-
physician visit temporal stability (r =.99). Physiotherapists’ ratings have excellent 
agreement with RA patients’ ratings (Treharne et al., 2006, Witney et al., 2006). 
4.3.2.5 Cytokines 
Pro-inflammatory cytokines (i.e. IL-1, IL-6 and TNFα) were assessed in stored 
serum in batches. As soon as the blood sample was collected, it was centrifuged 
at 4000rpm for 10 minutes (relative centrifuge force = 1650 g). The supernatant 
was collected in aliquots and frozen immediately at -70oC. Specimens were 
analysed, in groups of 48 (analyses were duplicated to assure accuracy of the 
results), using multi-analyte Biochip Array Technology (Evidence analyzer, 
Randox, USA). 
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4.3.2.6 Rheumatoid Factor and Anti-cyclic Citrullinated Peptide Antibodies 
Screening for the presence of rheumatoid factor (RF) and anti-CCP antibodies is 
carried out by a manual particle agglutination method (MAST diagnostics, 
Merseyside, UK). The test for RF and anti-CCP is based upon the immunological 
reaction between their concentration in serum and the corresponding human 
antibodies which are coated onto polysterene latex particles. If serum containing 
either of the two is mixed with the latex, a resulting agglutination will be observed. 
Positive tests are quantified using an Enzyme-Linked Immuno-Sorbent Assay (i.e. 
ELISA) test. Diluted serum is added to wells coated in purified antigen; the 
antibodies bind to the antigen. This is incubated at room temperature and 
unbound material is rinsed away. Then horseradish peroxidase conjugated anti-
IgG monoclonal antibody is added and binds to immobilised antibodies. After a 
second incubation and rinse cycle tetra-methyl benzidine substrate is added to 
each well. The presence of the antigen-antibody-conjugate complex turns the 
substrate a dark blue colour. Addition of a stop solution turns it yellow; the colour 
intensity measured by photospectrometry is proportional to the concentration of 
the antibodies in the original sample. 
4.3.2.7 Other Assessments of Rheumatoid Arthritis 
Review of patients’ clinical notes revealed duration of RA symptoms, current 
medication as well as joint surgery. Presence of joint erosions was assessed on x-
rays of hands and wrists by two independent rheumatologists; in case of 
disagreement, x-rays were jointly reviewed and a consensus opinion reached.  
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4.3.3 Assessments of Cardiovascular Parameters 
4.3.3.1 Blood Pressure  
Blood pressure (BP) was assessed three times on the brachial artery, using a 
Datascope Accutorr Plus (Datascope, Montvale, NJ, USA), while the patient was 
resting on a supine position. The average of the three measurements is reported 
herein. Patients with systolic BP≥140 and/or diastolic BP≥90 and/or receiving 
antihypertensive medication, were characterised as hypertensive (Williams et al., 
2004). 
4.3.3.2 Blood Lipids 
Triglycerides, total cholesterol, and high density lipoprotein (HDL) were measured 
using the same Vitros® 5.1 FS chemistry system (Johnson and Johnson Inc., 
Langhorne, PA, USA) as for the assessment of CRP. The same chip was used as 
well; however, instead of an enzymatic heterogeneous, this time a dye that binds 
to the chemical to be measured from the sample was used. This results in a shift 
in wavelength of the reflectance maximum of the free dye. The colour complex 
that forms is measured by reflectance spectrophotometry. The amount of 
chemically-bound dye is proportional to the concentration of the chemical being 
measured in the sample. 
In the case of low density lipoprotein (LDL), the kit was a dual chamber 
package instead of a chip that contains two different reagents. The first reagent 
selectively eliminates non-LDL cholesterol. The second reagent dissociates 
cholesterol from cholesterol esters and proteins and promotes the reaction with 
cholesterol esterase and cholesteroloxidase. Hydrogen peroxide is a by-product, 
which is then dyed and measured spectrophotometrically at 600nm.  
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Patients with increased levels of triglycerides (>1.7mmol/L), total 
cholesterol (>6.2mmol/L), LDL (>4.13mmol/L), decreased levels of HDL 
(<1.03mmol/L) or receiving lipid lowering therapy were characterized as 
dyslipidaemic (Expert Panel on Detection Evaluation and Treatment of High Blood 
Cholesterol in Adults, 2001). 
4.3.3.3 Insulin Resistance 
For the assessment of blood glucose, the same Vitros® 5.1 FS chemistry system 
(Johnson and Johnson Inc., Langhorne, PA, USA) as above was used and the 
same procedure as with cholesterol (not LDL) was followed. Insulin was estimated 
from serum stored at -20ºC. The method of detection involved a solid phase two-
site chemi-luminescence immunometric assay. The Immunolite 2000 insulin was 
used on the Immulite 2000 Analyser (Siemens Healthcare Diagnostics, Deerfield, 
IL, USA). Insulin resistance (IR) was evaluated from fasting glucose and insulin 
using the Homeostasis Model Assessment of insulin resistance (HOMA) 
(Radikova, 2003) and the Quantitative Insulin sensitivity Check Index (QUICKI) 
(Katz et al., 2000), and was defined as HOMA ≥ 2.5, QUICKI ≤ 0.333, presence of 
diabetes mellitus or use of anti-diabetic medication. 
4.3.3.4 Composite Assessments of Cardiovascular Risk  
The metabolic syndrome, a constellation of several risk factors was assessed 
according to the NCEP ATP III criteria (Grundy et al., 2004). Specifically, patients 
were diagnosed with the MetS if they presented three of the following: Increased 
waist circumference, high BP, high triglycerides, low HDL and/or fasting glucose 
above 110mg/dL. Smoking status was also noted and the Framingham 10-year 
CVD event probability score was calculated (Anderson et al., 1991).  
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4.3.4 Lifestyle Assessments 
4.3.4.1 Physical Activity 
The long version of the self-administered international physical activity 
questionnaire (IPAQ; Appenix 3) was utilized to record physical activity. This 
questionnaire is divided into five parts requesting information about the physical 
activities (job-related, transportation, housework, leisure time and time spent 
sitting) that the participants had undertaken over the previous seven days. The 
same nurse always helped the patients to fill in the questionnaire. The IPAQ has 
been extensively used for research purposes, and its validity and reliability have 
been assessed in 12 countries, including the UK (Craig et al., 2003). 
4.3.4.2 Energy Intake 
Energy intake was assessed with the use of a food diary (Appendix 4). This 
method requires the patients to keep a written record of anything they eat or drink, 
including portion sizes (Macdiarmid and Blundell, 1998). It is a relatively easy 
procedure that is considered valid and reliable, however obese individuals are 
known to underreport energy intake (Livingstone, 1995, Macdiarmid and Blundell, 
1998). In the present project, a simple three-day food diary was distributed to the 
participants. Relevant verbal and written instructions were given at the day of the 
assessment. They were asked to write in detail about all the food and drink they 
consumed over three non-consecutive days (including one weekend day) during 
the week following the assessment. They were also instructed to follow their 
normal diet. Total daily energy intake and percentage carbohydrate, fat and 
protein intake were calculated using diet analysis software (Recipe Calc 4.0). 
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4.4 Data Management and Analyses 
For all studies data were inserted in a purpose-designed spreadsheet (Microsoft 
Excel 2003) and audited for accuracy weekly. They were exported for analysis to 
The Statistical Package for Social Sciences version 15.0 (SPSS Inc. Chicago, IL, 
USA). The Kolmogorov-Smirnov test of normality assessed dispersion of the 
variables. Due to the complexity of the project several different analyses were 
used. These are described in detail in the respective studies. 
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Chapter 5: Studies 
5.1 Redefining Overweight and Obesity in Rheumatoid Arthritis  
(Published in the journal Annals of Rheumatic Diseases (2007), 66, 1316-21) 
5.1.1 Introduction 
Excess BF is a prominent health hazard (Van Pelt et al., 1997) significantly 
contributing to the development of cardiovascular disease (CVD) (Ross, 1999). 
About two-thirds of patients who have had a myocardial infraction (MI) exhibit 
increased body weight (Romero-Corral et al., 2006). Obesity increases the risk of 
coronary heart disease (CHD) through a number of different pathophysiological 
pathways, including insulin resistance, type 2 diabetes, hypertension and 
dyslipidaemia (Krauss et al., 1998, Pi-Sunyer, 2002). 
Assessments for overweight or obesity include the calculation of BMI (in 
kg/m2) or more accurate estimations of relative adiposity (BF) through a number 
of techniques (e.g., skinfold thickness, hydrostatic weighing, and bioelectrical 
impedance) (Nevill et al., 2004). BF estimations require sophisticated equipment 
and trained personnel, whereas BMI is easy to obtain and is widely used in the 
routine clinical setting.   
In the general population, BMI of <25, 25-30, and >30kg/m2 indicate 
healthy, overweight, and obese individuals and associate with low, medium, and 
high CVD risk, respectively (WHO, 1998, Calle et al., 1999). However, BMI is only 
a proxy of body fat (Wellens et al., 1996), and over recent years its validity has 
been questioned (Manson et al., 1995, Willett et al., 1995, Blew et al., 2002, Nevill 
et al., 2004, WHO, 2004, Romero-Corral et al., 2006). Overweight as defined by 
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BMI of >25, has poor specificity in detecting excess body fat in healthy men and 
women of all ages (Wellens et al., 1996) as well as in patients with coronary heart 
disease (Romero-Corral et al., 2006). In specific sub-populations, such as Indian-
Asian (WHO, 2004), women (Manson et al., 1995, Willett et al., 1995, Blew et al., 
2002), and large size athletes (Nevill et al., 2004), new BMI cut-off points have 
been suggested, that optimally reflect  BF and may better predict CVD risk.  
The weakness of BMI is that it does not distinguish between lean-body 
mass and fat mass. Consequently people of similar stature and weight, but 
different muscle content, will have the same BMI but different BF levels. This 
tends to be more evident in individuals with low BMI levels (Wellens et al., 1996). 
Such limitations of the BMI may explain the better cardiovascular outcomes 
observed in overweight and mildly obese patients with established CHD as 
compared to their normal-weight counterparts, who may have proportionately 
more BF (Romero-Corral et al., 2006). Therefore, although it is well established 
that CHD risk increases with advancing BMI levels (WHO, 1998), global cut-off 
points may be misleading for several populations.  
Central obesity poses a great risk for cardiovascular disease. Regional fat 
distribution, as measured by waist-to-hip ratio, has been proposed as a more 
accurate predictor of CHD risk than BMI (Hsieh and Yoshinaga, 1995, Rimm et 
al., 1995). Indeed, it has been suggested that obesity should be redefined based 
on waist-to-hip ratio instead of BMI, since waist-to-hip ratio is significantly 
associated with MI risk in most ethnic groups (Yusuf et al., 2005). However, its 
predictive strength can be negatively affected by gender and overall body weight 
(Li et al., 2006), in a way that pear- shaped or obese individuals might have 
optimal waist-to-hip ratio but increased overall body weight. More research is 
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necessary to identify the optimal definition of obesity as a predictor for CHD in the 
general population and specific sub-groups (Bray, 2004). 
Patients with RA have an increased risk for CHD events (Kitas and Erb, 
2003). RA is a chronic inflammatory disease which affects predominantly synovial 
joints, causing pain, swelling, stiffness and eventually irreversible damage and 
deformity, all of which may lead to significant reduction in physical activity. RA 
associates with increased mortality particularly from CHD (Kitas and Erb, 2003), 
most probably due to accelerated atherogenesis secondary to the metabolic and 
vascular effects of systemic inflammation (Stevens et al., 2005). Nearly two thirds 
of all individuals with RA experience involuntary loss of fat-free mass and 
progressively increased fat mass in the presence of stable or even slightly 
decreased weight, a condition referred to as rheumatoid cachexia (Rall and 
Roubenoff, 2004). The exact mechanisms causing rheumatoid cachexia remain 
undetermined, but muscle loss due to systemic inflammation and reduced 
physical activity may both contribute (Metsios et al., 2006). 
We hypothesised that for a given BMI, RA patients exhibit significantly 
higher proportions of fat mass than healthy individuals, or even than patients with 
movement restriction due to a non-inflammatory arthritis, such as OA. The 
possible consequences of this, in the context of the increased CVD mortality in 
RA, are obvious. In the present study we aimed to investigate whether BMI and 
BF differ according to arthritic disease (OA vs. RA) and within RA according to 
disease state (e.g. active vs. inactive, early vs. established disease). We also 
developed and validated RA-specific BMI cut-off levels and algorithms to calculate 
BF from BMI.   
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5.1.2 Methods  
Participants 
Consecutive patients attending routine rheumatology or orthopaedic outpatient 
clinics at the Dudley Group of Hospitals NHS Trust, UK, and healthy controls 
(Hospital and University staff) were invited to participate. The study had Local 
Research Ethics Committee approval by the Dudley Ethics Committee, and all 
volunteers provided informed consent.  The observation group (n=299) included 
174 volunteers with RA [1987 revised ACR criteria (Arnett et al., 1988)], 43 with 
OA of the hip (Altman et al., 1991) or knee (Altman et al., 1986), and 82 healthy 
controls (HC; individuals who by self-report did not have any known clinical 
conditions and were taking no medication). The validation group (n=342) 
consisted of RA patients only. Demographic and disease characteristics from all 
subjects appear in Table 9. 
Assessments 
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body weight 
was measured to the nearest 0.1kg. Body composition was assessed by 
Bioelectrical Impedance, using a Tanita BC-418 MA Segmental Body Composition 
Analyzer, which incorporates 8 tactile electrodes (Tanita Corporation, Tokyo, 
Japan). BMI (kg/m2) was calculated on the basis of measured height and weight. 
In RA patients, contemporary serological inflammation and clinical disease activity 
were assessed by the ESR, CRP and the DAS (Prevoo et al., 1995). Disease 
duration was recorded from review of the patients’ hospital notes. 
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Data management and analysis 
Data were inserted in a purpose-designed spreadsheet (Microsoft Excel 2003) 
and audited for accuracy weekly. They were exported for analysis to The 
Statistical Package for Social Sciences version 11.0 (SPSS Inc. Chicago, IL, 
USA). Preliminary evaluation of the variables using a Kolmogorov-Smirnov test of 
normality revealed that none of them required logarithmic transformation to reach 
normality. Means (sd) were calculated for all variables. 
The method of analysis was to define either BMI or BF as the dependent 
variable and then to incorporate all other known parameters thought to influence 
these measures of adiposity as either factors, in analysis of variance (ANOVA), or 
factors with covariates in analysis of co-variance (ANCOVA). Factors included 
gender and disease status (RA, OA and HC) while age, disease activity and 
duration, and serological inflammation were entered as continuous covariates. 
The initial ANCOVA analysis incorporated all these factors and covariates, but 
only those found to be significant were subsequently retained and reported in the 
prediction equation model below.  
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Table 9: Demographic and disease characteristics of all volunteers for study one and results of ANOVA [mean (sd)]  
 Observation group Validation Group 
 MALE (n= 110) FEMALE (n= 189) Male Female 
 RA OA HC RA OA HC RA RA 
N 56 15 39 118 28 43 99 243 
Age (years) 60.6 (11.8)** 56.7(13.3)* 45.1 (13.3) 59.6 (12.2)** † 52.8 (12.5)* 46.8 (11.5) 62.1 (11.6) 61.7 (11.9) 
Height (cm) 173.6 (7)* 171.3(6.7)* 177.3 (6.7) 159.1 (6.5)** 161 (5) 163.6 (6.9) 174 (6.8) 160,4 (6.7) 
Weight (kg) 83.6 (13.3) 78.4 (14.8) 80.9 (11.4) 68.6 (15) 70.8 (16.5) 68.1 (16.3) 82.7 (15.8) 70.2 (14.4) 
BMI (kg/m2) 27.7 (4.3)* 26.8 (4.7) 25.7 (3) 26.9 (5.7) 27.2 (5.7) 25.4 (5.5) 27.3 (4.4) 27.3 (5.3) 
BF (%) 28.7 (7.7)** 24.8 (7.9)* 19.2 (5.2) 38.3 (7.3)** † 35.2 (8.5) 32.1 (8.2) 27 (6.4) 38.3 (7.1) 
Trunkal Fat (%) 30.5 (8)** 26.6 (8.9)* 21.4 (6) 35.7 (8.6)** † 31.6 (9.6) 29.1 (8.7) 27.4 (7.7)§ 35.4 (8.1) 
DAS 4.2 (1.2)   4.3 (1.4)   4.1 (1.4) 4.3 (1.4) 
ESR (mm/h) 23.2 (18.5)   26 (22.1)   25.3 (21.5) 30 (26.3) 
CRP (mg/L) 15.6 (15)   15.8 (14.9)   16.8 (18.6) 17.6 (23.6) 
Disease Duration 
(years) 11.4 (10.2)   11.3 (9.9)   12.5 (11) 13.2 (11) 
* Significant difference compared to HC (p<0.05) ** Significant difference compared to HC (p<0.001)  
† Significant difference compared to OA (p<0.05) § Significant difference compared to experimental RA group (p<0.001) 
 
Within the RA population of the observation group, correlations of disease 
activity (DAS, ESR, and CRP) and disease duration with BMI and BF were 
obtained for each gender. RA patients were also sub-grouped according to their 
clinical disease activity [DAS remission < 2.6, mild 2.7 – 3.2, moderate 3.3 – 5.1, 
high > 5.1 (Prevoo et al., 1995)], serological inflammation [ESR (Brigden, 1999) 
and CRP (Black et al., 2004)], disease duration (early <3 years, established 3-10 
years, longstanding >10 years), rheumatoid factor positivity (ever), or 
corticosteroid administration (yes/no ever): differences between these sub-groups 
in relation to BMI and BF were assessed using ANCOVA (Table 9). The level of 
significance was set at p<0.05.  
The external validity of the predictive model was tested with the Limits of 
Agreement (LIMAG) method (Bland and Altman, 1986) against BF of the 
validation group. The Limits of Agreement were obtained as follows: 
We calculated the mean (d) and the standard deviation (s) of the 
differences that indicate the level of bias and the random variation between the 
two measures of BF (i.e. the predicted BF and measured BF of the validation 
group, respectively). Provided the differences are normally distributed, the 95% 
‘Limits of Agreement’ are given by: d ± (1.96×s). 
Bland and Altman (Bland and Altman, 1986) argue that, provided that 
differences within these limits are not clinically important, the two measurement 
methods can be used interchangeably.  
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5.1.3 Results 
Observation group 
Within the RA population of the observation group, no significant correlations were 
found between DAS, ESR, CRP, disease duration and BMI or BF. Similarly, when 
RA patients were grouped according to these variables as well as rheumatoid 
factor positivity and corticosteroid use, no significant differences for BMI and BF 
were observed (p>0.05 in all cases, see Table 10). 
Between the different disease groups, one-way ANOVA revealed 
significant differences in BMI (p<0.05) and BF (p<0.001; Table 9): RA males had 
higher BMI and BF (including trunkal fat) than HC males, and RA females had 
higher BF than HC females, even though their BMI did not differ significantly. 
ANCOVA revealed that BMI differences between the groups were mainly due to 
the significant effect of the covariate age (F1,  294 = 5.10, p <0.05) and not due to 
disease (F2, 294 = 1.00, p >0.05), gender (F1, 294 = 0.59, p >0.05), or their 
interactions. 
ANCOVA also revealed that RA and OA patients exhibited lower BMI levels 
than their HC for a given BF. However, differences were only significant for the 
RA patients [RA:-1.826 kg/m2 (p<0.001); OA: -0.352 kg/m2 (p>0.05)]. BMI was 
significantly (p<0.001) predicted by age, disease, gender and BF (R2= 0.58). 
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Table 10: BMI and BF of RA patients (observation group) according to 
categorisation based on their disease characteristics. 
Disease 
Characteristics 
Categories BMI BF 
  Male Female Male Female
Remission (<2.6)  27.2 
(3.46) 
27.2 
(5.6) 
26.5 
(7.6) 
39.5 
(6.7) 
Mild (2.7- 3.2) 28 (4.3) 27.3 
(4.6) 
28 (6) 39.3 
(6.6) 
Moderate (3.3 -5.1) 27.8 
(4.5) 
27 (5.3) 27.4 
(6.8) 
37.3 
(7.7) 
DAS  
 
High (>5.1) 25.3 
(5.5) 
27.3 
(5.5) 
26.1 
(5.6) 
37.7 
(7.2) 
Normal* 27.9 
(4.4) 
26.9 
(4.8) 
27.1 
(7.2) 
38.3 
(6.3) 
ESR (mm/h) 
High 26.4 
(4.6) 
27.6 
(6.1) 
26.7 
(5.9) 
37.6 
(8.9) 
CRP (mg/ L) Low (<3) 26.5 
(2.4) 
28.3 
(6.2) 
25.9 
(5.4) 
38.5 
(8.7) 
 Normal (3 – 8) 27.8 
(4.7) 
26.5 
(4.7) 
26.7 (8) 37.6 
(6.6) 
 High (>8) 26.9 
(4.6) 
27.6 
(5.7) 
27.3 
(5.8) 
38.3 
(7.9) 
Early (<3) 26.4 (5) 26.1 (5) 26.4 
(7.9) 
37.9 
(8.3) 
Established (3-10) 28.8 
(4.1) 
27.8 
(5.7) 
27.8 
(6.3) 
38.2 
(7.5) 
Disease 
Duration 
(years) 
Longstanding (>10) 26.8 
(4.4) 
27.1 
(5.1) 
27.7 
(5.7) 
38.8 
(6.7) 
Positive 26.6 
(3.6) 
27.2 
(5.7) 
25.1 
(6.7) 
38.3 
(7.3) 
Rheumatoid 
Factor (%) 
Negative 27.5 (5) 27.1 
(5.1) 
27.7 
(6.4) 
37.9 
(7.3) 
Yes 27.1 
(4.4) 
27.3 
(5.3) 
26.2 (6) 38.1 
(7.4) 
Corticosteroid 
Administration 
(%) No 24.5 
(4.9) 
26.7 
(5.3) 
27.8 
(7.3) 
37.7 (7) 
For all differences between groups: p>0.05 
* Normal ESR: < 50 years: male <15, female <20 
> 50 years: male <20, female <30 
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When BF was adopted as the dependent variable, ANCOVA identified 
significant differences between disease groups (F2-293= 18.70, p<0.001) and 
gender (F1-293= 380.90, p<0.001) together with a significant covariate, age (F1-293= 
22.43, p<0.001). The contribution of BMI as a covariate in this analysis was also 
significant (F1-293= 370.74, p<0.001). For a given BMI, RA patients exhibited 
significantly increased levels of BF (F2-293= 4.273, p<0.001) compared to healthy 
controls. The difference for OA patients was non-significant (F2-293= 1.648, 
p>0.05). The variation of BF was predicted by age, gender, BMI, and disease type 
(R2= 0.769, p<0.001). This was only very slightly improved (for RA) by the 
addition of RA disease duration (F1-293= 0.340, p>0.05) in the equation (from 
76.9% to 77.1%), so we did not include this variable in the final model. The 
predictive model obtained from this analysis is:  
• BF = Disease Status + Gender - 0.719 + 0.108 x Age + 1.059 x BMI 
o Where disease status: RA = 4.273; OA = 1.648; HC = 0 
o Where gender: Male = -11.294; Female = 0 
Validation group 
To establish external validity of our predictive model, we assessed its agreement 
with the measured BF in 342 patients with RA. Preliminary analyses for LIMAG 
revealed no heteroscedasticity, thus the LIMAG can be reported as absolute 
measurements (Bland and Altman, 1986). Our analyses suggested that the bias 
of our prediction is 0.4 (i.e., our model over-predicts BF by 0.4%) with a standard 
error of 3.2 (95%LIMAG= 6.17, coefficient of variation = 8.9; Figure 5). The 
difference is statistically significant (t = 2.3, p < 0.05), but the coefficient variation 
(CV = 8.9) is within acceptable limits. 
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Figure 5: Agreement between Measured and Predicted Fat in RA patients. 
 
  
BF was measured by BIA and predicted using the formula:  
BF = 4.273 + Gender - 0.719 + 0.108 x Age + 1.059 x BMI (R2= 0.769, p<0.001).  
Where gender: Male = -11.294; Female = 0 
 
95%LIMAG were 6.17 with a coefficient of variation of 8.9. 
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RA-specific BMI cut-off levels 
The fact that patients with RA exhibited increased BF values for a given BMI 
compared to HC, suggested that BMI cut-off points in the RA population would be 
more appropriate if they were reduced by approximately 2 kg/m2 (to 23 and 28 
kg/m2 for overweight and obesity respectively). We therefore compared the 
proportions of subjects in each group that would be correctly classified as 
overweight or obese using the widely accepted BMI cut-offs of 25 and 30 kg/m2 
vs. the proposed (for RA) 23 and 28 kg/m2 vs. the age- and gender specific cut-
off points of measured BF. This analysis showed that 9% of male and 15% of 
female RA patients would be misclassified as of normal weight based on 
traditional BMI cut-offs. Such misclassification was not a problem either for OA or 
HC, where if anything, BMI overestimated BF. Application of the proposed RA-
specific BMI cut-offs of 23 and 28 kg/m2 corrected this misclassification (Figure 
6a).  A modified, RA-specific BMI chart for the classification of patients with RA 
into underweight, normal, overweight and obese categories was developed and is 
provided in Figure 6b. 
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Figure 6a: Classification of male (top figure) and female (bottom figure) 
participants into obese, overweight, normal and underweight groups according to 
currently accepted BMI cut-off points (BMI), body fat content (BF) and RA-specific  
BMI cut-off points (RA-BMI).  
Accepting BF as the most accurate assessment of body fatness, currently 
accepted BMI cut-off points misclassify a significant proportion of both males and 
females with RA (notice the difference in the respective bars).  This 
misclassification is corrected when the proposed RA-specific BMI cut-off points 
are applied. 
RA: rheumatoid arthritis patients; OA: osteoarthritis patients; HC: healthy controls 
BMI: classification according to existing body mass index cut-off points of 25kg/m2 
for overweight and 30kg/m2 for obesity 
BF: classification according to age and gender specific cut-off points for body fat  
RA-BMI: classification according to the proposed RA-specific BMI cut-off points of 
23kg/m2 for overweight and 28kg/m2 for obesity 
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Figure 6b: BMI chart developed specifically for patients with RA.  
 
alues were calculated using the formula: BMI = weight (in kg) / height2 (in m) for 
  
 (m) 
 
V
the rheumatoid arthritis-specific BMI levels identified in the present study [23kg/m2 
for overweight, 28kg/m2 for obesity].  The generally accepted lower threshold for 
normal BMI [18.5 kg/m2] was not altered. 
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5.1.4 Discussion 
The validity of BMI as an acceptable measure of overweight or obesity, and as an 
accurate reflection of body fat (BF) content, has been repeatedly questioned and 
the need for population-specific BMI cut-off points has been highlighted (Manson 
et al., 1995, Willett et al., 1995, Blew et al., 2002, Nevill et al., 2004). Ideally, 
individualized assessment of BF should be pursued in the clinical setting, as BF 
percentage is a more reliable measure of fatness than BMI, at least in the general 
population (WHO, 2000). Indeed, our data indicate that only 58% of the variance 
in BMI can be predicted, as opposed to 77% in BF.  BF in vivo can be determined 
via a number of methods such as underwater weighing, dual-energy x-ray 
absorptiometry, total body water, total body nitrogen, 40K whole body counting, 
and urinary creatinine excretion (Oppliger et al., 1992, Demura et al., 1999, 
Demura et al., 2004). BF can also be estimated from the thickness of partial 
subcutaneous fat, near-infrared rays, and ultrasound (Ellis, 2000). However, none 
of these methods are practical for use in the routine clinical setting as they require 
sophisticated apparatus and specialised personnel (Demura et al., 1999). 
In recent years, a bioelectrical impedance method for the estimation of BF 
in different populations  has become popular and widely recommended, as it is 
reliable, objective, practical, relatively inexpensive, and does not require highly 
trained personnel (Demura et al., 1999, Demura et al., 2004). The validity of this 
method has been confirmed in various studies (Gray et al., 1989, Oppliger et al., 
1992, Tanaka et al., 1999, Bolanowski and Nilsson, 2001, Demura et al., 2004). 
Devices with eight tactile electrodes using single frequency electrical current, 
similar to the one used in this study, generate highly reproducible measurements 
of total BF and segmental fat distribution (Demura et al., 2005). Their correlation 
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with the “gold standards” of dual-energy x-ray absorptiometry and hydrostatic 
weighing is 0.90 and 0.80 respectively, with a standard error of around 3.0, 
producing a co-efficient of variation of <10% (Demura et al., 2004). This suggests 
that bioelectrical impedance measurements (especially when using eight 
electrodes) are valid and suitable for body composition studies (Bolanowski and 
Nilsson, 2001, Demura et al., 2004, Demura et al., 2005). Patients are usually 
happy to undergo such a measurement due to its simplicity and similarity to 
normal weighing.   
In the absence of the necessary equipment or expertise, the predictive 
model presented here can be used to easily calculate BF of RA patients from BMI. 
The cross-validation of this predictive model in patients with RA is reassuring. 
Even though there was a statistically significant difference between the measured 
and the predicted BF, closer examination of the means indicates that this 
difference is at a level of less than 0.5% of BF with a co-efficient of variation of 
<10%. The statistical significance of such a small difference can be attributed to 
the very large number of the validation group and is clinically not important. 
However, the parts of the equation referring to OA patients and healthy individuals 
need further prospective validation in sufficiently large samples of the relevant 
populations. 
BMI remains the most commonly used indicator of body fatness in the 
clinical setting, and the cut-off points of 25 and 30kg/m2 (for overweight and 
obesity, respectively) used for the general population are also routinely applied in 
RA patients. This study shows that application of these BMI cut-off points 
misclassified 9% of male and 15% of female RA patients in terms of actual body 
fatness. For a given BMI, RA patients exhibited an average 4.3% increase in BF 
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compared to healthy controls. In contrast, for the same level of BF, RA patients 
had BMI values almost 2 kg/m2 lower than those of healthy controls. We propose 
that BMI cut-off points in the RA population should be lowered to 23kg/m2 (from 
25kg/m2) for overweight, and 28kg/m2 (from 30kg/m2) for obesity. The lowest 
limit for normal BMI (i.e. 18.5kg/m2) should remain unaltered, as low BMI levels 
have been related to increased cardiovascular risk in patients with RA (Kremers et 
al., 2004, Escalante et al., 2005). We also provide a chart for the classification of 
RA patients in normal, overweight and obese categories according to these BMI 
cut-offs, for use in the routine clinical setting (Figure 6b). 
The most likely explanation for the BMI and BF differences observed in RA 
is rheumatoid cachexia associated with the chronic inflammatory response, given 
that such differences were not as prominent in OA. RA patients experience 
accelerated involuntary loss of fat-free mass, predominantly in the skeletal 
muscle, in excess of what is normally expected due to the aging process 
(Roubenoff et al., 1994).  Although the underlying mechanisms for rheumatoid 
cachexia remain unknown, possible contributing factors include the 
overproduction of inflammatory cytokines such as TNFα and IL-1 (Roubenoff et 
al., 1994, Lecker et al., 1999). Our sub-analyses within the RA population 
revealed that neither BMI nor BF were associated with current clinical or 
serological disease activity, seropositivity for rheumatoid factor (which tends to 
associate with more severe disease) or corticosteroid administration. This is not 
totally surprising as disease activity may vary within small periods of time, 
depending on medication and the disease itself, whereas changes in body 
composition are longer-term processes. On the other hand, disease duration 
appeared to be of some importance. It is possible that most alterations in body 
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composition of RA patients occur in the first few years of the disease, as it has 
previously been reported (Rall and Roubenoff, 2004), irrespective of disease 
characteristics or medical treatment.  
The results of the present study are reminiscent of the observations made 
for Asian populations, which have significantly higher CVD risk than Caucasians: 
BF in Asians has been found to be 3-5% higher than that of Caucasians with 
similar BMI, whereas BMI was 3-4 kg/m2 lower than that of Caucasians with 
similar BF (Demura et al., 2004). Differences in body build (trunk-to-leg-length 
ratio and slenderness) and in muscularity have been suggested as possible 
explanations for these discrepancies. As a result, new cut-off points for Asian 
populations have been set at 23 kg/m2 and 27 kg/m2 for overweight and obesity, 
respectively (WHO, 2004), and have been shown to be more sensitive in 
identifying Asians at increased risk for CVD (Deurenberg-Yap et al., 2002).  
In our participants, lowered BMI cut-off points would reflect an average 
reduction of 5-6 kg, or 8%, in the ideal weight (the weight one should have in 
order to be below the BMI cut-off for overweight). Such reductions in body weight 
are likely to lead to physiological benefits in the cardiovascular system: in the 
general population, even a 5% reduction of body weight is known to affect 
favourably most classical CVD risk factors (Volek et al., 2002, Wilson and Grundy, 
2003). 
The reduced BMI cut-off points for RA suggested here may be of 
significance both for the management of individual patients and for further 
research into the cardiovascular morbidity and mortality of RA.  In the clinical 
arena, the reduction of these thresholds would identify an additional 10-15% of 
people with RA as overweight or obese, and may trigger closer scrutiny for other 
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CVD risk factors and appropriate intervention, if necessary. Moreover, obesity, 
defined by the BMI, is one of the WHO criteria for the metabolic syndrome (Wilson 
and Grundy, 2003).  Aggressive identification and reduction of classical CVD risk 
factors in patients with RA is an obvious strategy for reducing the increased 
cardiovascular mortality of this disease (Kitas and Erb, 2003). From the research 
perspective, the new thresholds may trigger re-analysis of previously published 
cohorts or further analysis of prospective cohorts as to the importance of body fat 
as a predictor of CVD in RA and its association with other individual risk factors. 
We conclude that, in the clinical setting, body fatness of RA patients should 
be evaluated based on the BMI cut-off points of 23kg/m2 for overweight and 
28kg/m2 for obesity. In the absence of specialised equipment, if necessary, BF of 
patients with RA can be estimated from BMI using the equation provided. 
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5.2 Associations of Obesity with Disease Activity and Severity in 
Patients with Established Rheumatoid Arthritis 
(Published in the journal Clinical Rheumatology (2008) Dec 19; Epub ahead of 
print) 
5.2.1 Introduction 
RA is the commonest inflammatory arthritis (Buchan et al., 1988, Feldmann et al., 
1996). It affects predominantly the synovial joints, which are infiltrated by chronic 
inflammatory cells producing cytokines such as TNFα, IL-1 and IL-6 (Feldmann et 
al., 1996). Permanent joint damage and functional decline usually ensue (Minor 
and Lane, 1996), so the efforts of the scientific community have focused on 
symptom control and limitation of joint damage (Kitas and Erb, 2003). 
An indirect effect of RA is altered body composition. Almost two thirds of 
RA patients suffer from a condition termed rheumatoid cachexia, which is 
characterised by muscle wasting in the presence of stable total body weight 
(Roubenoff et al., 1994). As a result, RA patients present with significantly 
increased levels of body fat compared to healthy individuals of the same BMI 
(Stavropoulos-Kalinoglou et al., 2007).  
Adipose tissue, initially considered to be simply an energy reservoir, is now 
recognised as a metabolically active tissue. It secretes a number of bioactive 
proteins called adipokines or adipocytokines, including TNFα and IL-6 (Pi-Sunyer, 
2006). This could potentially result in more active disease in obese RA patients. 
However, studies in patients with early RA, of up to 3 years duration, surprisingly 
suggest that obesity may protect against joint damage (Kaufmann et al., 2003, 
Westhoff et al., 2007, van der Helm-van Mil et al., 2008). In contrast, studies in 
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unselected (for disease duration) RA patients suggest that obesity leads to worse 
quality of life (Garcia-Poma et al., 2007) indicating that its potential protective 
effects in early RA are diminished or reversed later on in the course of the 
disease. The present study aimed to assess the associations of body weight and 
body fat with RA characteristics in patients with well-established disease. 
5.2.2 Methods 
Participants 
Consecutive patients with RA [1987 revised ACR criteria (Arnett et al., 1988)] of 
more than 3 years duration since symptom onset, attending routine rheumatology 
clinics at the Dudley Group of Hospitals NHS Trust, UK, were invited to 
participate. The study had Local Research Ethics Committee approval, and all 
volunteers provided informed consent conforming to the declaration of Helsinki. A 
total of 294 (male=75, female=219) volunteers were assessed. Their demographic 
and disease characteristics appear in Table 11. 
Assessments 
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body weight 
was measured to the nearest 0.1kg. Body composition was assessed by 
Bioelectrical Impedance, using a Tanita BC-418 MA Segmental Body Composition 
Analyzer, which incorporates 8 tactile electrodes (Tanita Corporation, Tokyo, 
Japan). BMI (kg/m2) was calculated on the basis of measured height and weight. 
Waist circumference was measured to the closest 0.5cm using a Seca 200 
Circumference measuring tape (Seca gmbh & co. kg., Hamburg, Germany).  
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Table 11: Demographic and disease characteristics of all volunteers for study two 
[median (interquartile range) or percentage of positives]  
  
 MALE FEMALE 
N 75 219 
Age (years) 62.1 (54.2- 69.7) 62.1 (55- 68.1) 
Height (cm) 173.0 (168- 178) 160 (155.5- 164) 
Weight (kg) 83.6 (74.3- 93.6) 70 (60.9- 80.7) 
BMI (kg/m2) 27.6 (25.8- 30.3) 26.9 (24.1- 31.3) 
BF (%) 28.8 (24.1- 31.7) 38.9 (34.5- 43.2) 
ESR (mm/h) 18.5 (6.8- 31) 21 (10- 36) 
CRP (mg/L) 12 (6- 22.3) 8.0 (5- 20) 
DAS 4 (3.3- 4.9) 4.1 (3.3- 5.1) 
HAQ 1.4 (0.5- 2) 1.6 (0.9- 2.3) 
Presence of Erosions (%) 72.8 60.9 
Knee Surgery (%) 6.7 8.7 
Hip Surgery (%) 5.3 5.5 
Wrist/Hand Surgery (%) 10.7 9.1 
Elbow Surgery (%) 1.3 2.3 
Shoulder Surgery (%) 2.7 1.6 
Neck Surgery (%) 4 2.7 
Any Surgery (%) 30.7 29.9 
Disease Duration (years) 14.5 (7.8 – 20) 12 (7- 22) 
N: number; BMI: body mass index; BF: body fat percentage; ESR: erythrocyte 
sedimentation rate; CRP: C - reactive protein; DAS: disease activity score 28; 
HAQ: health assessment questionnaire. 
 
Positivity for RF and anti-CCP antibodies, as well as ESR and CRP 
concentrations were assessed in contemporary blood samples. Clinical disease 
activity and physical function were assessed by the DAS (Prevoo et al., 1995) and 
the Anglicised version of the HAQ (Kirwan and Reeback, 1986), respectively. X-
rays of hands and wrists were independently assessed by 2 rheumatologists for 
presence of erosions; in case of disagreement (9 in total), x-rays were jointly 
reviewed and a consensus opinion reached. Information on disease duration, 
smoking status and previous joint surgery (presence or absence) was obtained 
from patient interview and confirmed by reviewing the patients’ hospital notes.  
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Data Management and Analyses 
Data were inserted in a purpose-designed spreadsheet (Microsoft Excel 2003) 
and audited for accuracy weekly. They were exported for analysis to The 
Statistical Package for Social Sciences version 15.0 (SPSS Inc. Chicago, IL, 
USA). The Kolmogorov-Smirnov test of normality was used to assess dispersion 
of the variables. 
Spearman’s correlations were used to assess the association of weight, 
BMI and BF with disease activity and physical function (i.e. ESR, CRP, DAS, and 
HAQ). These associations were subsequently adjusted for age, gender, smoking 
status, RF and anti-CCP positivity and disease duration using multivariable 
analyses. 
Thereafter, binary logistic models, with backward elimination of statistically 
insignificant variables, were used to test the associations of weight, BMI and BF 
with the presence of erosions and joint surgery. For joint surgery, independent 
examination of the association for each joint area (i.e. neck, shoulder, elbow, 
hand and wrist, hip, knee, ankle and forefoot) was pursued. The total number of 
joint operations was calculated and its association with BMI and BF was tested 
using multinomial regression. Results were standardised for age, gender, smoking 
status, RF and anti-CCP positivity, and disease duration.  
Finally, participants were categorised according to RA-specific BMI 
(Stavropoulos-Kalinoglou et al., 2007) into four distinct subgroups (i.e. 
underweight, normal-, over-weight and obese). ANOVA was used to assess 
differences between groups for disease activity and physical function (i.e. ESR, 
CRP, DAS, and HAQ). ANCOVA was used to assess the independence of these 
associations from age, gender, smoking status, RF and anti-CCP positivity, and 
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disease duration. BMI groups were also subjected to a cross-tabulation with 
presence of erosions and total number of operations and chi-squared analyses 
were performed. 
Dispersion of data is reported as median (interquartile range) due to their 
not-normal distribution pattern. Results of the logistic models are reported as odds 
ratios with 95% confidence intervals (OR, 95% CI). Statistical significance was set 
at p<0.05. 
5.2.3 Results 
Weight correlated significantly only with CRP (r=0.161, p=0.002). BMI correlated 
significantly with ESR (r=0.145, p=0.012), CRP (r=0.178, p=0.002) and HAQ 
(r=0.117, p=0.044). BF correlated significantly with ESR (r=0.168, p=0.005) and 
HAQ (r=0.179, p=0.003). After adjustment for age, gender, smoking status, RF 
and anti-CCP positivity, and disease duration, the association of weight with CRP 
was lost. BMI retained its association only with ESR (F1, 290= 7.567; p=0.006) and 
HAQ (F1, 290= 4.059; p=0.045); BF was found to associate with ESR (F1, 290= 
5.767; p=0.017), CRP (F1, 290= 4.162; p=0.042) and HAQ (F1, 290= 7.726; p=0.006). 
The association of BF with DAS was borderline non-significant (F1, 290= 3.888; 
p=0.055). 
 Binary logistic regression showed no association of either weight, BMI or 
BF with presence of erosions. The same analyses revealed an inverse 
association of BMI with neck surgery (OR= 0.781, 95% CI: 0.637-0.958; p=0.018) 
and a positive association of BF with total knee replacement (OR= 1.146, 95% CI: 
1.094-1.201; p=0.046), but no other associations were found. Multinomial 
regression models showed no association of either BMI or BF with the total 
number of operated joints. 
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 Following patient grouping according to BMI into underweight, normal-
weight, overweight and obese, ANOVA demonstrated significant differences in 
CRP (p=0.046) and HAQ (p=0.034) between the groups: patients who were either 
underweight or obese had significantly worse CRP and HAQ than those who had 
normal weight, in an almost U-shaped mode (Figure 7).  A similar trend was seen 
with ESR and DAS also, but the differences were not significant (p=0.095 and 
p=0.063 respectively) (Figure 7). Chi-squared analyses failed to identify any 
differences between BMI subgroups for either the presence of joint erosions or 
total number of operations. 
 
 
120 
Figure 7: Disease activity and physical function among BMI categories 
Significant difference 
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5.2.4 Discussion 
This study aimed to identify possible associations between weight, BMI and/or 
Body Fat with RA activity and severity in patients with established disease of more 
than 3 years duration. Weight did not associate with any of the studied variables. 
However, BMI significantly associated with ESR and HAQ; BF also associated 
with ESR, CRP and HAQ. These associations appear to be U-shaped, as both 
low and high BMI and BF associate with unfavourable disease activity and 
physical function. The differences between weight, BMI and BF in the observed 
associations might be explained by their varying ability to assess actual adiposity. 
Weight is a very generic measure that allows for large errors in the estimation of 
adiposity. BMI also has an inherent inability to distinguish between fat and fat free 
body mass (Nevill et al., 2004), which makes it a less accurate marker of adiposity 
than BF (Wellens et al., 1996), particularly in conditions such as RA, which are 
characterised by significant alterations of body composition (Stavropoulos-
Kalinoglou et al., 2007). We were unable to find any associations of either weight, 
BMI or BF with the presence of erosions in radiographs of the hands and wrists. 
BMI was inversely associated with neck surgery, while BF associated positively 
with total knee replacement, but their overall influence on the total number of 
rated joints was not significant. 
Overall, the associations of adiposity with RA disease characteristics found 
his study are intriguing, in that some of them are relatively easy to explain, 
le others seem counterintuitive. Pro-inflammatory cytokines, such as IL-1, IL-6, 
 TNFα, are clearly implicated in the pathogenesis and progression of RA 
chan et al., 1988, Park and Pillinger, 2007). IL-6 stimulates liver production of 
P (Castell et al., 1990), a marker of inflammation and a measure of RA disease 
ope
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activity, and induces further release of IL-1 and TNFα (Lyon et al., 2003), which, 
amongst many other functions, can activate the transcription factor nuclear factor-
kappa beta (NF-κβ) (Okazaki et al., 2005); this is over-expressed in the inflamed 
synovium (Han et al., 1998), and plays a central role in the initiation and 
progression of the chronic inflammation of RA (Tak and Firestein, 2001). The 
extent to which adipose tissue directly produces or indirectly induces the 
production of cytokines is still under intense investigation, but it is widely accepted 
that pro-inflammatory cytokine levels (such as IL1, IL6, and TNFα) increase and 
anti-inflammatory cytokine levels (such as adiponectin, IL-1 receptor antagonist, 
and IL-10) decrease with increasing adiposity (Juge-Aubry et al., 2005). We did 
not directly assess cytokine levels in this study, but this mechanism would be a 
good explanation for the higher disease activity (in terms of ESR, CRP, or DAS) 
and physical dysfunction (as reflected in the HAQ) observed in participants with 
increased BMI or BF.  
This mechanism however, does not explain the worse disease profile 
observed in underweight patients with very low BMI, which is in line with evidence 
from other studies showing increased mortality levels among underweight RA 
patients (Kremers et al., 2004). In these patients, significantly reduced BMI is 
likely to be the result of highly active disease over many years (Roubenoff et al., 
1994) rather than vice versa, and it is interesting that low BMI appeared to 
associate with more neck surgery, which usually occurs in severe, uncontrolled, 
longstanding RA. The cross-sectional design of the present study and the 
relatively small number of underweight patients limit our ability to draw any 
definitive conclusions. 
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Counterintuitively, we were unable to demonstrate consistent associations 
between adiposity with the presence of erosions or joint surgery, despite the 
association of overweight and obesity with higher ESR, CRP and HAQ. Within the 
aforementioned limitations of the study, a possible explanation for this is the 
previously reported protective effect of BMI against joint damage in early RA 
(Kaufmann et al., 2003, Westhoff et al., 2007, van der Helm-van Mil et al., 2008). 
The protective effect seems to occur mainly in RF and/or anti-CCP positive 
patients (Westhoff et al., 2007, van der Helm-van Mil et al., 2008), to be present 
before the diagnosis of the disease, with overweight or obese RA patients 
exhibiting less joint damage than their normal weight counterparts at the time of 
diagnosis (Westhoff et al., 2007), and to continue during the first few years of the 
disease, with joint damage progressing less rapidly in obese than in normal-
weight RA patients (Kaufmann et al., 2003, Westhoff et al., 2007, van der Helm-
van Mil et al., 2008). It is not entirely clear whether this is solely an effect of 
increa
f body weight (mainly reflected in weight) and adiposity 
(mainly reflected in BF):  it is possible that the protective effects of body weight 
sed weight, for example through increased mechanical loading stimulating 
bone synthesis (Tremollieres et al., 1993), or also a reflection of joint damage at 
the time of first diagnosis. Our data suggest that although the protective effect of 
increased BMI may be less pronounced in established disease, it would still 
appear that obese patients with established RA do not exhibit increased levels of 
joint destruction, despite higher levels of systemic inflammation. A partial 
uncoupling between the acute phase response and joint damage in RA has 
previously been suggested (Smolen et al., 2006) and this may also be an 
explanation.  In addition to this, it would be interesting to speculate an uncoupling 
between the effects o
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(i.e. increased mechanical loading of the bones) continue throughout the disease, 
whereas the deleterious effects of adiposity (i.e. increased inflammatory load) only 
“kick in” later, once a critical amount of fat has accumulated through the body 
composition changes occurring in RA.   
In conclusion and within the limitations of this cross-sectional study, in 
established RA, both reduced and increased adiposity seem to be related to 
greater disease activity and physical dysfunction but not to more joint damage. 
These observations are independent from several potential confounders including 
RF and anti-CCP positivity. Further longitudinal studies are required to address 
this apparent dissociation.  
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5.3 Associations of Obesity with Modifiable Risk Factors for the 
(Publis
5.3.1 Introduction 
 2003). This is most likely a combination of genetic 
predisposition (Gonzalez-Gay et al., 2007), modifiable CVD risk factors and the 
inflammatory burden of the disease (Gonzalez et al., 2008). RA patients have 
significantly higher body fat content compared to healthy individuals of the same 
height and weight (Stavropoulos-Kalinoglou et al., 2007). This led to the 
development of RA-specific body mass index (BMI) thresholds for overweight and 
obesity that better identify RA patients with increased body fat (Stavropoulos-
Kalinoglou et al., 2007), and possibly CVD risk. 
In the general population, obesity is a major contributor to dyslipidaemia, 
hypertension, and insulin resistance (Grundy et al., 2004) and the underlying 
cause of the metabolic syndrome (MetS) (Grundy et al., 2004). The associations 
between obesity and CVD risk factors or the MetS in RA have not been 
extensively investigated. Obesity in this population is usually considered a 
confounder, against which data should be standardised, but not as the possible 
underlying cause for several CVD risk factors. The aim of this study was to 
quantify the associations of BMI with classical CVD risk factors in a large sample 
of RA patients.  
Development of Cardiovascular Disease in Patients with 
Rheumatoid Arthritis 
hed in the journal Annals of the Rheumatic Diseases (2009), Feb; 68(2): 
242-5) 
Rheumatoid arthritis (RA) associates with increased risk for cardiovascular 
disease (CVD) (Kitas and Erb,
 125
5.3.2 Methods 
Participants 
The study had ethical approval and all volunteers provided informed consent. A 
utive RA patients were assessed. Of them none 
s from the remaining 378 (276 female) patients are reported: their 
 in Table 12. 
Table 12: Demographic and disease characteristics of all volunteers for studies 
 
total of 400 (289 female) consec
had uncontrolled thyroid disease, but 22 were excluded due to cancer. The 
analyse
characteristics appear
three and five [median (interquartile range)]  
 MALE FEMALE 
N 102 276 
Age (years) 63.5 (13.6) 63 (14.8) 
Height (cm) 173.0 (9.8) 160.0 (8.0) 
Weight (kg) 83.3 (19.7) 70.0 (19.9) 
BMI (kg/m ) 27.6 (5.5) 26.7 (7.2) 2
DAS 4.0 (1.8) 4.2 (1.9) 
HAQ 1.2 (1.8) 1.6 (1.5) 
ESR (mm/h) 19.0 (30.0) 21.0 (28.0) 
CRP (mg/L) 10.0 (15.0) 8.0 (13.0) 
Disease 
Duration (years) 9.0 (15.0) 10.0 (15.0) 
 
 
Assessments 
Standing height, weight, BMI (kg/m2) and waist circumference were measured. 
CVD risk factors (BP, lipids) were assessed, smoking status noted and the 
Framingham 10-year CVD event probability was calculated. HOMA and QUICKI 
were used to determine IR. The NCEP ATP III criteria (Grundy et al., 2004) were 
used to identify patients with the MetS.  ESR, CRP, DAS, and the HAQ were also 
assessed. 
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Data Analysis 
The Statistical Package for Social Sciences version 15.0 was used (SPSS Inc. 
es. Multivariable analyses were used to asses 
.  
Following grouping according to RA-specific BMI (Stavropoulos-Kalinoglou 
et al., 2007) t, no e, ANOVA was 
used to asse  in B  IR betw . ANCOVA was 
then used to ardise for t possible c rs as above. Chi-
squared anal d to nce of each risk 
factor or the I nary logistic models were used to test 
e independence of these associations from the same possible confounders.  
Finally, patients were grouped according to the total number of risk factors 
VA was used to assess differences in BMI among these latter 
Chicago, IL, USA). Dispersion of the variables was assessed using the 
Kolmogorov-Smirnov test. Spearman’s correlations explored the associations of 
CVD risk factors and 10-year CVD event probability with BMI. Results were 
standardised for gender, age, smoking status, RA characteristics and CVD 
medication using univariable analys
the overall association of each of the possible confounders with the CVD risk 
actors and the 10-year CVD event probabilityf
in underweigh rmal-weight, overweight and obes
ss differen esc P, lipids and een groups
 stand he same onfounde
yses were use identify differences in the prevale
MetS between BM  groups. Bi
th
they had. ANO
groups and ANCOVA to adjust for the same possible confounders. Data are 
reported as median (interquartile range). Statistical significance was set to 
p<0.05. 
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5.3.3 Results 
correlated with ESR (r=0.128, p=0.011), CRP (r=0.155, p=0.002) and HAQ 
well as for gender, age, smoking, and CVD medication. BMI retained its 
1-354=10.439, 
p=0.001), HOMA (F
and also associated with diastolic BP (F =7,593, p=0.006), triglycerides (F
Different multivariate models, using BP, lipids and IR as dependent variables, 
 
lipid-lowering treatment (F
antihypertensive treatment (F =4.997, p=0.000) and male gender (F
ignificant differences between BMI sub-
groups (underweight, normal-weight, overweight and obese) for systolic BP (F1-
354=14.707, p=0.000), diastolic BP (F1-354=6.457, p=0.011), triglycerides (F1-
354=4.700, p=0.031), HDL (F1-354=7.545, p=006), HOMA (F1-354=9.720, p=0.002), 
QUICKI (F1-354=30.332, p=0.000) and 10-year CVD event probability (F1-
BMI and CVD risk factors 
BMI correlated significantly with systolic BP (r=0.240, p=0.000), HDL (r=-183, 
p=0.000), HOMA (r=0.302, p=0.000) and QUICKI (r=-0.300, p=0.000). BMI also 
(r=0.133, p=0.009), therefore results were standardised for these parameters as 
association with systolic BP (F1-354=23,372, p=0.000), HDL (F
1-354=11.311, p=0.001) and QUICKI (F1-354=34.678, p=0.000) 
1-354 1-
354=4.496, p=0.035) and 10-year CVD event probability (F1-354=5.857, p=0.016). 
gender and smoking status as factors and BMI, age, RA characteristics and CVD 
medication as covariates indicated that the variance observed in all CVD risk 
factors was more closely associated with BMI (F1-354=8.663, p=0.000), followed by
1-354=7.651, p=0.000), age (F1-354=7.541, p=0.000), 
1-354 1-
354=4.707, p=0.000).  
ANCOVA, with corrections for gender, age, smoking, RA characteristics 
and usage of CVD medication, showed s
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=3.981, p=0.046). Normal-weight patients had less CVD risk compared to other 
BMI groups. 
BMI subgroups and the prevalence of CVD risk factors 
Cross-tabulation of BMI s  
or the MetS demonstrated significant 
prevalence of hypertension (p=0.004), insulin resistance (p=0.005) and the MetS 
(p=0.000) (Figure 8). The binar  
with hypertension (OR=1.28, 95% CI=1.22-1.34; p=0.001), HDL (OR=1.10, 95% 
C
(OR=1.15, 95% CI: 1.08-1.
Following grouping for the total number of risk factors present, ANOVA 
showed significant differences in BMI 
ANCOVA revealed that this association was independent of gender, age, 
smoking, RA characteristics and us
54
ubgroups with presence or absence of each risk factor
differences between groups for the 
y logistic models indicated that BMI associated
I: 1.06-1.15; p=0.025), IR (OR=1.13, 95% CI=1.08-1.18; p=0.000) and the MetS 
21; p=0.000) independently of confounding factors. 
between groups (p=0.000; Figure 9), while 
age of CVD medication (p=0.000).  
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Figure 8: Prevalence of individual risk factors and the metab s ro for ea M o
 
 
Significant differences between BMI groups were found for the prevalence of hyperte n 0 ) u e ance (p=0.0
and the metabolic syndrome (p=0.000). Presence of risk factors w e re e m n a i p t
ch B I gr up 
nsio  (p= .004 , ins lin r sist
nt a ong orm l we ght atien s. 
olic ynd me 
as l ss p val
05) 
Figure 9: Mean (95% confidence interval of the mean) for BMI of parti nts 
according to risk factor grouping. 
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5.3.4 Discussion 
These results suggest an almost linear relationship between BMI and CVD risk in 
this patient group, with the risk profile worsening as BMI increases, in a pattern 
similar to that described in the general population (Grundy et al., 2004). These 
associations were independent of multiple confounders, and if anything, they 
became stronger following inclusion of CVD medication in the models.  
There is no reason to suggest that the mechanisms by which obesity 
increases CVD risk in RA are different from those in the general population. 
Excess adipose tissue releases nonesterified fatty acids in the circulation, which 
overload the liver and muscles with lipids and increase lipolysis, while reducing 
glucose utilization. Circulating glucose stimulates insulin production, leading to 
insulin resistance (Bray et al., 1998). Endothelial function is often impaired 
causing arterial stiffness and hypertension (Zizek et al., 2001). Obesity may also 
increase CVD risk by reducing adiponectin, activating the rennin-angiotensin-
aldosterone system, and increasing sympathetic activity and renal sodium 
reabsorption (Bray et al., 1998). However as we did not measure any of these 
arameters we can only postulate about their contribution to our observations.  
 described. In our study, lipid-lowering and 
anti-hypertensive drugs strongly associated with CVD risk factors; their inclusion 
in the models strengthened the association of BMI with all risk factors assessed. 
Such drugs, known to improve CVD risk and reduce mortality, are more frequently 
prescribed in obese than in non-obese individuals (Karelis et al., 2004). Thus their 
p
Recent studies in RA have shown no relation (Naranjo et al., 2008) or even 
a “paradoxical” protective effect of obesity against CVD (Escalante et al., 2005), 
although no potential mechanisms were
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inclusion in the analyses of studies investigating CVD risk and outcome in RA is of 
paramount importance.  
In the present study, neither disease characteristics nor smoking affected 
in the early years of the disease (Stavropoulos-Kalinoglou et al., 2007) or even 
 
coronary heart disease in RA patients precedes the ACR criteria-based diagnosis 
this is a result of the smoking-induced weight-loss we recently described in RA 
effects of smoking on risk factors. However, disease characteristics and smoking 
those with the MetS <30 kg/m2 and by applying general BMI thresholds would be 
classified as normal-weight and overwei
management of risk factors. 
the associations of BMI with CVD risk. This finding is similar to our previous 
observations indicating that alterations in body composition of RA patients occur 
prior to it. This could be the case for some CVD risk factors since “the risk of
of RA” (Maradit-Kremers et al., 2005). Similarly, smoking appears to confer less 
CVD risk in RA than in the general population (Gonzalez et al., 2008). Most likely, 
(Stavropoulos-Kalinoglou et al., 2008a) which may counteract the known negative 
were treated solely as possible confounders, thus their direct associations with 
CVD risk in RA cannot be assessed in this study. 
An important finding of the present study is the BMI level at which CVD risk 
increases.  Patients with one risk factor had a median BMI of <25kg/m2 whereas 
ght respectively; however, based on RA-
specific BMI thresholds they would be classified as over-weight or obese. This 
could be important in routine clinical practice, where such classifications may be 
used to target patients at increased risk for screening, early identification and 
In the general population, weight-loss can reverse the adverse effects of 
obesity. However, in a population with significant muscle wasting, such as RA, the 
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type of weight-loss intervention has to be carefully considered. Among existing 
weight-loss regimens, exercise and especially resistance training, is the only one 
proven to increase muscle mass in the general population (Franz et al., 2007) and 
may be applied in RA patients without aggravating their disease (Metsios et al., 
2008c). Moreover, exercise is known to further reduce CVD risk irrespective of 
weight-loss (Gaesser, 2007). Research focusing on weight-loss interventions and 
their effects on CVD in RA are necessary.  
Within its limitations, this study shows that increasing BMI in RA patients 
associates with increased CVD risk. The use of RA-specific BMI thresholds better 
identifies RA patients at increased CVD risk. Weight-loss regimens specific for RA 
patients need to be developed and evaluated. 
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5.4 Subtypes of Obesity in Rheumatoid Arthritis 
a higher risk for CVD (Bray, 1995). 
Howev
een identified (Karelis et al., 2004). 
The first subtype, termed metabolically-obese but normal-weight (MONW), 
consists of individuals with normal weight who exhibit increased levels of insulin 
resistance and accumulation of other modifiable CVD risk factors (i.e. 
hypertension, dyslipidaemia) (Ruderman et al., 1981, Ruderman et al., 1982). The 
second subgroup, termed metabolically-healthy but obese (MHO), exhibits 
increased levels of BMI and BF but no other metabolic complications (Sims, 
2001). The prevalence of MONW in the general population ranges between 5% 
(Park et al., 2003) and 45% (Molero-Conejo et al., 2003), however most studies 
suggest that ~15% of normal weight individuals are MONW (Conus et al., 2007). 
Similarly, among obese individuals, ~20% are MHO (Ferrannini et al., 1997, 
Bonora et al., 1998, Karelis et al., 2004). Significantly, both subtypes associate 
with different inflammatory profile. MONW exhibit increased levels of inflammation 
compared to other normal-weight individuals (Hyun et al., 2008), while MHO 
5.4.1 Introduction 
Obesity is a condition that develops from a quantitative imbalance between 
energy intake and energy expenditure and is characterised by increased adiposity 
(Abdel-Hamid, 2003); it associates with metabolic abnormalities such as insulin 
resistance and obese individuals are at 
er, not all obese individuals exhibit such metabolic abnormalities or 
increased CVD risk and not all normal-weight individuals are metabolically healthy 
or free from CVD (Karelis et al., 2004).  
Two distinct subtypes of obesity have b
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exhibit reduced levels of inflammation compared to other obese individuals (Shin 
et al., 2006, Karelis and Rabasa-Lhoret, 2008).  
monest inflammatory arthritis and associates with increased 
ds to significant increases in body fat of 
RA pa
 RA is the com
joint pain and stiffness, leading to irreversible joint damage and functional 
disability (Alamanos and Drosos, 2005). The inflammation of the disease, coupled 
with the classical CVD risk factors (Gonzalez et al., 2008), has been implicated in 
atherosclerotic and thrombogenic processes in RA patients (Sattar et al., 2003). 
Obesity, a common cause of increased CVD risk, is frequently observed in RA 
(Stavropoulos-Kalinoglou et al., 2007); increased muscle breakdown caused by 
inflammation (Metsios et al., 2008b) lea
tients (Stavropoulos-Kalinoglou et al., 2007). Insulin resistance is also 
frequently reported in this population (Sattar et al., 2003) as are the other 
modifiable CVD risk factors (Panoulas et al., 2007).  
In RA, obesity associates with increased prevalence of CVD risk factors 
(Stavropoulos-Kalinoglou et al., 2008b), increased disease activity and diminished 
quality of life (Garcia-Poma et al., 2007); however, some studies report a 
protective effect of it against CVD death (Escalante et al., 2005) and joint 
damage. The existence of subtypes of obesity in this population could possibly 
explain this discrepancy and identification of such individuals could affect the 
clinical intervention they receive. Furthermore, effective control of inflammation 
could improve the metabolic status of RA patients and consequently affect their 
obesity subtype. Thus the aim of this study is 1) to estimate the prevalence and 
identify predictors of the subtypes of obesity in RA, 2) to investigate their 
associations with body composition, CVD risk factors, and RA disease 
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characteristics and 3) to assess the effects of anti-tumour necrosis factor alpha 
(anti-TNFα) treatment on the metabolic status of MONW and MHO. 
5.4.2 Methods 
Consecutive patients attending routine rheumatology clinics at the Dudley Group 
Research Ethics Committee approval by the Dudley Ethics Committee, and all 
assessed. Of them 22 (male=9, female=13) were excluded from analysis as they 
cohort.  The analyses from the remaining 378 (male= 102, female=276) 
volunteers are reported. Their demographic 
treatment within the duration of this study were retrospectively examined. Data on 
initial assessment) patients that were not categorised as either MONW or MHO 
 
 
Participants 
of Hospitals NHS Trust, UK, were invited to participate. The study had Local 
volunteers provided informed consent. A total of 400 (male=111, female= 289) 
volunteers with RA [1987 revised ACR criteria (Arnett et al., 1988)] were 
had cancer. There were no patients with uncontrolled thyroid disease in this 
and disease characteristics appear in 
Table 12. 
Further to the data collected during their initial assessments, clinical notes 
of patients characterised as MONW or MHO who embarked on anti-TNFα 
BMI, CVD risk factors and RA disease characteristics were collected for these 
patients following 6-8 months of treatment. The total of six (three MONW and 
three MHO) patients fulfilled these criteria. Their results were compared against 
those of age, gender, BMI, disease duration and smoking status matched (at 
but also embarked on anti-TNFα treatment.  
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Assessments 
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body weight 
was measured to the nearest 0.1kg. Body composition was assessed by 
BC-418 MA Segmental Body Composition 
Analyzer, which incorporates 8 tactile electrodes (Tanita Corporation, Tokyo, 
The recently published RA-specific BMI cut-off points (i.e. 23kg/m2 for overweight 
measured using a Seca 200 Circumference measuring tape (Seca gmbh & co. 
>102cm for males or >88cm for females (Lean et al., 1995). 
≥140 and/or diastolic BP≥90 and/or receiving antihypertensive 
medication, et al.
low-density-lipoprotein (LDL >4.13mmol/L), decreased levels of high-density-
were considered as insulin resistant. Patients exhibiting normal BMI (i.e. 18.5-
terised as MONW. Obese 
n sensitivity where characterised as 
Bioelectrical Impedance, using a Tanita 
Japan). BMI (kg/m2) was calculated on the basis of measured height and weight. 
and 28kg/m2 for obesity) were used to classify them as under-, normal-, over-
weight, or obese (Stavropoulos-Kalinoglou et al., 2007). Waist circumference was 
kg., Hamburg, Germany). Cut-offs for increased waist circumference were 
BP, blood lipids, glucose and insulin were also assessed. Patients with 
systolic BP
 were characterised as hypertensive (Williams , 2004). Patients 
with increased levels of triglycerides (>1.7mmol/L), total cholesterol (>6.2mmol/L), 
lipoprotein (HDL <1.03mmol/L) or receiving lipid lowering therapy were 
characterized as dyslipidaemic (Expert Panel on Detection Evaluation and 
Treatment of High Blood Cholesterol in Adults, 2001). Patients with HOMA ≥ 2.5, 
QUICKI ≤ 0.333, presence of diabetes mellitus, or use of anti-diabetic medication 
23kg/m2) but increased levels of IR where charac
patients (BMI>28kg/m2) with normal insuli
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MHO. Smoking status was also noted and the Framingham 10-year CVD event 
terquartile range) due 
to thei
probability score was calculated as previously described (Anderson et al., 1991).  
Contemporary serological inflammation was assessed by ESR and CRP. 
DAS was used to assess clinical disease activity (Prevoo et al., 1995). The 
anglicised version of the HAQ (Kirwan and Reeback, 1986) was used to measure 
functional disability as a proxy for disease severity. Disease duration was 
recorded from review of the clinical notes. 
Data Management and Analyses 
Data were inserted in a purpose-designed spreadsheet (Microsoft Excel 2003) 
and audited for accuracy weekly. They were exported for analysis to The 
Statistical Package for Social Sciences version 15.0 (SPSS Inc. Chicago, IL, 
USA). The Kolmogorov-Smirnov test of normality was used to assess dispersion 
of the variables. Dispersion of data is reported as median (in
r abnormal distribution pattern. Results of the logistic models are reported 
as odds ratios with 95% confidence intervals (OR, 95% CI). Statistical significance 
was set at p<0.05. 
Prevalence and predictors of subtypes of obesity in RA 
The frequency of occurrence of each subgroup was examined in the descriptive 
statistics of our sample. Regression analyses were used to identify significant 
predictors for subtype allocation. Specifically: age, gender, BF, FFM, waist 
circumference, ESR, CRP, DAS, HAQ, disease duration, smoking habits and 
medication were included in several different logistic models. Insignificant 
variables were eliminated until only the significant predictors remained in the 
model. 
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Differences in body composition, CVD risk and RA disease characteristics 
between subtypes of obesity  
ANOV
ration, smoking status and medication. 
 subtypes of obesity
A was used to test for differences between MONW and normal weight-
metabolically healthy participants as well as between MHO and metabolically 
unhealthy obese patients in: body composition, conventional CVD risk factors, 10-
year CVD event probability, and RA disease characteristics. The results were 
corrected for age, gender, BMI, disease du
Effects of anti-TNFα medication on  
5.4.3 Results 
tors of subtypes of obesity in RA
Initially, repeated measures ANOVA was used to assess the effects of anti-TNFα 
treatment on BMI and insulin resistance of MONW, MHO and their age, gender, 
BMI, disease duration and smoking status matched counterparts. The same 
analyses were then used to assess the effects of anti-TNFα on blood pressure, 
lipids and RA characteristics among the same participants. 
Prevalence and predic  
d 
were characterised as MONW. Normal-weight patients with higher BF were more 
(OR= 0.479, 95% CI: 0.200- 0.855; p=0.012) were less likely to be MONW.  
ticipants 24 (19.9%) had normal insulin resistance 
and where classified as MHO. Low BF (OR= 1.603, 95% CI: 1.186-2.165; 
p=0.002), small waist circumference (OR= 1.769, 95% CI: 1.251-2.506; p=0.001) 
Among our normal-weight participants 21 (22.4%) exhibited insulin resistance an
likely to be characterised as MONW (OR= 2.781, 95% CI: 2.073- 4.009; p=0.007) 
as were patients with larger waist circumference (OR= 1.482, 95% CI: 1.029- 
2.134; p=0.035). On the contrary, patients with increasing levels of FFM (OR= 
0.221, 95% CI: 0.060-0.815; p=0.023) and those receiving anti-TNFα treatment 
Among the obese par
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and increased FFM (OR= 1.173, 95% CI: 1.039-1.498, p=0.013) were significant 
predictors of MHO allocation. Also, current smokers were more likely to be MHO 
compared to never smokers (OR= 2.778, 95% CI: 1.937-3.32; p=0.014) or ex-
smokers (OR=1.667, 95% CI: 1.141-2.503; p=0.040). 
Differences in body composition, CVD risk and RA disease characteristics 
between subtypes of obesity  
Compared to their metabolically healthy normal-weight counterparts, MONW 
individuals had significantly higher BF (p=0.010) and larger waist circumference 
al-weight participants 
(p=0.016). Finally, MONW individuals scored significantly higher in HAQ 
(p=0.002) and presented higher levels of ESR (p=0.043). A trend for higher DAS 
 healthy normal-weight 
p=0.062 respectively). Corrections for age, gender, BMI, disease duration and 
1, 96 
and smaller waist circumference (p=0.022) compared to other obese participants. 
They also differed in systolic BP (p=0.0
(p=0.003). They also exhibited higher systolic blood pressure (p=0.030), 
triglycerides (p=0.004), glucose (p=0.000) and insulin (p=0.000). Total cholesterol 
did not differ significantly between groups but MONW had significantly lower HDL 
cholesterol (p=0.012). Their overall 10-year CVD event probability was also 
significantly higher compared to that of other norm
and CRP among MONW compared to metabolically
patients was also observed but it was borderline insignificant (p=0.073 and 
smoking status did not alter the results. However, following correction for gender, 
FFM was found to differ significantly between these two subtypes of obesity (F
= 4.037; p=0.038).  
On the other hand, MHO individuals had significantly lower BF (p=0.008) 
34), triglycerides (p=0.000), glucose 
(p=0.000), insulin (p=0.000) and 10-year CVD event probability (p=0.000). 
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Moreover, MHO had significantly lower HAQ scores (p=0.002) and ESR levels 
(p=0.045) than the other obese participants. They also tended to have lower DAS 
scores (p=0.070) and CRP levels but the differences were not significant. Again 
following correction for gender, FFM was found to differ significantly between 
 status did not influence the results in any other 
MHO and obese (F1, 110= 8.344; p=0.005) Correction for age, gender, BMI, 
disease duration and smoking
way. ANOVA results for all subtypes are presented analytically in Table 13. 
Effects of anti-TNFα medication on subtypes of obesity 
Anti-TNFα treatment did not affect BMI of any of the participants irrespective of 
subtype allocation (p>0.05). Repeated measures ANOVA indicated that 
inflammation (as indicated by ESR, CRP and DAS) was equally reduced in all 
groups (p for differences between groups >0.05 in all cases). However, it resulted 
in greater decreases in HOMA (p=0.031) and QUICKI (p=0.025) in MONW 
patients compared to other normal weight patients. Similarly, anti-TNFα treatment 
resulted in greater decreases in systolic BP (p=0.048) and triglycerides (p=0.034) 
in these patients. On the other hand, it marginally improved insulin sensitivity in 
both MHO and obese individuals; however no differences in the magnitude of 
improvements between the two groups were observed (p>0.05 for both HOMA 
and QUICKI). Similarly no differences between groups in the changes in other 
CVD risk factors were observed. 
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Table 13: ANOVA results for the differences in anthropometric, CVD and RA 
 
characteristics between subtypes of obesity (median [interquartile range]) 
 Normal weight MONW MHO Obese 
21 73 24 97 N 
dy Fat (%) 30 33.8* 41.2# 43.4 Bo
 (24.4-34.2) (28.6-36.5) (31.7-43.4) (35.3-47.05) 
t Free Mass (kg) 39.3 38.6^ 50.5⌂ 50 Fa
(36.7-43.6) (35.8-47) (47.8-58.7) (44.9-63.1)  
Waist Circumference (cm) 83 86.5* 104 110 #
 -115.5) (80-86) (83.5-92.8) (101-111) (105
Systolic BP (mmHg) 131 141.5* 140# 148 
 (125-153) (137.5-167) (122-144) (135-150) 
Diastolic BP (mmHg) 79 75.5 80 84 
(70-83) (70-84.3) (71-86) (73-90)  
Triglycerides (mmol/L) 1 1.4* 1.1# 1.5 
 (0.8-1.3) (1.1-1.8) (0.9-1.6) (1-2.3) 
Total Cholesterol (mmol/L) 5.2 5.4 5.4 5.8 
 (4.7-5.5) (5-6.3) (4.2-5.6) (4.4-6.9) 
HDL Cholesterol (mmol/L) 1.7 1.5* 1.6 1.4 
(1.5-1.9) (1.4-1.7) (1.3-1.8) (1.2-1.7)  
cose (mmol/L) 4.8 5.3* 4.9# 5.5 Glu
(4.5-5) (4.7-5.4) (4.6-5.1) (4.9-6.2)  
Insulin (pmol/L) 35 60.8* 50 127 #
 ) (23.5-49) (36.3-88) (35-57.1) (91.5-180.5
CVD (%) 3 6* 5# 11 
(1-5.5) (3.3-12.8) (2-8) (5-19)  
HA #Q 1.1 1.5* 1.6 1.9 
(0.3-1.6) (1.1-2.2) (0.7-2.1) (1.3-2.3)  
DAS 3.6 4 4.2 4.6 
 (2.9-6.1) (3.1-4.7) (3-5) (3.4-5.5) 
ESR (mm/h) 16 20* 20# 25 
 (8-28) (12.5-30.5) (9-31) (15.5-36) 
CR 12.5 13 15 P (mg/L) 7 
 (4-15.5) (4-16.8) (5-19) (6-24) 
Disease Duration (years) 9 11.5 8 10 
 (3-17.5) (4.3-25.8) (3-15) (5-15.5) 
* Significantly different to normal weight (p<0.05) 
^ Significantly different to normal weight following correction for gender (p<0.05) 
# Significantly different to obese (p<0.05) 
⌂ Significantly different to obese following correction for gender (p<0.0 
MONW: metabolically obese normal weight; MHO: metabolically healthy obese; 
BP: blood pressure; HDL: high density lipoprotein; CVD: 10-year cardiovascular 
event probability; HAQ: health assessment questionnaire; DAS: disease activity 
score 28; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein 
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5.4.4 Discussion 
This study is the first to investigate the existence of subtypes of obesity in RA. Its 
aims were 1) to estimate the prevalence and identify predictors of the subtypes of 
A, 2) to investiga ociations with body comp
isease characteristics and 3) to assess the effects of anti-tumour 
i-T ) treatment on the metabo tus of MONW and 
MHO. Our results suggested a prevalence r d 
MHO. BF, waist circumfere M we nt for
allocation for both MONW and MHO. Interestingly though, anti-TNFα medication 
y for nd sm ly M ad 
D  and worse RA characteristics compared to other 
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that of MHO or obese partic
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inflammatory profiles observed among different subtypes are thought to be th
e eposition (Conus et al., 2007).  ffect rather than the cause of altered fat d
From a clinical point of view, the reason for studying the subtypes of 
obesity lies in the clinical interventions these individuals receive. CVD risk of 
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MONW usually remains undiagnosed, due to their “healthy” stature, and thus they 
lso lead to reduced FFM (Roubenoff et al., 
1994).
 be the 
explan
do not receive the appropriate treatment (Conus et al., 2007). On the contrary, 
MHO might receive treatment that they do not need and could possibly trigger 
some different health conditions (Karelis et al., 2004). Identification of predictors 
of subtype allocation is thus very important. In our participants, BF and waist 
circumference (an indicator of abdominal/visceral fat) were significant predictors 
for subtype allocation indicating that the cause of this phenomenon is similar in 
RA patients and the general population. FFM was also a significant predictor for 
subgroup allocation among RA patients. From the existing literature it is not clear 
whether reduced FFM is directly implicated in insulin resistance; it is however well 
established that the main cause for FFM reduction in the general population is 
physical inactivity (Bray and Bellanger, 2006). Such inactivity can result in insulin 
resistance directly, via reduced insulin action on the muscle, or indirectly due to 
increases in BF (Bray and Bellanger, 2006). In the RA population, inflammation 
associated with the disease can a
 Chronic overproduction of cytokines, especially of TNFa, is implicated in 
rheumatoid cachexia; a condition characterised by involuntary loss of FFM at the 
presence of stable or slightly increased body weight (Roubenoff et al., 1994). This 
eventually leads to increased overall BF (Stavropoulos-Kalinoglou et al., 2007). 
Moreover acute increases in pro-inflammatory cytokines during active disease can 
directly increase insulin resistance in RA patient (Dessein et al., 2002, Sattar et 
al., 2003). This suggests a more significant role of inflammation in insulin 
resistance of RA patients compared to the general population and it could
ation for the slightly increased prevalence of MONW among RA patients. 
To further support that, anti-TNFa medication -which is known to control 
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inflammation- was found to associate only with the normal-weight/MONW groups. 
In our cross-sectional observations anti-TNFa reduced the chances of a normal-
weight patient to be insulin resistant. In the retrospective branch of the study, anti-
TNFa was found to improve insulin resistance and overall CVD risk of MONW 
more than that of other normal weight participants. Interestingly though, anti-TNFa 
medication or any other marker of disease activity, did not affect subtype 
allocation in obese participants. Additionally, following 6-8 months of anti-TNFa 
treatment, metabolic and CVD parameters of MHO and obese individuals were 
altered in similar fashion leading to the notion that among obese individuals, 
adiposity rather than inflammation is the major cause of insulin resistance. The 
fact that obese smokers had less chances of being insulin resistant compare to 
never- or ex-smokers further supports that. As we have recently shown 
(Stavropoulos-Kalinoglou et al., 2008a), active smoking relates to reduced BMI 
and BF in RA patients whereas smoking cessation relates to the opposite.  
From a scientific point of view, the importance of studying the subtypes of 
obesity lies on the mechanisms that lead to their altered CVD and inflammatory 
profiles. As stated previously, MONW individuals present with increased levels of 
visceral fat compared to other normal weight individuals (Conus et al., 2007) 
whereas MHO have significantly less visceral fat compared to their obese 
counterparts (Sims, 2001). The reason for this inter-individual differentiation is not 
known, however genetic factors and age of obesity onset have both been 
implicated (Ailhaud and Hauner, 1998, Freedland, 2004). Visceral fat is mainly 
composed of white adipose tissue (WAT) (Matsuzawa, 2005). In contrast to brown 
adipose tissue, which is mainly developed during the embryonic and early infant 
years, WAT is developed throughout the life of an individual and is the major site 
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for excessive fat storage (Ailhaud and Hauner, 1998). In order to facilitate fat 
storage, adipocytes of WAT have to expand in size, as differentiation of pre-
adipocytes to adipocytes in this tissue is limited (Freedland, 2004).  While smaller 
adipose cells are insulin sensitive, when they are enlarged they develop insulin 
resistance (Freedland, 2004). Insulin resistance in such cells is though to be a 
defence mechanism developed to protect them against excessive fat storage 
(Freedland, 2004). However, this mechanism deviates fat storage to non-fat 
tissues, such as liver, muscles and the heart (i.e. ectopic fat storage), and is also 
reflected in the circulation as hyperlipidaemia (Freedland, 2004). Furthermore, 
adipose tissue with enlarged adipocytes shows consistent low-grade inflammation 
(Matsuzawa, 2005). Recent studies have attributed this to localised tissue hypoxia 
(Trayhurn and Wood, 2004, Hosogai et al., 2007, Ye et al., 2007). WAT has 
limited vascularisation and a small number of mitochondria (Ailhaud and Hauner, 
1998) resulting in its relatively poor oxygenisation; enlargement of adipose cells 
further limits oxygen delivery to them (Trayhurn and Wood, 2004). This results in 
a dysregulation of the expression and secretion of pro-and anti- inflammatory 
cytokines (i.e. increased IL-6 and TNFα and decreased adiponectin) (Hosogai et 
al., 2007, Wang et al., 2007, Ye et al., 2007, Trayhurn et al., 2008). Increased 
levels of pro-inflammatory molecules have been implicated in the process of 
atherosclerosis (Ross, 1999), specifically by inducing endothelial dysfunction 
(Alexander, 1995, Bhagat and Vallance, 1997), the first step of atherosclerosis. 
Endothelial dysfunction is also known to associate with hypertension (Rizzoni, 
2002). Even though in this study we did not assess adipose hypoxia or any 
adipokines, the above described mechanism, responsible for the differing CVD 
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and inflammatory profiles between subtypes of obesity, should also be valid in the 
RA population. 
In conclusion and within the limitations of this study our results suggest that 
the prevalence of MONW in RA is slightly increased compared to that in the 
general population, while that of MHO is similar. Total and central adiposity are 
significant predictors for both. Inflammation seems to associate more with insulin 
resistance in MONW than in obese. Adiposity seems to be the major cause of 
insulin resistance in the latter subtype. The underlying mechanisms for the 
existence of subtypes of obesity in RA are far from clear. Further research 
focusing on specific adipose depots and their metabolic properties should be 
conducted. 
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5.5 Association of Cigarette Smoking with Body Weight and 
Muscle M
t (Walsmith and Roubenoff, 2002, Metsios et al., 2006). Body 
omposition changes, particularly BF increase, may remain largely undetected by 
traditional assessments, such as the BMI (Stavropoulos-Kalinoglou et al., 2007). 
Increased BF, together with reduced levels of physical activity due to joint 
inflammation and damage (Walsmith and Roubenoff, 2002, Metsios et al., 2008c), 
are associated with several co-morbidities, including CVD (Orzano and Scott, 
2004, Poirier et al., 2006) as well as increased  mortality (Walsmith and 
Roubenoff, 2002).   
Cigarette smoking is an important risk factor for several diseases (Frieden 
and Bloomberg, 2007).  It is also known to decrease body weight in healthy 
individuals by reducing appetite, and increasing REE (Akbartabartoori et al., 
2004). In contrast, smoking cessation may associate with significant weight 
increase, which constitutes a major deterrent to smoking control (Eisenberg and 
Quinn, 2006).  
ass of Patients with Rheumatoid Arthritis 
(Published in the journal Arthritis Research and Therapy, 2008, 10, R59) 
5.5.1 Introduction 
RA, the commonest inflammatory arthritis, associates with altered metabolism 
(Roubenoff et al., 1994). Compared to healthy controls, RA patients exhibit 
elevated resting energy expenditure (REE) and enhanced muscle catabolism (Rall 
and Roubenoff, 2004). Such changes may lead to rheumatoid cachexia, i.e. 
involuntary loss of FFM with proportional increase of BF, in the presence of stable 
body weigh
c
 149
We have recently demonstrated that smoking further increases REE in RA 
(Metsios et al., 2008a), and this could potentially augment rheumatoid cachexia in 
position and the 
 muscle 
king, is important. The aim of this cross-sectional study was 
5.5.2 Methods 
Consecutive patients attending routine rheumatology clinics at the Dudley Group 
and governmental regulations concerning the ethical use of human volunteers 
volunteers provided informed consent. A total of 400 (male=108, female= 292) 
assessed. Of them 8 (6 males) were excluded from the analyses due to missing 
data for body composition. Data f
Assessments 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body weight 
Body composition was assessed by 
Bioelectrical Impedance, using a Tanita BC-418 MA Segmental Body Composition 
Analyzer, which incorporates 8 tactile electrodes (Tanita Corporation, Tokyo, 
these patients. Given the RA-related alterations in body com
comorbidity associated with them, examination of potential contributors to
wasting, such as smo
to detect potential associations between smoking and body weight, body 
composition and rheumatoid cachexia in RA patients. 
Participants 
of Hospitals NHS Trust, UK, were invited to participate. All applicable institutional 
were followed during this research. The study had Local Research Ethics 
Committee and Research and Development Directorate approvals, and all 
volunteers with RA [1987 revised ACR criteria (Arnett et al., 1988)] were 
rom the remaining 392 [median age: 63.1 (55.5- 
69.6); median disease duration: 10 (4- 18) years] were analysed. 
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
was measured to the nearest 0.1kg. 
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Data management and analyses 
Data were analysed using the Statistical Package for Social Sciences version 
ago, IL, USA). Preliminary evaluation of the variables using a 
Kolmogorov-Smirnov test of normality revealed that none of them required 
all variables. Differences in BMI, BF and FFM between smoking groups are 
gender. ANCOVA was employed to determine whether the differences observed 
rent smokers and ex-smokers groups, further associations 
patients in these groups were divided into quartiles according to pack-years. 
). BMI (kg/m2) was calculated on the basis of measured height and weight. 
Waist circumference was also measured. 
Contemporary disease activity was assessed by ESR, CRP and the DAS 
(Prevoo et al., 1995). The Anglicised version of the 40-item HAQ (Kirwan and 
Reeback, 1986) was used to measure physical dysfunction, as a proxy of disease 
severity. Patients’ self-reported smoking status and intensity (i.e. pack-years) 
were noted.  
15.0 (SPSS Inc. Chic
transformation to reach normality. Mean ± standard deviation was calculated for 
presented as mean differences with 95% confidence intervals (95% CI). 
According to their smoking status, patients were grouped into never-
smokers, current smokers and ex-smokers. ANOVA assessed differences in 
demographic characteristics, BMI and body composition between groups for each 
were attributed to smoking status or other confounding factors (e.g. gender, age 
and disease characteristics).  
In the cur
between pack-years with BMI and body composition were examined. Thereafter, 
ANOVA was employed to assess differences in the measured variables between 
these sub-groups. ANCOVA was used to correct for any confounding factors.  
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Thereafter, patients were grouped according to a) RA-specific BMI 
(Stavropoulos-Kalinoglou et al., 2007) and b) gender specific BF (WHO, 2000) 
thresh
roups (Schutz et al., 2002). Chi-squared analyses were employed to 
king groups in the prevalence of overweight, 
5.5.3 Results 
Table 14 illustrates means ± standard deviation and the ANOVA results for all 
okers 
(mean differences: male -2.6, 95
compared to ex-smokers (mean difference: male: -4.3, 95% CI: -7.5 to -1.2; 
ale: -2.1, 95% CI: -4 to -0.2). FFM did not differ 
between these groups
never smokers male: -2.7, 95% CI: -9.2 to 3.9; female: 0.1, 95% CI: -2.4 to 2.4). 
 
-2.1) but not never-smokers (mean difference: male: -2.9, 95% CI: -10.6 to 4.9; 
olds into: underweight, normal-weight, overweight and obese. 
Subsequently, they were grouped based on gender specific cut-off points for waist 
circumference (Expert Panel on Detection Evaluation and Treatment of High 
Blood Cholesterol in Adults, 2001) into low or high risk, and of FFM into low or 
normal FFM g
assess differences between smo
obesity, high risk and low FFM. For all tests the level of significance was set at 
p<0.05. 
studied parameters. Current smokers had significantly lower BMI than ex-sm
% CI: -3.5 to -1.7; female: -2.6, 95% CI: -4.8 to -
0.5) and never smokers (mean differences: male -1.8, 95% CI: -3 to -0.6; female: -
1.4, 95% CI: -2.4 to -0.4). Current smokers also had significantly lower BF 
female: -3.4, 95% CI: -6.4 to -0.4) and never smokers (mean difference: male: -
3.3, 95% CI: -6.3 to -0.4; fem
 (mean difference: current smokers vs ex-smokers male: -
4.6, 95% CI: -10.7 to 1.6; female: -1.2; 95%CI: -3.8 to 1.4; current smokers vs 
Current smokers had significantly smaller waist circumference than ex-smokers 
(mean difference: male: -6.2, 95% CI: -10.4 to -1.9; female: -7.8, 95% CI: -13.5 to
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female
d the effect of smoking on FFM (p>0.05).  
 There was a significant negative correlation between pack-years and BF 
(r=-0.46; p<0.001) in the current smokers and the ex-smokers groups. This 
remained significant after adjustment for gender, age, DAS, HAQ and disease 
1, 389
 
elimination of ESR, CRP, DAS, HAQ and disease duration) revealed a significant 
3, 217  
differences (p<0.05) in the prevalence of overweight and obese among smoking 
: -3.9, 95% CI: -9.2 to 1.5). Also, ex-smokers had larger waist 
circumference than never-smokers but the difference was significant only for 
males (mean difference: male: 3.3, 95% CI: 0.4 to 6.3; female: 3.9, 95% CI: -0.4 
to 8.1).  
 In ANCOVA with gender and smoking as factors, and age, DAS, HAQ and 
disease duration as covariates, smoking was a significant and independent 
predictor for BMI (F2, 387=8; p<0.001), BF (F2, 387=4.4; p<0.05) and waist 
circumference (F2, 387=7.9; p<0.001). Smoking also emerged as a significant 
predictor of FFM (F2, 387=5.1; p<0.05), but inclusion of body mass as a covariate 
eliminate
duration (F =4.8; p<0.05). Following pack-year grouping into quartiles (pack-
group) ANOVA did not reveal any differences for BMI or body composition among 
current and ex-smokers pack-groups. However, an ANCOVA model with gender
and pack-group as factors and age and weight as covariates (following stepwise 
effect of pack-group on FFM (F =2.7; p<0.05) with heavy smokers exhibiting
the lowest values. Mean (95% CI) of this variable in the pack-year sub-groups 
appear in Figure 10. 
Following BMI and BF grouping, chi-squared analyses showed significant 
groups with obesity being more prevalent in ex-smokers (50%), followed by never 
smokers (39%) and current smokers (30%). Similarly, ex-smokers had 
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significantly (p<0.05) higher prevalence of increased waist circumference (69%) 
compared to never smokers (60%) and current smokers (49%). However, FFM 
did not differ between groups (p>0.05) (Figure 11). 
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classified as current smokers (CS), ex-smokers (XS) and never-smokers (NS) 
 *Significant difference compared to XS (p<0.05)  
** Significant difference compared to XS (p<0.001) 
P
†
PSignificant difference compared to NS (p<0.05)  
P
†† Significant difference compared to NS (p<0.001) 
BMI= body mass index; BF= body fat; FFM= fat free mass; WC= waist 
circumference; ESR= erythrocyte sedimentation rate; CRP= C-reactive protein; 
DAS= disease activity score 28; HAQ= health assessment questionnaire. 
 
Gender Male (n=102) Female (n=290) 
Table 14: Mean ± standard deviation of measured variables of participants 
Smo CS XS NS king Status CS XS NS 
N 20 50 32 49 97 144 
Age  58.8 ±8.1* 65.2 ±9.9† 58.8 ±15 
57.4 
±13.3*
64.1 
±11.2†
60.7 
±11.8 
(years)
Height (cm) 
171.3 
±7.1 
174.3 
±6.9 
172.7 
±7.7 
160.9 
±6.9 
160.8 
±6.8 
159.5 
±6.8 
Weight (kg) 
76 
±12.9**†
85.8 
±13.6 
84.1 
±14.8 
67.5 
±14.2*
74.8 
±15.2 
69.9 
±13.6 
BMI (kg/m2) 
25.8 
±3.3**†
28.4 ±3.8 27.6 ±4.6
26.1 
±5.5*†
28.6 
±5.4 
27.5 ±5 
BF (%) 
24.5 
±6.4**††
28.8 ±6.8 27.8 ±5.6
35.9 
±7*†
39.2 
±6.5 
38.1 
±6.7 
FFM (kg) 57.2 ±9.4 61.7 ±7.7 
59.8 
±10.3 
42.5 
±4.8 
43.7 
±6.1 
42.5 
±6.1 
WC (cm) 100 ±7.9**
106.2 
±10.8†
102.9 
±9.3 
90.8 
±12.8*
98.6 ±13 
94.7 
±12.7 
ESR (mm/h) 
26.5 
±20.5 
22.8 
±21.3 
20.7 
±19.7 
30.5 
±26 
34.3 
±32.7†
25.5 
±19.8 
CRP (mg/L) 13.3 ±9.4 
16.1 
±20.4 
16 ±24.3 
21.9 
±23.2†
21.4 
±32.7†
11.9 
±12.5 
DAS 4 ±0.9 4.1 ±1.5 3.9 ±1.6 4.5 ±1.5 4.3 ±1.5 4.1 ±1.2 
HAQ 0.9 ±0.8 1.4 ±1 1.1 ±0.9 1.5 ±0.9 1.5 ±0.9 1.5 ±0.9 
Disease 
Duration (years) 
8.6 ±7.8 
11.9 
±10.6 
14.6 
±12.7 
11.4 
±9.8 
13.5 
±10.8 
13.5 
±11.1 
Figu  
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roups Figure 11: Prevalence of overweight and obesity, increased waist circumference, and low FFM in smoking g
Figure 11a: Prevalence of overweight and obesity based on RA-specific BMI for 
current-, ex-, and never smokers  
Figure 11b: Prevalence of overweight and obesity based on body fat for current-, 
ex-, and never smokers 
Figure 11c: Prevalence of high risk based on waist circumference for current-, ex-, 
and never smokers 
ure 11d: Prevalence of low fat free mass for current-, ex-, and never smokers 
-squared analyses identified significant defences among smoking groups for 
valence of: a) overweight and obesity based on body mass index (p<0.05), b) 
rweight and obesity based on body fat (p<0.05) and, c) increased waist 
umference (p<0.05). Prevalence of low fat free mass did not differ between 
ups (p>0.05). 
.4 Discussion 
s is the first study to identify significant associations between smoking, body 
ght and body composition of RA patients: current smokers had significantly 
er BMI and BF compared to never-smokers. Both BMI and BF were 
ificantly increased in ex-smokers, whereas very heavy smoking appeared to 
ociate with reduced FFM.  
Our observations for BMI are consistent with those in the general 
ulation. Both male and female smokers tend to have decreased BMI 
pared to their non-smoking counterparts (Albanes et al., 1987, 
artabartoori et al., 2004). In contrast, significant BMI increases have been 
ed after smoking cessation (Eisenberg and Quinn, 2006). Smokers have 
eased levels of leptin (Nicklas et al., 1999), which regulates food intake and fat 
osition (Klok et al., 2007) and reduced hypothalamic neuropeptide Y (Chen et 
2006), which regulates appetite (Billington et al., 1991). Smoking-induced 
eases in the levels of epinephrine, nor-epinephrine and thyroid hormones lead 
ncreased energy expenditure at rest (Collins et al., 1994, Collins et al., 1996) 
 during light physical activity (Perkins et al., 1989, Perkins, 1992, Walker et al., 
9). However, these effects are short-lived: after smoking cessation, leptin 
Fig
Chi
pre
ove
circ
gro
 
5.5
Thi
wei
low
sign
ass
pop
com
Akb
not
incr
dep
al., 
incr
to i
and
199
158 
decreases to levels below those expected for non-smokers of similar weight 
(Nicklas et al., 1999), while resting energy expenditure (REE) returns to normal 
(Dallosso and James, 1984). 
In RA patients, smoking has been shown to elevate REE (Metsios et al., 
lthough we did not assess energy intake and expenditure or related regulators 
 likely that the mechanisms behind the reduced body weight 
olism is through reduction in neuropeptide Y. This 
molecu
2008a); however no data are available on other potential contributors to smoking-
related weight-loss or smoking cessation-related weight-gain for this population. 
A
(such as leptin), it is
of current smokers and the increased body weight of ex-smokers with RA are 
similar to those described for the general population.   
 Interestingly, the lower BMI of current smokers in the present study seems 
to be due to decreased BF rather than FFM. A possible mechanism by which 
smoking may affect fat metab
le, not only stimulates food intake, but also promotes white fat lipid storage 
and decreases brown fat thermogenesis (Billington et al., 1991), so its inhibition 
through smoking would be expected to have the opposite effects. Additionally, 
smoking results in decreased adipose tissue lipoprotein lipase (LPL) activity 
(Chajek-Shaul et al., 1990), which diverts fat storage away from adipose tissue 
and towards utilization by muscle (Sztalryd et al., 1996), possibly leading to the 
decreased BF of smokers (Chajek-Shaul et al., 1990, Ferrara et al., 2001). In the 
present study, the inverse association between smoking and BF appeared to be 
dose-dependant: increasing pack-years associated with reducing BF levels. 
Smoking cessation is thought to result in reversal of the mechanisms described 
above, leading to increases in BF (Chajek-Shaul et al., 1990) and most 
importantly abdominal fat (Canoy et al., 2005). Indeed, amongst these RA 
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patients, ex-smokers seemed to be the most “unhealthy” group in terms of body 
weight and composition, as they exhibited the highest BMI, BF and waist 
circumference values. 
In predominantly healthy people, without muscle-wasting disease, from the 
general population, smoking of any intensity has been implicated in muscle 
wasting (Akbartabartoori et al., 2004) by impairing the process of muscle protein 
synthesis (Petersen et al., 2007). In contrast, in the present study, only very heavy 
smoking appeared to associate with reduction in FFM. It is possible that the effect 
of smoking on muscle is of less significance than the muscle loss associated with 
RA itself, as part of rheumatoid cachexia. This hypothesis is supported by the 
finding that increased duration of smoking (i.e. pack-years) associated with lower 
FFM in both current and ex-smokers, which suggests the existence of a threshold 
below which smoking does not induce further muscle loss in RA patients. A 
longitudinal study of the impact of smoking intensity (and cessation) on the body 
composition of patients with RA may throw more light on the mechanistic basis of 
these observations. 
Overall, this study suggests that in RA, smoking associates with reduced 
body mass and fatness without inducing further muscle loss, except in very heavy 
smokers; in contrast, smoking cessation associates with increased body mass 
and fatness. This should not be interpreted as favouring what is a very unhealthy 
habit. Smoking cessation, even if it occurs in mid-life, reduces most of the later 
risk of death from tobacco (Boyle et al., 2003). However, smoking cessation is 
known to result in body weight increase, and this may affect some peoples’ 
decision to stop smoking (Ferrara et al., 2001, Canoy et al., 2005, Eisenberg and 
Quinn, 2006). Therefore, any smoking-cessation regimen should be underpinned 
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by more generalised lifestyle counselling, including advice on exercise and weight 
management. This is emphasized by the fact that based on recently described 
RA-specific BMI (Stavropoulos-Kalinoglou et al., 2007), BF (WHO, 2000) and 
waist circumference thresholds (Grundy et al., 2004) ex-smokers have the highest 
prevalence of obesity – both total and abdominal. FFM did not differ between 
groups and the prevalence of low FFM was comparable to that expected in age 
and gender matched healthy individuals (Schutz et al., 2002). 
Within the limitations of this study, it is concluded that RA smokers have 
lower BMI and BF than RA non-smokers, whilst heavy smokers also have 
reduced FFM. A history of smoking cessation appears to associate with increases 
in BMI, BF and waist circumference. Nevertheless, given the numerous adverse 
effects of smoking on health, RA smokers should be actively advised against it, 
but smoking cessation programmes should include wider lifestyle counselling for 
weight control, also focusing on increased physical activity and a healthy diet. 
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5.6 Association of Habitual Physical Activity, Energy Intake and 
5.6.1 Introduction 
Obesity is a major health concern in the general population. It associates with 
several different diseases (Jung, 1997) but most importantly it is an independent 
predictor for the development of CVD (Hubert et al., 1983). Obesity is caused 
from a quantitative imbalance between energy intake and expenditure. Physical 
inactivity and overfeeding are the two main reasons for its development in 
otherwise healthy individuals (Bray and Bellanger, 2006); genetic characteristics 
can only enhance or minimise the effects of any lifestyle (Weinsier et al., 1998).  
 In RA, the pathophysiology of obesity may be more complicated. RA, the 
most common inflammatory arthritis, is characterised by increased systemic 
inflammation that leads to joint pain and damage and eventually to physical 
dysfunction (Arend, 1997). Increased levels of pro-inflammatory cytokines affect 
energy metabolism and body composition (Roubenoff et al., 1994). RA patients 
exhibit increased levels of resting energy expenditure (Metsios et al., 2008b); 
however the excess calories come from muscle breakdown (Roubenoff et al., 
1994) leading to reduced muscle mass at the presence of stable body weight, a 
condition known as rheumatoid cachexia (Rall and Roubenoff, 2004). Ultimately, 
this results in increased BF content for a given BMI (Stavropoulos-Kalinoglou et 
al., 2007). Control of inflammation, despite reducing disease activity, does not 
improve BMI or BF of RA patients (Metsios et al., 2007). This indicates that other 
stimuli, such as increased physical activity and optimised energy intake are 
Inflammation with Body Weight and Composition of Patients with 
Rheumatoid Arthritis. 
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necessary to initiate calorific expenditure and muscle synthesis. It is however not 
known whether they can indeed influence that sequence and reduce (or increase) 
dy was to assess the associations between physical 
e and inflammation with body weight and composition in 
patients with RA. 
) 
the negative effect of inflammation on body weight and composition of RA 
patients. The aim of this stu
activity, energy intak
5.6.2 Methods 
Participants 
Consecutive patients attending routine rheumatology clinics at the Dudley Group 
of Hospitals NHS Trust, UK, were invited to participate. The study had Local 
Research Ethics Committee approval by the Dudley Ethics Committee, and all 
volunteers provided informed consent. A total of 126 (male= 42, female= 84
volunteers with RA [1987 revised ACR criteria (Arnett et al., 1988)] were 
assessed. Their demographic and disease characteristics appear in Table 15. 
Assessments  
Standing height was measured to the nearest 0.5cm on a Seca 214 Road Rod 
portable stadiometer (Seca gmbh & co. kg., Hamburg, Germany). Body 
composition was assessed by Bioelectrical Impedance, using a Tanita BC-418 
MA Segmental Body Composition Analyzer, which incorporates 8 tactile 
electrodes (Tanita Corporation, Tokyo, Japan). BMI (kg/m2) was calculated on the 
basis of measured height and weight. The recently published RA-specific BMI cut-
off points (i.e 23kg/m2 for overweight and 28kg/m2 for obesity) were used to 
categorise patients into underweight, normal-weight, over-weight, or 
obese(Stavropoulos-Kalinoglou et al., 2007).  
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Table 15: Demographic, body composition and disease characteristics of 
 
participants 
 Males Females 
N 42 84 
Age (years) 60 (59-64) 59 (55-64) 
Disease Duration (years) 7 (4-12) 9 (5-14) 
Height (cm) 176 (170-179) 158 (155-161) 
Weight (kg) 85.2 (74.9- 92.4) 63.6 (59.7-67.6) 
BMI (kg/m ) 2 27.5 (24.4-29.6) 25.5 (23.8-27) 
BF (%) 26.1 (23.7-30.4) 34.8 (30-40.4) 
IPAQ (METmin/week) 2607 (2179-3412) 2369 (1959-2978) 
Total Energy inta
(kcal/day) 
ke 2637.4 (2298.8-2902.2) 2281.2 (1812.4-2506.6) 
Carbohydrates (%) 57 (49-60) 59 (55-61) 
Fats (%) 24 (19-27) 23 (21-28) 
Proteins (%) 19 (16-21) 18 (16-22) 
IL-1 (pg/mL) 13.3 (6.1-24.8) 15.5 (11-25.5) 
IL-6 (pg/mL) 28.1 (18.3-40.8) 23.7 (11.7-39.3) 
TNFα (pg/mL) 19.2 (9.1-26.9) 16.3 (4.7-30.1) 
ESR (mm/h) 17 (4-31) 21.0 (6-40) 
CRP (mg/L) 18 (11-28) 11.0 (6-24) 
DAS 4.4 (2.6-5.3) 3.8 (2.9-5.1) 
HAQ 1.4 (0.6-1.8) 1.6 (1-1.9) 
BMI: body mass index; BF: body fat; IPAQ: international physical activity 
erythrocyte sedimentation rate; CRP: C-reactive protein; DAS: disease activity 
 
 was assessed by ESR and CRP. 
The DAS was used to assess clinical disease activity (Prevoo et al., 1995) and the 
questionnaire; IL: interleukin; TNFα: tumour necrosis factor alpha; ESR: 
scorer 28; HAQ: health assessment questionnaire 
 
The long version of the self-administered international physical activity 
questionnaire (IPAQ) was utilized to record physical activity. After relevant verbal 
and written instructions, a simple food diary was distributed to all participants. 
They were asked to write in detail about all the food and drink they consumed 
over three non-consecutive days (including a weekend day) during the week 
before the assessment. Total daily energy intake and percentage carbohydrate, 
fat and protein intake were calculated using diet analysis software (Recipe Calc 
4.0). 
Contemporary serological inflammation
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HAQ to measure functional disability as a proxy for disease severity (Kirwan and 
eeback, 1986). Disease duration and smoking habits were recorded from review 
the clinical notes. Pro-inflam tory cytokines (i.e. IL-1, IL-6 and TNFα) were 
 ba
ment and Analyse
 serted in a purp eadshee cel 2003) 
racy w rt  
or Social version 15.0 Chicago, IL, 
lmogorov-Smirno rmality was used to assess dispersion 
s.  
lytic strategy co  steps. Th  used to 
ssociations of BM linear variab cal activity, 
nd BF in RA [i.e. age, gender 
(Stavropoulos-Kalinoglou et al., 2007) and smoking (Stavropoulos-Kalinoglou et 
al., 20
BMI in underweight, normal-weight, overweight and obese. ANOVA was 
used t
R
of ma
assessed in stored serum in tches.  
Data Manage s 
Data were in ose-designed spr t (Microsoft Ex
and audited for accu eekly. They were expo ed for analysis to The
Statistical Package f  Sciences (SPSS Inc. 
USA). The Ko v test of no
of the variable
The ana mprised of four e first step was
assess the a I and BF as les with physi
energy intake, pro-inflammatory cytokines and HAQ [as a surrogate of cumulative 
disease activity (Provan et al., 2008)] using Spearman’s correlations. Results 
ere corrected for variables known to affect BMI aw
08a)]. The second step investigated potential interactions between physical 
activity, energy intake, pro-inflammatory cytokines and disease characteristics in 
their association with BMI and BF again as continuous variables. Univariate 
analyses using either BMI or BF as dependent variables and physical activity, 
energy intake, pro-inflammatory cytokines and HAQ as covariates were used for 
that purpose. 
The third step of the analyses involved grouping of patients according to 
their 
o trace differences between groups for physical activity, energy intake, pro-
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inflammatory cytokines and HAQ. Results were again standardised for age, 
gender and smoking using analysis of ANCOVA. Binary logistic models were 
devised to identify which of the variables: IPAQ, energy intake, pro-inflammatory 
cytokines or HAQ, associated closer with obesity or underweight. Age, gender 
ed in the initial models, however, following 
fat, overfat and obese. Precisely the same analyses as in step 
three w
5.6.3 Results  
11, p=0.000) and positively with energy 
intake (r=0.331, p=0.016) and HAQ (r=0.133, p=0.042). BF inversely correlated 
 
independent of any potential confounding factors.  
and smoking were again includ
elimination of insignificant variables, only those that associated significantly 
qualified for the final model. 
The fourth and final step of the analyses involved re-grouping of the 
patients this time according to gender specific BF cut-off points (WHO, 2000) in 
underfat, normal-
ere conducted. Namely: ANOVA for differences between groups in IPAQ, 
energy intake, pro-inflammatory cytokines and HAQ; ANCOVA to standardise the 
results for age, gender and smoking; binary logistic to assess which of the 
variables (IPAQ, energy intake, pro-inflammatory cytokines or HAQ) associated 
closer with obesity or underfat. 
Dispersion of data is reported as median (interquartile range). Results of 
the logistic models are reported as odds ratios with 95% confidence intervals (OR, 
95% CI). Statistical significance was set at p<0.05.  
Step 1 
BMI inversely correlated with IPAQ (r=-0.5
with IPAQ (r=-0.575, p=0.000) and positively with HAQ (r=0.201, p=0.037). 
Neither BMI nor BF correlated with any of the cytokines. These associations were
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Step 2 
When the interactions of IPAQ, energy intake, cytokines and HAQ were 
examined, univariable analyses indicated that BMI associated with IPAQ (F1, 125= 
12.01; p=0.001) and total energy intake (F1, 125= 6.624; p=0.014), whereas BF 
only with IPAQ (F1, 125= 11.858; p=0.001). The previous observed associations of 
BMI and BF with HAQ were lost and cytokines again did not associate with either 
of the dependent variables. 
Step 3
ble confounders. Binary logistic models indicated 
that a
% CI: 4.432- 8.991; p=0.001) 
and those in the second lowest 4.5 (OR= 4.571, 95% CI= 2.903- 6.012; p=0.032) 
compared to those in the highest IPAQ quartile. On the contrary, energy intake 
 (OR=0.990, 95% CI: 0.982-0.999; 
 
 
Normal-weight patients were more physically active compared to both overweight 
(p=0.006) and obese (p=0.000) whereas underweight patients consumed 
significantly less calories compared to all other patients (p>0.05 in all case; Figure 
12a and 12b). Normal weight patients had lower HAQ scores compared to all 
other participants however the differences were not statistically significant. Levels 
of pro-inflammatory cytokines did not differ between groups. The above results 
were independent of any possi
mong the tested variables, IPAQ was the sole predictor of obesity 
(OR=0.988, 95% CI: 0.982-0.996; p=0.023). Patients in the lowest IPAQ quartile 
were six times more likely to be obese (OR=6.0, 95
was the only predictor for underweight
p=0.025). 
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r between groups. Following corrections 
ons for physical activity persisted. 
 
 
 
Step 4 
Normal-fat patients were significantly more physically active compared to both 
over-fat (p=0.004) and obese (p=0.000) whereas the underfat consumed 
significantly less calories compared to overweight (p=0.028) and obese 
participants (p=0.000; Figure 12c and 12d). Again normal-weight patients tended 
to have lower HAQ but the differences between groups were not statistically 
significant. Cytokines again did not diffe
for age, gender and smoking, the observati
However, following corrections for smoking (alone and in combination with age 
and gender) the difference in energy intake between groups was nonexistent 
(F1,125= 2.114; p=0.112). In the binary logistic models, where the interaction of 
physical activity, energy intake and inflammation was tested, only IPAQ was found 
to associate with obesity (OR=0.991, 95% CI: 0.983-0.997; p= 0.008). Patients in 
the lowest quartile of IPAQ were >7 times more likely to be obese (OR=7.562, 
95% CI: 4.499-12.152; p=0.004) and those in the second lowest 5.5 (OR=5.500, 
95% CI: 2.145-8.412; p=0.033). None of the variables in question (i.e. physical 
activity, energy intake and inflammation) were able to predict underfat. 
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Figure 12: Differences in IPAQ and energy in
Figure 12a: Differences in IPAQ between BMI groups ig 1 : D e s n  k t n  p
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Figure 12c: Differenc between BF groups 
 
* Significant difference with normal weight or normal fat (p<0.05) 
** Significant difference with normal weight or normal fat (p<0.001) 
P
# Significant difference with underweight or underfat (p<0.05) 
P
## Significant difference with underweight or underfat (p<0.001) 
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5.6.4 Discussion 
s is the first study to assess possible interactions between habitual physical 
vity, diet and inflammation in their associations with body weight and 
position in RA patients. Our results indicate that increased habitual physical 
vity associated with reduced BMI and BF; physically active patients were less 
ly to be overweight or obese compared to their inactive counterparts. Energy 
ke on the other hand did not differ between normal-weight, overweight and 
se patients. However, underweight patients consumed significantly less 
ries compared to other participants even though their activity levels were 
parable. Inflammation did not differ between the patients and body weight 
sification was not affected by it.  
In individuals free from any metabolic disorders, body weight and 
composition depend almost exclusively on lifestyle (Bray et al.
rgy needs are met by energy supply, body weight is maintained. Disturbances 
his balance can cause weight gains or losses. Increasing physical activity or 
r-, under-feeding are the main such disturbances. Overall, physical activity 
uces body weight by burning away BF while preserving or slig ing 
scle mass. Overfeeding results in increased body weight mainl ing 
 underfeeding results in reduced body weight from concomitant decreases in 
h BF and muscle mass (in a ratio of about 3:1) (Bray et al., 1998
The mechanisms leading to weight gain or loss in RA seem to be the same 
in the general population: imbalance between energy intake and expenditure. 
mmation as measured via the cytokines did not seem to affect he 
in reason for that is the fluctuation in disease activity. While changes in body 
composition occur over a long period of time (Bray et al., 1998) disease activity, 
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and with it inflammation, can vary enormously within very short periods.  However, 
the chronic inflammatory load of the disease, as reflected in the HAQ (Provan et 
al., 2008), seemed to associate both with BMI and BF in our initial analyses. 
have beneficial effects on body weight and composition of RA patients. This is in 
(Metsios et al., 2008c) and it doesn’t cause any further damage to the joints (de 
or BF in our study, it is known to significantly affect body composition of RA 
secretion of cytokines – 
especially of IL-1, IL-6 and TNFα – enhance muscle wasting (Arshad et al., 2007). 
et al.
muscle-cell membrane of amino acids essential for proteinosynthesis (Rall and 
ibition of 
TNFα alone (Roubenoff 
processes are decelerated (Arshad et al., 2007).  
When IPAQ was introduced as a confounder though, these associations were 
lost. It seems that physical activity, irrespective of the severity of the disease can 
line with current evidence suggesting that exercise is helpful for all RA patients 
Jong et al., 2004).   
Even if inflammation didn’t show up as a significant predictor of either BMI 
patients. During periods of high disease activity, hyper
TNFα is known to activate nuclear factor kappa-beta dependent processes which 
can both enhance proteinolysis (Li et al., 2003) and inhibit proteinosynthesis 
(Langen , 2001) in the muscle. TNFα also reduces insulin action in the 
muscle (Hotamisligil et al., 1994); this results in limited transportation through 
Roubenoff, 2004). IL-1 and -6 have an additive effect to that of TNFα in muscle 
catabolism. The exact mechanism by which they do that is not clear; however 
inhibition of both IL-1 and TNFα better prevents muscle wasting than inh
et al., 2002). During periods of less active disease, these 
However, in order for the muscle to initiate its anabolic processes an 
adequate stimulus needs to be present (McArdle et al., 2001). Physical activity, 
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even at very low levels, is probably the best such stimulus. Low-intensity aerobic 
exercise is known to acutely and chronically improve insulin action on the muscle 
allowing for greater amino-acid delivery which can then be used to built protein 
(Fujita et al., 2007). Resistance exercise initiates muscle reconstruction 
mechanisms, mainly through activation of the “mammalian target of rapamycin” 
signalling pathway (Kubica et al., 2005). Energy expenditure is also increased 
both during as well as for several hours following exercise (Poehlman, 1989, 
Stavropoulos-Kalinglou, 2002). This excess energy is mainly supplied by stored 
fat (Holloszy and Kohrt, 1996) and eventually results in reductions in BF (Bray et 
al., 19
sses occur. However, the most 
likely 
98). Nutrition also plays a significant role in these changes in body 
composition. In order for the exercise-induced muscle synthesis to occur, diet 
needs to provide adequate supply of amino-acids (Hebuterne et al., 2001). On the 
contrary, in order for someone to lose weight, energy intake should be lower than 
the energy demands. Even if energy intake and expenditure are balanced, 
exercise can stray nutrient storage away from BF and towards glycogen; coupled 
with the increases in muscle mass, this results in stable total body weight but 
reduced BF (Holloszy and Kohrt, 1996). This is also the most likely explanation for 
the association of energy intake with underweight (as indicated by low BMI) but 
not with  underfat (as indicated by low BF). In a disease that is associated with 
muscle wasting, underfeeding could result in accelerated muscle depletion 
leading to decreased overall weight but not BF (Roubenoff et al., 1994).  
The design of our study does not allow us to draw safe conclusions about 
the sequence at which the above described proce
path by which inflammation, physical activity and diet affect body 
composition is the following: during active disease inflammatory processes reduce 
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muscle mass. Physical activity during these periods is lowered (Metsios et al., 
2008c) and generally patients consume less calories (Metsios et al., 2007). During 
periods of less active disease, physically active patients provide adequate stimuli 
for their muscles to initiate reconstructive processes and also expend enough 
energy to reduce their body weight/fat. Those who do not meet their energy needs 
with their diet continue to lose body weight and muscle mass.  
However, the main question still remains, how much exercise is enough? 
Only the most active of our participants, achieved activity levels comparable to 
those reported for the general population (Rütten et al., 2003). However, both in 
terms of calories and of nutrient composition, their diet was well balanced (apart 
from underweight) (Krauss et al., 2000). From our data, it seems that even very 
low levels of physical activity when accompanied by a balanced diet are adequate 
to maintain a desirable BMI and BF. This is in agreement with observations made 
in the general population. Individuals who exhibit moderate levels of habitual 
physical activity throughout their lives have significantly lower BMI compared to 
those with low levels of habitual physical activity or even those who engage in 
opportunistic exercise (Wareham et al., 2005). We need to mention though that 
some studies have investigated the effects of exercise on aspects of body 
composition in RA and their conclusions were in favour of intensive exercise (de 
Jong et al., 2003, Marcora et al., 2005b). Even though, such observations are 
extremely useful in the design of exercise interventions, more basic counselling 
focusing on increasing habitual physical activity is equally important. Our 
observation on the balanced diet of RA patients is not new (Arshad et al., 2007). It 
is the first time though, that reduced energy intake has been associated with 
underweight status in this population. In a similar line are the data of Marcora et 
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al. (Marcora et al., 2005a) suggesting that increased protein intake can reverse 
cachexia in RA patients.  
In conclusion, increased levels of habitual physical activity associate with 
reduced BMI and BF. Most likely, during periods of reduced disease activity, such 
physical activity is able to increase muscle mass and reduce body fat. Energy 
intake, even though generally well balanced in RA patients, is a major determinant 
of und
 
 
 
erweight. Given the adverse effect of obesity and its high prevalence in RA, 
patients should be advised towards a more active lifestyle. However, exercise 
professionals should always take into account the movement limitations of these 
patients. Those with increased levels of inflammation need to consume protein-
rich diet in order to prevent excessive muscle loss. Further research investigating 
the suitability of exercise modalities and diet, and the resulting effects on RA is 
advocated. 
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Chapter 6: General Discussion 
The ai
 for overweight and 30kg/m2 for obesity). However, as indicated in the 
rst study of this project, the use of these cut-offs in RA patients is incorrect. 
ificantly increased levels of BF compared to patients 
and, more importantly, compared to 
healthy controls of the same BMI. This has led to the redefinition of overweight 
and obesity for RA patients (i.e. 23kg/m2 for overweight and 28kg/m2 for obesity);  
the new RA-specific BMI cut-off points are able to better identify individuals with 
increased BF (Stavropoulos-Kalinoglou et al., 2007). 
Proper classification of adiposity is important in both the management of 
RA as well as the prevention of relevant health conditions and most importantly 
CVD. The second study of the present project identified a significant association 
of BMI with disease activity. Interestingly, both underweight and obese patients 
exhibited worse disease characteristics compared to their normal-weight 
m of the current PhD work was to investigate aspects of obesity in patients 
with chronic inflammatory diseases, and especially RA. Specifically, this project 
focused on the definition of obesity, its associations with RA characteristics and 
CVD risk as well as the significant contributions of lifestyle, and especially 
physical activity, in its development. The main findings of this study expanded our 
understanding on selected parameters of obesity in RA and emphasised the 
significance of physical inactivity in the development of it. 
As highlighted in the literature review, obesity in this population has 
attracted minimal scientific and clinical attention. The few studies that have 
addressed this issue have used BMI cut-off points devised for the general public 
(i.e. 25kg/m2
fi
These patients, exhibit sign
without wasting diseases, such as OA, 
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counterparts. Furthermore, the third study found significant association of BMI 
with classical CVD risk factors. As ex h 
d to target patients at 
increa
patients with RA. Smoking, 
physic
pected, CVD profile deteriorated wit
increasing BMI. The significant finding of this study however, was the BMI at 
which CVD risk, as indicated by the risk factors, increased. Patients with one risk 
factor had a median BMI of <25kg/m2 whereas those with the MetS <30 kg/m2 and 
by applying general BMI thresholds would be classified as normal-weight and 
overweight respectively; however, based on RA-specific BMI thresholds they 
would be classified as over-weight or obese. This could be important in routine 
clinical practice, where such classifications may be use
sed risk for screening, early identification and management of risk factors 
(WHO, 2000). 
However, adiposity does not affect all individuals in the same way. The 
fourth study of this project was able to identify normal-weight individuals with a 
metabolic phenotype typically related to obesity and others who, despite being 
obese, exhibited a metabolic phenotype related to normal-weight. These distinct 
subtypes of the population also exhibit altered inflammatory profiles, thus their 
identification might have significant clinical implications for the treatments they 
receive.  
 The final two studies of this project were able to identify factors that 
influence obesity, both in terms of BMI and BF, in 
al activity and to a lesser extent diet were found to exert significant effects 
on BMI and BF. Smoking was found to have a significant protective effect against 
obesity while smoking cessation associated with significantly increased adiposity. 
This however should not be interpreted as favouring a generally unhealthy habit. 
Smoking cessation, an effective means of reducing smoking related health risks, 
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should be accompanied by weight management in patients with RA. Physical 
activity also had a protective effect against obesity. Physically active patients had, 
on average, lower BMI and were less likely to be obese compared to their 
physically inactive counterparts. Energy intake on the other hand was not 
associated with increased but rather with decreased BMI. Underweight patients 
consumed significantly less calories compared to the rest participants. The most 
important finding of this study however, was probably the lack of association 
between inflammation and any aspect of adiposity. The weak associations of 
disease severity with BMI and BF were eliminated as soon as physical activity 
was introduced in the statistical models. This on its own provides a very strong 
justification for the use of exercise in the prevention and treatment of obesity in 
RA pa
n though this project did not assess any possible interventions to 
tients. Such interventions also have the potential to reduce CVD risk 
(Metsios et al., 2008c) and to improve physical function without aggravating the 
disease or causing any further joint damage (de Jong et al., 2003, de Jong et al., 
2004). These observations, coupled with the potential direct benefits of exercise 
on inflammation (reviewed in Handschin and Spiegelman, 2008) underscore the 
importance of exercise in the management of RA. 
 Eve
counteract obesity, it is a very useful tool in the hands of health or exercise 
professionals who might want to do so. Over all, the present project has 
highlighted the significant impact of obesity on health of RA patients. This has 
provided a strong rational for its treatment, something that was lacking until now. 
Having assessed the factors that influence obesity, it has also provided definite 
directions for future research protocols or clinical interventions with exercise 
appearing to be the most promising modality for weight control in these patients.  
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Chapter 7: Limitations 
•
interesting and can serve for hypothesis generation, but they do not provide 
definitive evidence for causality or directionality, which can only be addressed 
in long-term prospective studies.   
•
et al., 2004, Demura et al., 
2005). It correlates well with the “
Even though the methodology of the present project was carefully designed, 
several potential limitations might have influenced our findings. Depending on 
whether they affect the whole project or individual studies, limitations are listed 
below as general or study specific respectively.  
7.1 General  
 The cross-sectional nature of the observations: the associations found are 
 Body composition was assessed by bioelectrical impedance. This method, has 
been validated (Gray et al., 1989, Oppliger et al., 1992, Tanaka et al., 1999, 
Bolanowski and Nilsson, 2001, Demura et al., 2004) and is thought to be 
suitable for body composition studies in diverse populations (Bolanowski and 
Nilsson, 2001, Lofthouse et al., 2002, Demura 
gold standards” of dual-energy x-ray 
absorptiometry and hydrostatic weighing (Demura et al., 2004) and is widely 
used in RA research (Lemmey et al., 2001, Lofthouse et al., 2002, 
Stavropoulos-Kalinoglou et al., 2007, Stavropoulos-Kalinoglou et al., 2008a, 
Stavropoulos-Kalinoglou et al., 2008b) (Metsios et al., 2007, Metsios et al., 
2008b), but it has not actually been specifically validated in the RA population.   
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7.2 Study Specific 
• Study 2: The presence of erosions was assessed only qualitatively in 
radiographs of the hands and wrists: this does not allow quantitative analysis 
as all methods for quantification of erosions require x-rays from several 
different joints. Thus, patients with erosive disease were grouped together 
irrespective of the extent of erosive damage, and severity of joint damage 
e inferred by joint surgery. However, we have included these 
• 
not be used to draw definite conclusions. 
• 
participants. It is difficult to assess any other selection bias: the prevalence of 
current-, ex- and non-smokers among the participants of this study was similar 
to that reported for local general population subjects of similar age (General 
could only b
measures only as simple indications and we do not draw any of our major 
conclusions from them.  
Study 4: The prospective, longitudinal branch of this study had a very small 
number of participants and it can
Comparisons with the general population are based on the existing literature 
and not on a control group. Thus, the mechanisms described in the study are 
based entirely on the available literature and not on our assessments. On the 
other hand, the size of the cohort and the prospective collection of data in a 
standardised, systematic manner are important strengths, as they minimised 
missing values and selection bias.  
Study 5: Although self-report of smoking, especially smoking history, is 
generally reliable, both under- and over-reporting can occur (Fendrich et al., 
2005). This is unlikely to have influenced the primary findings of this study, i.e. 
the differences between current-, ex-, and non-smokers, while any miss-
reporting in pack-years may have been smoothed by the large number of 
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Household Survey 2005, 2006), although it was different to another RA cohort 
• 
 
established more than 10 years ago (Saag et al., 1997). 
Study 6: The methods used to assess energy intake and expenditure depend 
on self-reported information. Even though widely used in research and 
extensively validated (Craig et al., 2003), IPAQ has not been tested for RA 
patients; on the other hand, individuals who consume excessive amounts of 
food are known to underreport their energy intake in food diaries (Heitmann 
and Lissner, 2005). 
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Chapter 8: Suggestions for Future Research 
infl
con
pat
nee
needs. Overall, studies confirming the findings of the present project, especially if 
sing improved methodology that eliminated the limitations, are advocated.  
The first study proposed lower BMI thresholds for overweight and obesity 
them to be more accurate for the identification of 
patients at risk in this population. A re-examination of existing cohorts and other 
interventional studies based on the newly proposed RA-specific BMI cut-off points 
might increase our understanding of obesity in this population. The findings of the 
second and third studies need to be confirmed in longitudinal investigations. 
Cohorts assessing the change in BMI and BF over a period of years and the 
resulting changes in RA and CVD characteristics are highly useful as are those 
with death as their endpoint.  
In terms of scientific potential, the findings of the fourth study are very 
intriguing. Differences in white and brown adipose tissue, their vascularisation and 
the effects of weight gain or loss are largely unknown even in the general 
population. The fourth study of the present project has proposed a theory by 
which increasing adiposity might affect RA and CVD profile in some patients but 
not in others. This theory remains to be tested in clinical and basic investigations. 
This project is the first systematic approach to obesity in patients with chronic 
ammation, and especially RA and also the first to propose a more significant 
tribution of physical activity, compared to inflammation, in obesity of these 
ients. It has viewed this population as a group of individuals with different 
ds from the general population and was thus able to focus on their specific 
u
and the following studies proved 
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The results of such experiments will most likely provide useful information for the 
general population as well. 
s, or 
preven
nderweight, identified both in this project and in 
severa
In terms of clinical application the final two studies have probably provided 
the most interesting information. The association of smoking cessation with 
increases in adiposity is worrying. If confirmed in longitudinal studies, weight 
management programmes that will be used in conjunction to smoking cessation 
should be developed. This is probably the greatest challenge for researchers that 
will decide to continue the steps of this project. As discussed in the final study, 
exercise seems to be the most likely method that will induce weight los
t weight gain, in RA patients. Due to the manifestations of the disease, (i.e. 
joint pain, swelling, and stiffness) and limited mobility of the patients, exercise 
professionals need to adapt their methods to the individual needs of each patient. 
Also the frequency and severity of flares related to RA need to be taken into 
account and incorporated into the programme so that the benefits gained through 
exercise are not lost due to inactivity.  
Finally, even though not among the main questions of the present project, 
an association between poor diet and underweight was observed. Due to the 
significant health effects of u
l other studies, this association should receive some further attention. 
Dietary modification, possibly in combination with exercise, especially resistance 
training, could improve the status of these individuals. 
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LONG LAST 7 DAYS SELF-ADMINISTERED FORMAT 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domai s asked independently) and short (4 
generic items) versions for use by either telephone or self-administered methods 
are available. The purpose of the questionnaires is to provide common 
instruments that can be used to obtain in rnationally comparable data on health–
related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in 
Geneva in 1998 and was followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000. The final results suggest 
that these measures have acceptable measurement properties for use in many 
settings and in different languages, and are suitable for national population-based 
prevalence studies of participation in physical activity. 
Use of the IPAQ instruments for monitoring and research purposes is 
ncouraged. It is recommended that no changes be made to the order or wording 
f the questions as this will affect the psychometric properties of the instruments.  
Translation from English and Cultural Adaptation 
Translation from English is encouraged to facilitate worldwide use of IPAQ. 
Information on the availability of IPAQ in different languages can be obtained at 
www.ipaq.ki.se
 
n
te
 
Using IPAQ  
e
o
 
. If a new translation is undertaken we highly recommend using the 
prescribed back translation methods available on the IPAQ website. If possible 
please consider making your translated version of IPAQ available to others by 
contributing it to the IPAQ website. Further details on translation and cultural 
adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical 
Activity Prevalence Study is in progress. For further information see the IPAQ 
website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in 
the development of IPAQ instruments is available at www.ipaq.ki.se and Booth, 
M.L. (2000). Assessment of Physical Activity: An International Perspective. 
Research Quarterly for Exercise and Sport, 71 (2): s114-20. Other scientific 
publications and presentations on the use of IPAQ are summarized on the 
website. 
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IN  
 
We a ople 
o as part of their everyday lives. The questions will ask you about the time you 
us and moderate activities that you did in the last 7 days. 
igorous physical activities refer to activities that take hard physical effort and 
 harder than normal. Moderate activities refer to activities 
id jobs, farming, volunteer 
ork, course work, and any other unpaid work that you did outside your home. Do 
paid work you might do around your home, like housework, yard 
 did you do vigorous physical 
ctivities like heavy lifting, digging, heavy construction, or climbing up stairs as 
ly those physical activities that you did for at 
s per week 
job-related physical activity  Skip to question 4 
nutes per day 
 
 
 
 
TERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE
re interested in finding out about the kinds of physical activities that pe
d
spent being physically active in the last 7 days. Please answer each question 
even if you do not consider yourself to be an active person. Please think about the 
activities you do at work, as part of your house and yard work, to get from place to 
place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigoro
V
make you breathe much
that take moderate physical effort and make you breathe somewhat harder than 
normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes pa
w
not include un
work, general maintenance, and caring for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
 Yes 
 
 No     Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as 
part of your paid or unpaid work. This does not include traveling to and from work. 
 
2. During the last 7 days, on how many days
a
part of your work? Think about on
least 10 minutes at a time. 
 
_____ day
 
 No vigorous  
 
3. How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
 
_____ hours per day 
_____ mi
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4. Again,  least 10 
inutes at a time. During the last 7 days, on how many days did you do moderate 
kip to question 6 
inutes per day 
ys did you walk for at least 10 
inutes at a time as part of your work? Please do not count any walking you did 
No job-related walking Skip to PART 2: TRANSPORTATION 
How much time did you usually spend on one of those days walking as part 
____ minutes per day 
s, on how many days did you travel in a motor vehicle 
ke a train, bus, car, or tram? 
____ days per week 
No traveling in a motor vehicle   Skip to question 10 
pend on one of those days traveling in a 
ain, bus, car, tram, or other kind of motor vehicle? 
____ minutes per day 
ow think only about the bicycling and walking you might have done to travel to 
nd from work, to do errands, or to go from place to place. 
 
think about only those physical activities that you did for at
m
physical activities like carrying light loads as part of your work? Please do not 
include walking. 
 
_____ days per week 
 
 No moderate job-related physical activity  S
 
5. How much time did you usually spend on one of those days doing 
moderate physical activities as part of your work? 
 
_____ hours per day 
_____ m
 
6. During the last 7 days, on how many da
m
to travel to or from work. 
 
_____ days per week 
 
  
 
7. 
of your work? 
 
_____ hours per day 
_
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to 
places like work, stores, movies, and so on. 
 
8. During the last 7 day
li
 
_
 
  
 
9. How much time did you usually s
tr
 
_____ hours per day 
_
 
N
a
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10. During the last 7 days, on how many days did you bicycle for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 place to place   Skip to question 12 
m 
lace to place? 
____ minutes per day 
 days, on how many days did you walk for at least 10 
inutes at a time to go from place to place? 
No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
3. How much time did you usually spend on one of those days walking from 
____ hours per day 
y 
ART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
his section is about some of the physical activities you might have done in the 
ur family. 
 
ast 7 days, on how many days did you do vigorous 
hysical activities like heavy lifting, chopping wood, shoveling snow, or digging in 
__
5. How much time did you usually spend on one of those days doing vigorous 
e garden or yard? 
____ hours per day 
 
 No bicycling from  
 
1 How much time did you usually spend on one of those days to bicycle fro1. 
p
 
_____ hours per day 
_
 
12. During the last 7
m
 
_____ days per week 
 
CARING FOR FAMILY 
1
place to place? 
 
_
_____ minutes per da
 
P
 
T
last 7 days in and around your home, like housework, gardening, yard work, 
general maintenance work, and caring for yo
 
14. Think about only those physical activities that you did for at least 10 
minutes at a time. During the l
p
the garden or yard? 
 
_  days per week __
 
 No vigorous activity in garden or yard   Skip to question 16 
 
1
physical activities in th
 
_
_____ minutes per day 
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16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
ctivities like carrying light loads, sweeping, washing windows, and raking in the 
__
7. How much time did you usually spend on one of those days doing 
ivities in the garden or yard? 
____ hours per day 
_
8. Once again, think about only those physical activities that you did for at 
ime. During the last 7 days, on how many days did you do 
oderate activities like carrying light loads, washing windows, scrubbing floors 
 sw
 
_____ days per week 
 
RECREATION, SPORT 
AND LEISURE-TIME 
PHYSICAL ACTIVITY 
9. How much time did you usually spend on one of those days doing 
a
garden or yard? 
 
_  days per week __
 
 No moderate activity in garden or yard   Skip to question 18 
 
1
moderate physical act
 
_
____  minutes per day 
 
1
least 10 minutes at a t
m
eeping inside your home? and
No moderate activity inside home Skip to PART 4: 
 
1
moderate physical activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
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PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely 
for recreation, sport, exercise or leisure. Please do not include any activities you 
ave already mentioned. 
0. Not counting any walking you have already mentioned, during the last 7 
 least 10 minutes at a time in your 
isure time? 
isure time    Skip to question 22 
 
ical activities that you did for at least 10 
ute s d ou ro
physical ac  fast bicyclin
leisure time? 
 
____ days per week 
 did you usually spend on one of those days doing vigorous 
r leisure time? 
hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
physical activities like bicycling at a regular pace, swimming at a regular pace, 
and doubles tennis in your leisure time? 
 
_____ days per week 
No moderate activity in leisure time Skip to PART 5: TIME 
SPENT SITTING 
 
25. How much time did you usually spend on one of those days doing 
moderate physical activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
h
 
2
days, on how many days did you walk for at
le
 
_____ days per week 
 
 No walking in le  
 
 
 
21. How much time did you usually spend on one of those days walking in your 
leisure time? 
 
____ hours per day _
_____ minutes per day
2. Think about only those phys2
m s at a time. During the last 7 days, on how many day id y  do vigo us 
tivities like aerobics, running, g, or fast swimming in your 
in
_
 
 No vigorous activity in leisure time   Skip to question 24 
 
23. How much time
physical activities in you
 
_____ 
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PART 5: TIME SPENT SITTING 
and during leisure time. This may include time spent 
itting at a desk, visiting friends, reading or sitting or lying down to watch 
6. During the last 7 days, how much time did you usually spend sitting on a 
____
____ minutes per day 
7. During the last 7 days, how much time did you usually spend sitting on a 
 
The last questions are about the time you spend sitting while at work, at home, 
while doing course work 
s
television. Do not include any time spent sitting in a motor vehicle that you have 
already told me about. 
 
2
weekday? 
 
_  hours per day 
_
 
2
weekend day? 
 
_____ hours per day 
_____ minutes per day 
 
 
This is the end of the questionnaire, thank you for participating. 
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Appendix 4: Food Diary 
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FOOD IARY 
 
Name: 
Date:    Week of Treatment: 
Participant Code: 
 
With this diary we will record your every day food consumption.  
We need you to describe in every detail
D
 
: 
1. Exactly what you eat and drink (e.g. chicken breast without skin, semi-
skimmed milk). 
2. How much of each ingredient you use (in household measures such as 
teaspoons or tablespoons; glasses; small, medium or large portions etc.). 
3. And how you cook it (e.g. fried, in the oven). 
 
 
Example of one day food diary: 
 
Breakfast 
 
Lun
 
2 fried eggs 
medium size 
 
2 slices of 
bacon  
1 fish fillet 
fried 
 
1 portion of 
fries large size
 
two 
tablespoons 
of ketchup 
 
2 glasses of 
white wine 
1 medium 
portion of 
spaghetti with 
canned 
tomato sauce  
and garlic 
 
1 medium 
salad with half 
lettuce 2 
tomatoes with 
2 tablespoons 
of olive oil 
 
1 glass of 
fresh orange 
juice 
  
2 slices of 
white medium 
sliced bread 
with two 
teaspoons of 
butter 
 
1 chocolate 
muffin 
 
1 can of diet 
coke 
8 glasses 
 
ch Dinner Snacks Water 
1 glass of 
semi-skimmed 
milk 
Fill it in on ONE of the following days: Monday or Tuesday or Wednesday 
 
Date: 
Breakfast Lunch D r ter inne Snacks Wa
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
226 
Fill it in on ONE of the following days: Thursday, or Friday 
 
Date: 
Breakfast Lunch Dinner Snacks Water 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
227 
Breakfast Lunch Dinner Snacks Water 
228 
Fill it in on ONE of the following days: Saturday or Sunday 
     
 
Date: 
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“Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with 
One Stone? 
Tracey E. Toms1,#, Vasileios F. Panoulas1,#, Antonios Stavropoulos-Kalinoglou1 and  
George D. Kitas1,2,* 
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Abstract: The introduction of statins and drugs blocking the renin angiotensin aldosterone system in the treatment of car-
diovascular diseases (CVD) in the general population has led to substantial reductions in morbitity and mortality. Recent 
evidence suggests multiple actions of these agents, including modulation of the immune response and attenuation of in-
flammation. Even though several studies have addressed the anti-inflammatory properties of these drugs in the general 
population, only few studies have focused on their potential benefit when administered to patients with rheumatoid arthri-
tis (RA), a chronic systemic disease characterised by both inflammatory joint damage and excess cardiovascular mortality. 
The present review focuses on the potential role of these agents in reducing the excess CVD (by controlling cardiovascu-
lar risk factors, improving endothelial dysfunction, reducing size and increasing stability of atheromatous plaques, activat-
ing the fibrinolytic system and reducing systemic inflammation) and in controlling the disease itself (both systemic and 
localised joint inflammation), in RA patients. Overall, the review has strong evidence to support the effects of statins on 
reducing cardiovascular risk, however by comparison the evidence supporting their efficacy in RA is relatively weak. 
INTRODUCTION 
 Diseases of the cardiovascular system are the commonest 
cause of death in the United Kingdom and consume a sig-
nificant proportion of the National Health Service Budget 
[1]. Of the cardiovascular diseases (CVD), coronary heart 
disease (CHD) is the most prevalent and its magnitude is 
escalating exponentially. It is predicted that by 2031 the 
number of cases of CHD will have increased by 44% [2]. 
Therefore, it is not surprising that the use of drugs such as 
statins, angiotensin converting enzyme inhibitors (ACE-I), 
angiotensin II - type 1 receptor blockers (ARBs) and the 
anti-obesity drugs orlistat/sibutramine/rimonabant are in-
creasingly being used to treat dyslipidaemia, hypertension 
and obesity respectively, all of which are well-established 
CHD risk factors. 
 Patients with rheumatoid arthritis (RA), a chronic in-
flammatory disease primarily of the synovial joints, have an 
abnormal lipid profile [3,4], a high prevalence of hyperten-
sion [5,6] and a tendency towards a higher body fat:lean 
mass ratio [7,8]. In RA there may be an increased prevalence 
of clustering of these risk factors, the metabolic syndrome 
(MetS) [9,10], which identifies cardiovascular risk beyond 
the sum of its components and is considered an independent 
CVD risk factor in its own right [11]. Therefore, therapy 
with the types of drugs mentioned above may prove of par-
ticular cardiovascular benefit in RA patients. 
 
*Address correspondence to this author at the Department of Rheumatology, 
Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Pensnett 
Road, Dudley, West Midlands, DY1 2HQ, United Kingdom; Tel: +44-1384-
244842; Fax: +44-1384-244808;  
E-mail: gd.kitas@dgoh.nhs.uk or g.d.kitas@bham.ac.uk 
#Both authors have equally contributed to this work and therefore share first author-
ship. 
 Although these drugs were initially designed to target 
specific risk factors for CHD with a net effect of reducing 
morbidity and mortality, over time it has become apparent 
that they may have other beneficial actions. In particular, 
much interest has focused on their immunomodulatory and 
anti-inflammatory properties [12]. This interest is likely to 
have been driven by substantial advances in basic science, 
illuminating the role of inflammatory processes in the patho-
genesis of atherosclerosis [13]. It is now thought that in-
flammation may be the fundamental key element to the de-
velopment of atherosclerosis, and as a consequence this has 
spurred the development and adoption of inflammatory bio-
markers for cardiovascular risk prediction, such as high sen-
sitivity C-Reactive Protein (hsCRP) [2]. All three classes of 
drugs (statins, ACE-I/ARBs and anti-obesity medications) 
have been shown to have anti-inflammatory properties [14-
16], thus they may act via a two-pronged approach to combat 
CHD: affect their specific target and modulate the inflamma-
tory response. 
 Over the last 50 years [17], mounting evidence associates 
RA with an increased mortality and reduced life expectancy 
compared to the general population [18,19]. Almost 50% of 
RA deaths are due to CVD [20] and of these the majority are 
a consequence of Ischaemic Heart Disease (IHD), particu-
larly myocardial infarction and chronic heart failure. Al-
though conventional cardiovascular risk factors are thought 
to be more prevalent in RA [4-6, 21, 22], these do not fully 
account for the increase in ischaemic events, and therefore 
much of the excess risk has been attributed to novel risk fac-
tors, particularly the heightened inflammatory state [23], but 
also uric acid [24], corticosteroids [25-27] as well as genetic 
predisposition [28, 29], the exact role of which remains un-
clear. 
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 The endothelium is a dynamic structure that plays a piv-
otal role in cardiovascular homeostasis. Altered endothelial 
function is now widely accepted to be the earliest stage of 
atherosclerotic plaque formation [30]. Virtually all known 
traditional cardiovascular risk factors have been shown to 
have a negative impact on the endothelium. Interestingly, the 
majority of these changes can be reversed by effective treat-
ment and correction of the risk factors [31]. In the early 
stages of the RA disease process, pro-atherogenic changes in 
endothelial function have been detected in middle-aged pa-
tients without CVD risk factors [32]. Endothelial dysfunction 
in RA has been linked with high inflammatory activity [33], 
and this notion is supported by an improvement in endothe-
lial function following treatment with disease modifying 
anti-rheumatic drugs [34]. Therefore, drugs with a dual ac-
tion (cardiovascular and anti-inflammatory) such as statins 
or ACE-I/ARBs may prove of particular benefit in RA pa-
tients, particularly at the early stages of their disease. 
 Of note is, that RA patients have less histological evi-
dence of atherosclerosis but greater evidence of inflamma-
tion and plaque instability compared to controls at autopsy 
[35]. It is therefore possible that the scope of benefit in RA 
patients treated with statins and ACE-I/ARBs via the plaque 
stabilisation actions of these drugs [36-38] may be consid-
erably higher than that observed in states of low grade in-
flammation. Currently there are no studies to formally assess 
the effects of statins or ACE-I on atherosclerotic plaque 
composition or stability in patients with RA. 
 RA also associates with a hypercoagulable state, repre-
sented by elevations of markers of activation of haemostasis, 
such as fibrinogen, von Willebrand factor (vWF), plasmino-
gen activator inhibitor type 1 (PAI-1) and fibrin D-dimer, 
and a reduction in fibrinolytic factors such as tissue plasmi-
nogen activator (t-PA) [39]. It is possible that this contrib-
utes to the increased cardiovascular mortality seen in RA by 
increasing cellular adhesion to unstable plaques and acceler-
ating thrombus formation following plaque rupture. In the 
general population, it appears that statins and ACE-I/ARBs 
can improve the fibrinolytic balance and reduce atheroscle-
rotic plaque thrombogenicity [40, 41]. In RA, in the presence 
of such an intense prothrombotic environment, it is possible 
that the anti-thrombotic effects of statins and ACE inhibitors 
may be even more important; however there are no specific 
studies to confirm or refute this. 
 Statins and ACE-I contribute to CVD risk reduction by 
indirectly intervening at various stages of atherosclerotic 
plaque development, via their effects on common inflamma-
tory pathways. They act to improve endothelial dysfunction, 
increase nitric oxide (NO) bioavailabilty and antioxidant 
properties, inhibit inflammatory responses and the activation 
of the thrombolytic system and stabilise atherosclerotic 
plaques [42, 43]. (Fig. 1) Their precise modes of action are 
discussed in detail later in this review. 
 Knowledge of the cellular involvement in RA and the 
mechanisms involved in the disease has improved signifi-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The pathways by which statins reduce atherosclerotic plaque formation (Adapted from [249]). 
LDL: low density lipoprotein, ROS: reactive oxygen species, PAI-1: plasminogen activator inhibitor-1. 
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cantly. The synovial fluid in active RA is greater in volume 
and rich in cells, predominantly polymorphs, but also T cells 
[T helper 1 (Th1) most commonly] and macrophages along 
with scanty numbers of dendritic cells and B cell derivatives 
[44]. uclear factor-kappa  (NF-), a key transcription 
factor in the inflammatory cascade, is over expressed in the 
inflamed synovium [45]. It is a pivotal regulator of the initia-
tion and perpetuation of chronic inflammation [46]. NF-B 
regulates the transcription of genes for pro-inflammatory 
cytokines [eg. tumor necrosis factor-alpha (TNF-) and in-
terleukin six (IL-6)], adhesion molecules [e.g. intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1)], chemokines [e.g. monocyte chemo- 
attractant protein-1 (MCP-1) [47]] and protein subunits of 
reactive oxygen species (ROS) generating enzymes [e.g. 
reduced form of nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase] [48-51]. In RA, NF- activation 
is inhibited by many conventional anti-inflammatory and 
disease modifying drugs, such as glucocorticoids and sul-
phasalazine [52]. Similarly statins [53] and ARBs [54] have 
demonstrated NFkB inhibitory effects, suggesting a poten-
tial disease modifying role of the latter. 
 Many striking parallels have been drawn between the 
synovium of an actively inflamed joint in RA and the athero-
sclerotic plaque [55]. These include the infiltration by simi-
lar populations of pro-inflammatory cells (mainly macro-
phages and T cells) [56], collagen degradation, local expres-
sion of adhesion molecules (ICAM-1, VCAM-1 and E-
selectin) [57, 58] and neoangiogenesis [59, 60], suggesting 
that largely similar inflammatory pathways are involved in 
the pathogenesis of RA synovitis and atherosclerotic CHD 
[61]. Thus, the pleiotropic immunomodulatory, anti-infla- 
mmatory effects of statins, ACE-I/ARBs and anti-obesity 
drugs, sparked speculation over their potential benefit in RA, 
both as therapy able to reduce the increased cardiovascular 
risk, as well as modify joint disease, thus “killing two birds 
with one stone”. 
 In this review, after providing some pharmacological 
information about each of these classes of drugs, we discuss 
in more detail the mechanisms by which they reduce cardio-
vascular risk and may modify the course of RA. 
Statins 
Pharmacology 
 The HMG CoA reductase inhibitors, statins, first intro-
duced in the 1980’s, have revolutionised the treatment of 
hypercholestrolaemia, and are a most important component 
of primary and secondary prevention of CHD [62]. 
 Statins are competitive inhibitors of HMG-CoA reduc-
tase, the rate-limiting step in cholesterol biosynthesis. The 
binding of a statin to the HMG-CoA reductase active site 
triggers an alteration in the enzyme, preventing HMG-CoA 
reductase from attaining a functional structure. The change 
in conformation at the active site makes these drugs very 
effective and specific. Through this, they prevent the conver-
sion of HMG-CoA to mevalonic acid, resulting in decreased 
hepatic cholesterol synthesis, which in turn promotes 
upregulation of LDL receptors and subsequent removal of 
LDL from plasma [63]. However, by inhibiting mevalonic 
acid synthesis, statins also prevent the synthesis of other in-
termediates downstream, such as farnesylpyrophosphate 
(FPP) and geranylgeranylpyrophosphate (GGPP). These sub-
strates are crucial for multiple cellular functions and may 
also have immuno-modulatory potential via their interaction 
with other signalling pathways. An example is the indirect 
effect of GGPP modulation by statins resulting in activation 
of peroxisome proliferator-activated receptors (PPAR)  
[64], and subsequent inhibition of inflammatory pathways. It 
is through such mechanisms that statins may exhibit their 
pleiotropic, anti-inflammatory effects [65] (Fig. 2). 
 Statins are classified according to: the pathway used 
when metabolised by the liver; the process by which they are 
obtained; their physico-chemical properties; and their active 
forms. The metabolism of statins in the liver is largely either 
via the cytocrome P450, CYP 3A4 pathway as for simvas-
tatin, atorvastatin and lovastatin, or via the CYP 2C9 path-
way as used by Fluvastatin and Rosuvastatin [66]. Pravas-
tatin has only minimal interaction with the cytocrome P450 
system and much of its metabolism is dependant on glucu-
ronidation [67]. This may be important in terms of their po-
tential for drug interactions, particularly in conditions char-
acterised by polypharmacy [68], such as RA [26]. Statins can 
be obtained either by fungal fermentation (pravastatin, lovas-
tatin, simvastatin), or by synthesis (fluvastatin and atorvas-
tatin). The division of statins according to their physico-
chemical properties allows distinction between those that are 
hydrophilic (pravastatin), hydrophobic (simvastatin, lovas-
tatin, atorvastatin), and those that display intermediate char-
acteristics (fluvastatin) [69]. The final classification system, 
distinguishes between statins that are metabolically active on 
administration (atorvastatin, fluvastatin, pravastatin) and 
those that are administered as inactive compounds requiring 
enzymatic modification to the active form (simvastatin, lo-
vastatin) [66]. 
Cardiovascular Risk Reduction 
Control of Risk Factors 
 Statins are primarily used for the reduction of total cho-
lesterol (TC) and low-density lipoproteins (LDL), however, 
they have also been found to affect other aspects of the lipid 
profile, such as high density lipoproteins (HDL) and triglyc-
erides (TG). Total cholesterol is reduced by 15-40%, LDL 
by 20-60% and TG by 10-30%, whereas HDL can increase 
by 5-15% [70]. The relative improvement observed in the 
lipid profile varies between the different drugs and can be 
explained through the differences in chemical structure and 
route of metabolism. Rosuvastatin appears to be more potent 
than atorvastatin, simvastatin, or pravastatin at equivalent 
doses, resulting in a significantly greater reduction in LDL 
levels [71]. It is hypothesized that the differences in potency 
may also influence their ability to exhibit their anti-inflamma- 
tory properties, but this remains to be proven. 
 The landmark Scandinavian Simvastatin Survival Study 
trial (4S) established the benefits of statins on mortality in 
patients with atherosclerosis [62]. A meta-analysis of 34 
trials, studying the association of statin use and CHD in sec-
ondary prevention, has confirmed a 13% overall reduction in 
CV mortality [72]. Subsequent, large multi-centre, random-
ised controlled trials (RCTs), including the West Of Scotland 
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Coronary Prevention Study (WOSCOPS) [14], the Anglo-
Scandinavian Cardiac Outcomes Trial –Lipid Lowering Arm 
(ASCOT-LLA) [73], and the air force/Texas coronary athe-
rosclerosis prevention study (AFCAPS/TexCAPS) [74], have 
reinforced the 4S findings, as well as affirming a reduction 
in cardiovascular (CV) morbidity and mortality in patients 
without established atherosclerosis. These findings were 
irrespective of age, gender or baseline cholesterol concentra-
tion. 
 Some of the vascular benefits arising from statin treat-
ment may associate with blood pressure control and arise 
from their inhibitory effects on NF-k. Statins have been 
shown to reduce NF-k activation in vascular smooth muscle 
cells and mononuclear cells [53], and abolish TNF-alpha-
induced NF-k activation in human endothelial cells [75]. 
Furthermore, statins provide some of their anti-oxidant prop-
erties that preserve endothelial function by attenuating an-
giotensin II-induced free radical production in the vascular 
smooth muscle cells by inhibiting NAD(P)H oxidase activity 
and down-regulating AT 1 receptor expression [76]. These 
actions may be particularly pertinent to states of high-grade 
inflammation, such as RA. Arterial stiffness was found to be 
significantly reduced in 29 patients with RA treated with 
atorvastatin [77], and these changes were more pronounced 
in patients with higher levels of inflammation. Collectively, 
the mechanisms outlined above may act upon central or pe-
ripheral control of blood pressure to contribute to the re-
ported anti-hypertensive effects of statins [78, 79]. In 2007, a 
meta-analysis of 20 randomised control trials, including 828 
hypercholestrolaemic patients on stable anti-hypertensive 
medication, has confirmed a small but statistically significant 
effect of statins on blood pressure in the general population 
[80], however, there have not been any studies to endorse 
these findings in patients with RA. 
Improvement of Endothelial Function and Anti-Oxidant 
Potential 
 Statins preserve endothelial function by inhibiting the 
expression of adhesion molecules, such as VCAM and 
ICAM, thus reducing leukocyte recruitment and inflamma-
tion [81]. Changes in endothelial function and endothelium 
dependant vasomotion have been observed as early as 24 
hours after initiation of statin treatment, in normocholestro-
laemic and hypercholestrolaemic patients [82, 83]. Statins 
have a positive impact on nitric oxide bioavailability, by up-
regulating endothelial nitric oxide synthase (eNOS) expres-
sion [84, 85], and reversing the inhibitory effect of oxidised 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mechanism of action of statins. 
HMG CoA: 3-hydroxy-3-methyl-glutaryl-CoA reductase, Ras: a small G protein, Rho: A member of the Ras superfamily, RhoGDP: inactive 
form of Rho Protein, RhoGTP: active form of Rho Protein, Rho-kinase: a serine/threonine-specific protein which is activated by GTP-bound 
Rho. 
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LDL on eNOS [86,87]. The overall impact is improved NO-
dependant vasorelaxation. A single study specifically in RA 
showed that patients treated with simvastatin 40mg, had im-
proved endothelial function as measured by flow mediated 
dilation, and this was greater in those with higher baseline 
CRP levels; there was also a decrease in oxidised LDL [88]. 
 Statins do not only reduce circulating oxidised LDL but 
they also inhibit their uptake by macrophages [89], and thus 
subsequent foam cell formation, a critical step in atheroscle-
rosis. Patients treated with atorvastatin may have reduced 
macrophage uptake of oxidised LDL as a consequence of 
decreased activity of macrophage CD36, a recognised recep-
tor for oxidised LDL [90]. However, this mechanism is now 
under scrutiny as a recent study has shown conflicting re-
sults, indicating upregulation of CD36 on macrophages with 
statin therapy, and an additive effect of PPAR- ligands to 
this phenomenon [91]. 
Reduction of Plaque Size and Increase in Plaque Stability 
 Although all stages of plaque formation are important 
and should be considered as potential targets for therapy, it is 
plaque instability and rupture that have the most devastating 
clinical consequences, as they are responsible for the acute 
coronary syndromes (ACS). Statins contribute to plaque sta-
bility by reducing plaque size or by altering physicochemical 
properties [36]. The infiltration of atherosclerotic plaques by 
monocytes/macrophages is reduced, and secretion of prote-
olytic enzymes, matrix metaloproteinases (MMPs) that con-
tribute to thinning of the fibrous atherosclerotic cap is de-
creased in patients receiving statin therapy [92] (Fig. 1). In 
one study, patients received either pravastatin 40mg or pla-
cebo for 3 months prior to carotid endarterectomy. The 
plaques in those treated with pravastatin had a more stable 
morphology with a lower lipid content, less oxidised LDL, 
fewer macrophages and T cells, less MMP-2, more tissue 
inhibitor of MMP-1 and a higher collagen content [93]. 
 In two recent trials, REVERSAL [94] and ASTEROID 
[95], statins have been shown to induce coronary plaque re-
gression. REVERSAL compared the effects of atorvastatin 
and pravastatin on coronary plaque progression by intravas-
cular ultrasound. In patients receiving atorvastatin, a reduc-
tion in the progression of coronary atherosclerosis was ob-
served, however, these results were not mirrored in the 
pravastatin arm where atherosclerotic lesions progressed. 
ASTEROID produced impressive results, with a significant 
reduction in plaque volume following treatment with rosu-
vastatin over a two-year period. The observed plaque regres-
sion was linked to a significant reduction in their LDL levels 
(53.2%) and an increase in their HDL levels (14.3%). Al-
though these results are promising, the trial was limited by 
the lack of a control group. 
 Patients with RA have a worse outcome and a higher re-
infarction rate after an ACS [96], and although direct evi-
dence is lacking, this has been attributed at least in part to 
increased instability of atherosclerotic plaques associated 
with the enhanced inflammatory environment and the pres-
ence of CD4+CD28- T cells [97]. Plaque stabilisation 
through statin (or other) therapies may therefore be particu-
larly important in RA, but there are no studies addressing 
this in the RA population. 
 Any studies performed within an RA population should 
take into account the possibility that the inflammatory bur-
den may actually alter the functional capacity of these drugs, 
and as a consequence higher doses may be required to gain 
clinical benefit. A recent study suggests for example that 
inflammatory cytokines disrupt LDL-receptor feedback regu-
lation and cause a degree of statin resistance [98]. 
Effects on the Fibrinolytic System 
 Statins exert their positive effects on the fibrinolytic sys-
tem by lowering levels of PAI-1 and increasing levels of t-
PA in hypercholestrolaemic patients. However, such results 
have not been replicated in patients with mixed-type hyper-
lipidaemia [99]. A study performed on rats demonstrated a 3-
fold increase in tPA activity and a reduction in PAI-I activ-
ity, in those treated with a statin [100]. A reduction in 
plasma fibrinogen levels and blood viscosity has also been 
observed in type 2 hypercholestrolaemic patients treated 
with pravastatin but not with simvastatin [101]. Several in-
vestigators have also reported additional effects of statins on 
platelet aggregation, with a reduction in platelet deposition 
on damaged vessel walls at high shear stress rates observed 
with both atorvastatin and pravastatin [102-104]. These find-
ings may be attributed to a reduction in platelet membrane 
RhoA expression [103] and plaque levels of tissue factor 
[105]. There are no studies of the effects of statins on the 
fibrinolytic system in patients with RA. 
Reduction of Systemic Inflammation 
 The hypothesis that statins provide benefit beyond their 
lipid lowering effects is supported by evidence provided in 
multiple large clinical trials, including CARE (Cholesterol 
And Recurrent Events) [106] and WOSCOPS [14]. They 
indicate that despite comparable serum cholesterol levels 
amongst the statin and placebo groups, statin-treated indi-
viduals had a significantly lower risk of CHD than age-
matched placebo controls [106-108]. The CARE trial of 
pravastatin vs placebo demonstrated an improvement in 
baseline CRP levels and a marked risk reduction in those 
with elevated baseline CRP, despite comparable LDL levels 
[106]. The sub-analysis of the Pravastatin or Atorvastatin 
Evaluation and Infection – Thrombolysis in Myocardial In-
farction (PROVE IT-TIMI) 22 trial, suggests that the clinical 
benefits achieved with statin therapy in patients with ACS 
are greater in those with a lower CRP level post statin ther-
apy than those with higher CRP levels, irrespective of the 
resultant level of LDL cholesterol [109]. These trials indicate 
that the benefit of statin therapy may extend to patients with 
a low total and LDL cholesterol, but with a heightened in-
flammatory state as measured by their CRP (10), such as 
those with RA. In the general population, this hypothesis is 
currently being evaluated by the JUPITER (Justification for 
the Use of statins in Primary prevention: an Intervention 
Trial Evaluating Rosuvastatin) trial [110], where 17,802 
healthy individuals with low LDL cholesterol (<130) but 
elevated high sensitivity CRP (>/=2) are being randomised to 
either Rosuvastatin or placebo. A large RCT in RA is also 
underway, the TRial of Atorvastatin for the primary preven-
tion of Cardiovascular Events in patients with Rheumatoid 
Arthritis (TRACE RA) [111] : this is the first and largest 
hard end-point trial of statin therapy in patients with RA in 
the world, and much needed, as this population has been 
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systematically excluded from all large statin trials to date. 
This pivotal trial, will hopefully provide definitive evidence 
about the role of statins in the primary prevention of cardio-
vascular events in RA, but will also produce useful informa-
tion about effects of statins on disease activity, biochemical 
and metabolic parameters, blood pressure and the prevalence 
of side effects. 
RA Disease Modifying Potential 
Reduction of Systemic Inflammation 
 The anti-inflammatory actions of statins in RA have been 
formally assessed by a double-blind randomised placebo-
controlled Trial of Atorvastatin in RA (TARA), involving 
116 RA patients [112]. Participants were allocated either to 
atorvastatin 40mg or placebo, in addition to their existing 
disease modifying therapy (DMARD). Despite randomisa-
tion, the atorvastatin arm included more patients taking 
methotrexate and there was some usage of corticosteroids in 
both arms during the course of the trial. Notwithstanding 
these shortcomings, at six months, there was a significantly 
higher fall in disease activity score (DAS28), swollen joint 
count, CRP and ESR in the atorvastatin arm compared to 
placebo, providing promise that statins may mediate clini-
cally apparent anti-inflammatory effects both on haemato-
logical and clinical markers of disease activity in RA. The 
investigators of a subsequent large observational study in-
volving 4152 RA patients, described similar results with a 
significant reduction in CRP levels, but failed to demonstrate 
a change in DAS 28 or the Health Assessment Questionnaire 
(HAQ), a proxy of disease severity [113]. 
Effects on RA Synovitis 
 In RA, statins may also act at a more local level, on the 
synovium. This mode of action can be attributed both to their 
anti-inflammatory properties and their effect on the lipid 
content within the synovial fluid [114, 115]. 
 There is good evidence that statins act by inhibiting the 
production of cytokines such as IL-6 and IL-8 [116, 117], as 
well as by reducing the expression of MCP-1 mRNA in the 
joint with an overall effect of reducing the number of in-
flammatory cells found in the synovial membrane [118]. In a 
murine model of collagen-induced arthritis, simvastatin was 
shown to have anti-arthritic effects by suppression of the Th1 
immune response [119]. Significant immuno-modulatory 
actions of low dose simvastatin on the Th1 pathway have 
been observed in a recent study of 28 patients with RA 
[120]. At 12 weeks, immunological assessment revealed a 
reduction in the Th1/Th2 and CD4/CD8 ratios, along with a 
significant reduction in median levels of biochemical mark-
ers of inflammation (CRP, ESR and Rheumatoid factor). 
One report suggests that lipophilic statins, such as fluvas-
tatin, exert novel anti-inflammatory effects by inducing 
synovial cell apoptosis in RA [121]; hydrophilic statins do 
not appear to have a similar action, indicating this is unlikely 
to be a class effect. Another report suggests that statins at-
tenuate the insertion of GGPP into the plasma membrane 
with a resultant decrease in viability and an increased apop-
tosis of synovial fibroblasts [122]. 
 As far back as the 1960’s, major differences were ob-
served between the lipid content of synovial fluid obtained 
from inflamed joints of RA patients, compared to fluid from 
normal joints [114]. In RA, the level of all lipid components 
in the synovial fluid is increased significantly, with the most 
dramatic elevations occurring in cholesterol and phospholip-
ids [114]. It is known that the synovial fluid lipids and phos-
pholipase A2 activity correlate well with RA disease activity 
[123, 124]. This phenomenon may be partially due to the 
high levels of IL-1 found in RA, stimulating synoviocytes to 
release phospholipase A2 into the extracellular space [125]. 
There is now evidence demonstrating that an increase in 
synovial fluid lipoproteins may contribute to the synovitis in 
RA through participation in the arachidonic acid pathway 
within the joint space [126]. Statins may have the ability to 
alleviate much of this by modifying the lipid profile, particu-
larly cholesterol levels within the joint. Yet again, there is no 
direct evidence from clinical trials of statins in RA to support 
or refute this hypothesis. 
ACE-I AND ARBs 
Pharmacology 
 ACE-I were developed in the late 60s from the venom of 
the Brazilian pit viper, Bothrops jararaca [127]. Over thou-
sands of years, the same environmental pressures that forced 
the Yanomamo Indians [128] and the terrestrial animals in 
northern Brazil to evolve a hyperactive renin-angiotensin-
aldosterone system (RAAS), also led Bothrops jararaca to 
conserve an efficient killing mechanism that targeted its 
enemies’ haemodynamic vulnerabilities. Modern hyperten-
sion may represent the kidney’s attempt to reconcile a mis-
match between conserved RAAS activity and high dietary 
salt intake. This results to pressure natriuresis, which helps 
establish the salt homeostasis at the expense of hypertension-
related cardiovascular and renal damage [129]. 
 After numerous animal and clinical studies, the first 
ACE-I to be approved by the USA Food and Drug Admini-
stration (FDA) was captopril in the early 80’s [127]. ACE-I 
are classified in three categories according to the group that 
binds the zinc atom of the ACE molecule: those containing  
a sulfhydril (benazepril, captopril, zofenopril), a carboxyl 
(cilazapril, enalapril, lisinopril, perindopril, quinapril, rami-
pril, spirapril, trandolapril) or a phosphoryl (fosinopril) 
group as zinc ligand [130]. ACE-I competitively inhibit the 
angiotensin converting enzyme, which is involved in the 
metabolism of many small peptides including the conversion 
of angiotensin I, an inactive octapeptide, into angiotensin II. 
Kininase, an enzyme that catalyses the degradation of brady- 
kinin and other potent vasodilator peptides, is also competi-
tively inhibited by ACE-I, leading to increases of bradykinin 
levels, which in turn stimulate the B2 receptors leading to 
the release of nitric oxide (NO) and vasoactive prostagland-
ins (prostacyclin and prostaglandin E2) [131, 132]. 
 There are a number of approved nonpeptide selective 
blockers of the binding of angiotensin II to type 1 (AT1) 
angiotensin receptors on the cell membrane, thereby inhibit-
ing the action of angiotensin II [133]. The first ARB, losar-
tan, was licensed for use in clinical medicine in the treatment 
of hypertension in 1994 [134]. Subsequently, five other 
members of this class of compound have been licensed in the 
United Kindom, valsartan, irbesartan, candesartan, telmisar-
tan and eprosartan [134]. 
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 Recently the cloning of an ACE homologue [135, 136] 
with different substrate affinities and insensitivity to block-
ade with ACE inhibitors prompted a reconsideration of the 
accepted thinking about the biochemical constituents, mode 
of action, and function of RAAS. The complexity of the in-
tegration responsible for the formation and degradation of 
molecules participating in vascular tone, growth and cellular 
signalling is demonstrated in Fig. (3). 
 The system not only shows a high degree of hierarchy, 
but it also displays modularity because functionally linked 
molecules (or nodes) are working together to achieve a 
relatively distinct function. These important concepts under-
score the weakness of the previously accepted view of the 
system as a linear and sequential biochemical cascade pri-
marily responsible for the formation of angiotensin II [137]. 
Visualization of the interplay between the two ACEs in 
determining product formation and metabolism may be par-
ticularly useful in interpreting the effects of ACE-I because 
blockade of the ACE enzyme will not only suppress the for-
mation of angiotensin II but also inhibit the metabolism of 
both angiotensin (1-7) and bradykinin, leading to increased 
levels of the latter two (Fig. 3). Similarly, apart from antago-
nizing angiotensin II action on AT1 receptors, ARBs lead to 
angiotensin (1-7) level augmentation due to facilitation of 
the conversion of angiotensin II to angiotensin (1-7) and due 
to a renin-mediated increase in angiotensin I (reflecting the 
blockade of the negative feedback that AT1 receptors exert 
on renin release) (Fig. 3) [138]. The anti-inflammatory prop-
erties of ACE-I and ARBs are thought to be due to inhibition 
of the action of angiotensin II on AT1 receptors, which en-
hances inflammatory responses via several mechanisms, and 
due to increased levels of angiotensin (1-7), which may act 
as an anti-inflammatory agent [138]. ARBs may offer an 
additional advantage by activating the AT2 receptor, which 
promotes anti-proliferation, differentiation and vasodilation 
[139, 140]. The significant role of angiotensin II-independent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The complexity of the renin angiotensin aldosterone system and the nodes were ace inhibitors and angiotensin II receptor 
type 1 blockers exert their effects. 
Due to blockade of the ACE enzyme (red star), ACE-I will not only suppress the formation of angiotensin II but also inhibit the metabolism 
of both angiotensin (1-7) and bradykinin, leading to increased levels of the latter two (red up-arrows). Similarly, apart from antagonizing 
angiotensin II action on AT1 receptors (yellow star), ARBs lead to angiotensin (1-7) level augmentation due to facilitation of the conversion 
of angiotensin II to angiotensin (1-7) (yellow up-arrows). 
LDL: low density lipoprotein, ROS: reactive oxygen species, ACE: angiotensin converting enzyme, AT: angiotensin, EP: endopeptidases, 
mas R: mas receptor, ACE-I: ace inhibitors, ARBs: aniotensin receptor blockers. 
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mechanisms, which probably reflect increased levels of 
angiotensin (1-7), in the anti-atherogenic and anti-inflamma- 
tory effects of ACE-I has been demonstrated on apolipopro-
tein E-deficient mice, which were co-administered angio-
tensin II and enalapril [141]. 
Cardiovascular Risk Reduction 
Control of Risk Factors 
 Hypertension is one of the major classical risk factors for 
CVD and accounts for approximately 18% of the general 
population attributable risk of a first MI [142]. Several stud-
ies among patients with RA have demonstrated that it asso-
ciates with subclinical atherosclerosis [143-145] and is one 
of the most significant independent predictors of CVD, with 
relative risk ranking from 1.49-4.3 [146-148]. Using data 
from the Framingham heart study in the US and the Third 
(US) National Health and Nutrition Examination Survey 
(NHANES III), it was projected that a 20 mmHg increase in 
systolic BP in RA patients would associate with 1572 addi-
tional ischaemic heart disease events and 602 additional 
stroke events over 1 year [149]. ACE-I and ARBs are first 
line treatment in most cases of hypertension [150,151], with 
50-60% of Caucasian patients demonstrating a good re-
sponse to monotherapy [152, 153]. In the CONSENSUS trial 
[154], patients in NYHA class IV heart failure (HF) were 
followed for an average of 188 days. Mortality at 6 months 
was significantly reduced in the ACE-I group (enalapril) 
(26% vs. 44% in the control group). In SOLVD [155], pa-
tients in NYHA class II and III HF were followed for a mean 
of 3.45 years. The cumulative mortality was 39.7% in the 
placebo group compared to 35.2% in the active treatment 
group. In the meta-analysis of the ACE-I in Myocardial In-
farction Collaborative Group, including over 100,000 pa-
tients [156], mortality at 30 days was reduced from 7.6% in 
the placebo group to 7.1% in the ACE-I group. Meta-analysis 
of late intervention (treatment initiated >48h after MI and 
continued long term) trials [157], mortality was reduced from 
29.1% to 23.4% with ACE-I therapy after an average follow-
up of 2.6 years. Later on, randomised controlled trials com-
paring ACE-Is with ARBs demonstrated similar effects of 
these agents on the reduction of mortality in patients with 
Heart Failure (HF) or MI [158, 159]. In a recent meta-analy- 
sis of 38.080 chronic heart failure patients [160], ARBs were 
associated with reduced all-cause mortality (OR=0.83, 
95%CI, 0.69 to 1.00) and HF hospitalizations (OR=0.64, 
95%CI, 0.9 to 1.26) compared to placebo. The above benefi-
cial effect of ACE-I/ARBs on CVD mortality is partly ex-
plained by their anti-proliferative effects (reduction of vascu-
lar and cardiac hypertrophy and extracellular matrix prolif-
eration) and reduction of ventricular remodelling after myo-
cardial infarction [161, 162]. 
 In addition, ACE-I/ARBs are used for risk reduction in 
particular populations at risk, due to beneficial renal effects: 
they prevent progression of microalbuminuria to overt prote-
inuria [163], attenuate the progression of renal insufficiency 
in patients with a variety of non-diabetic nephropathies [164] 
and prevent or delay the progression of nephropathy in pa-
tients with insulin-dependent diabetes mellitus [165]. 
 A pertinent question for patients with high-grade in-
flammation, such as those with RA, is whether inflammation 
affects in any way the potency of these pharmacological 
agents. At least for ARBs, inflammation appears to have no 
down-regulating effect, therefore not altering the anti-hyper- 
tensive effect of drugs such as valsartan [166] and losartan 
[167] in RA patients. On the contrary, a trend towards up-
regulation of the above receptors is evident, which favours 
treatment with ARBs in this patient group. Interestingly, 
even though there are reduced concentrations of losartan’s 
active metabolite EXP 3174 (because of inhibition of the 
metabolising enzymes CYP2C9 and CYP3A4) amongst RA 
patients compared to controls, the potency of AT1R antago-
nists does not appear to be reduced by inflammation [168]. 
The latter could be attributed possibly to a pharmacological 
effect of the parent drug and/or AT1R upregulation of in-
flammatory mediators. 
Improvement of Endothelial Function And Anti-Oxidant 
Potential 
 Angiotensin II has been shown to play a role in neointi-
mal monocyte infiltration and endothelial dysfunction through 
NF-k activation and MCP-1 expression in a model of accel-
erated atherosclerosis in rabbits [169]. It is thought therefore, 
that inhibition of angiotensin II may reduce endothelial infil-
tration by monocytes, restore endothelial function and ulti-
mately inhibit progression of atherosclerosis. 
 Accumulating evidence suggests that oxidant stress (me-
diated by ROS) alters many functions of the endothelium, 
including modulation of vasomotor tone [170]. Many ROS 
possess unpaired electrons and thus are free radicals. These 
include molecules such as superoxide anion (O2-·), hydroxyl 
racial (HO·), nitric oxide (NO·), and lipid radicals. NADPH 
appears to be the major source of superoxide in blood vessels 
[171]. Incubation of human umbilical vein endothelial cells 
(HUVECs) with angiotensin II has been shown to result in a 
time- and dose-dependent induction of superoxide O2- forma-
tion, which was associated to similar dose-dependent regula-
tion of NADPH oxidase subunit gp91-phox [15]. In the same 
study, AT1 receptor blockade therapy, but not ACE-I ther-
apy, before coronary bypass surgery, was shown to down-
regulate gp91-phox expression in internal mammary artery 
biopsies of patients with coronary artery disease (CAD). In a 
cross-sectional study of 33 normotensive patients with stable 
CAD, superoxide level decreased by 52% after a 24-week 
period of irbesartan treatment [172]. In another RCT, cande-
sartan significantly reduced plasma levels of malondialde-
hyde, the end-product of lipid peroxidation by ROS [173]. 
Similarly another RCT demonstrated significant reductions 
in plasma levels of 8-isoprostane, a marker of oxidative 
stress, in the irbesartan group compared to placebo [174]. 
This reduction in ROS generation would also potentially 
reduce oxidative damage to lipids, amino acids and proteins 
and therefore lead to lower levels of oxidized LDL, which is 
crucial in the formation of foam cells [175]. Indeed in a 
study of 47 patients with documented CAD who were 
treated for 12 weeks with irbesartan, lipid peroxidation de-
creased by 36% in comparison to placebo [176]. 
 The ability of ACE-I and ARBs to prevent or restore en-
dothelial function [177] may also be explained, in part, by a 
shift of the balance between vasoconstrictive forces (angio-
tensin II) and vasodilatative factors (bradykinin and NO) 
towards vasodilatation. Evidence supporting this notion has 
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been provided by a randomized, double-blind, placebo-
controlled, crossover study comparing placebo and candesar-
tan 16 mg daily over two months in 45 patients with mild-to-
moderate hypertension [173]. Compared to placebo, cande-
sartan improved significantly the percent flow-mediated dila-
tor response to hyperaemia. Similar results were obtained in 
a randomised double blind control trial of irbesartan vs. pla-
cebo in patients with the Metabolic Syndrome (MetS). After 
4 weeks of therapy, endothelium dependent flow mediated 
vasodilation of the brachial artery was increased by 67% in 
the irbesartan group compared to placebo [174]. 
 In addition to these findings, there has been speculation 
over the effect of ACE-I on the rate of endothelial cell apop-
tosis. The current theory is that ACE-I may correct endothe-
lial dysfunction as a consequence of a reduction in the rate of 
endothelial cell apoptosis. A recent study [178], confirmed 
inhibition of endothelial cell apoptosis in vivo following ad-
ministration of ACE-I, which was most marked with perin-
dopril; interestingly these results were not replicated in the in 
vitro arm of the trial carried out on HUVECs [178], which 
reinforces the usual conundrum of how transferable in vitro 
observations are in the in vivo situation, and vice versa. 
 Despite the increased prevalence of endothelial dysfunc-
tion in RA patients, and the compelling evidence regarding 
the beneficial effect of ACE-I/ARBs on endothelial function, 
to date there is only sparse data examining the effect of these 
drugs on endothelial function in RA. A study involving 45 
RA patients who were randomised either to placebo, simvas-
tatin (20mg/day) or quinapril (10mg/day), demonstrated a 
significant lowering of CRP and TNF-a and improvement in 
endothelial function in the simvastatin arm, along with a 
tendency to an increase in endothelium-dependent vasodila-
tion in those treated with quinapril. It is possible that the 
limited efficacy of quinapril may be related to inappropriate 
dosage or inadequate length of treatment [179]. Further 
larger scale trials are required in RA to evaluate the effects 
of ACE-I on endothelial function. 
Reduction of Plaque Size and Increase in Plaque Stability 
 Angiotensin II, AT1 receptors and ACE are expressed at 
strategically relevant sites of human coronary atherosclerotic 
plaques in the shoulder region and may contribute to in-
flammatory processes within the atherosclerotic vascular 
wall and to development of acute coronary syndromes [180]. 
In apolipoprotein E-deficient mice, 4 weeks of subcutaneous 
admistration of angiotensin II induced histomorphologic 
features of unstable plaque (increased foam cell area, intrale-
sional neovasculature and haemorrhage, active matrix MMP-
2 colocalization within macrophage foam cells and increased 
MCP-1 and VCAM expression) [181]. The effects of angio-
tensin II antagonism on extracellular matrix components of 
advanced atherosclerosis have been assessed in twenty four 
week old apolipoprotein E-deficient mice [182]: although 
there was no difference in the macrophage component, an-
giotensin II antagonism increased the relative collagen por-
tion of the lesions, lessened elastin fragmentation, increased 
the total elastin content of the aorta and reduced the mRNA 
and activity/protein of the elastolytic proteases, cathepsin S 
and MMP-9. In line with these are the results of another 
study [38] which demonstrated an attenuation of the degree 
of atherosclerosis, increased collagen production and lower 
percentage of macrophage to total plaque amongst candesar-
tan-treated rabbits. These effects are thought not only to de-
crease further expansion of advanced lesions but also to sta-
bilize the established atherosclerotic plaques and may under-
lie the decreased incidence of acute cardiovascular events 
that are observed in patients in whom angiotensin II antago-
nism is begun after atherosclerosis is already established. In 
a small non-randomised study [37], administration of an 
ARB associated with a reduction in coronary plaque burden 
as assessed by intravascular ultrasound, which implies a 
more favourable long term outcome in patients with coro-
nary atherosclerosis. So far, no relevant data exist in patients 
with RA. 
Effects on the Fibrinolytic System 
 ACE-I also modulate vascular fibrinolytic balance by 
decreasing angiotensin II, a potent stimulus for PAI-1 syn-
thesis and by increasing bradykinin levels, a potent stimulus 
for tissue plasminogen activator [183]. Thus, ACE-I lowers 
plasminogen activator inhibitor type 1 (PAI-1) concentra-
tions and the molar ratio of PAI-1/t-PA. ACE-I also counter-
act the platelet aggregation induced by angiotensin II since 
they increase the production of NO and prostacyclin. In a 
study of type 2 DM patients with a diagnosis of mild essen-
tial hypertension, 129 patients were randomly allocated to 
candesartan or enalapril treatment. Patients in both treatment 
groups had significant reductions in their serum levels of 
vWF, fibrinogen and PAI-1 [184]. Again, there are no stud-
ies addressing these potential effects in patients with RA. 
Reduction of Systemic Inflammation 
 In several clinical trials, ARBs and ACE-I demonstrate 
an anti-inflammatory effect by lowering the levels of in-
flammatory mediators such as IL-6, TNF- and TNF-a re-
ceptor [15, 172, 174, 184, 185], adhesion molecules (ICAM-1, 
VCAM-1) [172, 184-186], chemokines (monocyte chemo 
attractant protein MCP-1) [173] and acute phase proteins 
such as C-reactive protein [185, 187, 188] and serum amy-
loid A [189]. These effects seem to be independent of the 
degree of blood pressure reduction [188]. 
 The first in vivo study regarding the effect of either 
ARBs or ACE-I on either reactive oxygen species (ROS) 
generation or other mediators of inflammation came from 
Dandona et al. [190] who studied four groups of 8 subjects 
who were given valsartan, quinapril, simvastatin or placebo 
for one week. Their data showed that valsartan inhibited 
ROS generation by both polymorphonuclear cells (PMN) 
and mononuclear cells (MNC) and suppressed NF-kB and its 
pro-inflammatory properties. The ineffectiveness of quinapril 
to suppress inflammatory mediators was mainly attributed to 
the slower reduction of angiotensin II levels in patients ad-
ministered ACE-I. CRP fell significantly over 30% in the 
first week, a magnitude that is greater than the one reported 
in a different study (14%) following pravastatin therapy for 6 
months [191]. 
 Of note is, that the anti-inflammatory effects of Valsartan 
(i.e. reduced expression of MCP-1, TNF-a, IL-6 and IL1b 
alongside reduced infiltration of leukocytes and macro-
phages in the injured arteries) were attenuated in AT2 recep-
tor knock out mice, therefore suggesting that the stimulation 
of AT2 receptor after AT1 blockade is important in the im-
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provement of the inflammatory vascular injury [192]. Tel- 
misartan, an AT1 receptor antagonist, acts upon T cells to 
inhibit the expression of a pro-inflammatory integrin (beta2-
integrin MAC-1). These effects are independent of angio-
tensin II and therefore suggest an AT1 receptor independent 
atheroprotective effect of Telmisartan [193]. 
RA Disease Modifying Potential 
Reduction of Systemic Inflammation 
 ACE-I and ARBs express some of their anti-inflamma- 
tory properties by modulating the balance of T cell subsets 
(Th1-Th2). A study performed on rats, demonstrated an im-
balance towards a Th1 phenotype and an associated eleva-
tion in IFN- and IL-4, when infused with angiotensin II. 
Subsequent treatment of the rats with candesartan corrected 
this imbalance [194]. It is through the action of these drugs 
on T cells that clinical benefit in predominantly Th1-driven 
diseases, such as RA, may be observed, but this remains to 
be proven. The first clinical trial exploring the use of ACE-I 
as a potential treatment for RA took place in the mid 80s, 
when no improvement was demonstrated in RA clinical fea-
tures or ESR in three RA patients after 16 weeks of treat-
ment with enalapril, a non-thiol possessing ACE-I [195]. 
Another trial reported that captopril improved arthritis symp-
toms, clinical scores, plasma viscosity and CRP in patients 
with active RA [196]: captopril is a thiol containing ACE-I 
which has a close structural similarity to D-penicillamine, a 
drug that at the time was commonly used for treatment of 
RA. It was therefore difficult to attribute the disease modify-
ing properties of captopril to ACE inhibition or to the pres-
ence of a thiol group. A later study investigated the effects of 
pentopril (CGS-13945), a non-thiol containing ACE-I, in 15 
patients with active RA [197]. Even though the drug exerted 
its pharmacological effects, as shown by a modest BP drop 
and reduction in serum ACE activity, it produced little clini-
cal or serological improvement, suggesting that the therapeu-
tic benefit of captopril in RA probably lies in its thiol group 
rather than in its enzyme inhibition properties. Nevertheless, 
the dose of captopril which may be appropriate in RA is 
about five times lower than the required dose of D-penicill- 
amine, suggesting an additional mode of action that remains 
unknown [198]. A randomised, double blind, placebo con-
trolled, multicentre study assessing the effect of lisinopril  
20 mg vs. placebo on rheumatoid disease activity score 
(DAS28) is also ongoing (Trial in Rheumatoid Arthritis of 
LISinopril-TRALIS) [199]. The main study objectives in-
clude the assessment of whether lisinopril has disease-
modifying activity and whether it improves vascular health. 
Effects on RA Synovitis 
 Even though the results regarding serum ACE activity in 
RA are controversial, synovial fluid ACE levels are univer-
sally increased in RA patients compared to patients with 
osteoarthritis (OA) [198, 200-203]. Elevated ACE activity 
has been demonstrated in blood monocytes [201], nodules 
[204], and synovial tissue (particularly endothelial cells, 
monocytes and fibroblast-like stromal cells) [200, 205] of 
patients with RA, and AT1 receptors are present in human 
synovial tissue [206]. However, levels of RAAS activity did 
not directly reflect membrane vascularity, monocyte or 
macrophage number, or the thickness of the lining layer 
[207]. Renin, which catalyzes the generation of angiotensin I 
from angiotensinogen seems to be both filtered from circula-
tion [208] and locally generated in the inflamed synovium 
[203]. Furthermore, inactive renin is converted into the ac-
tive form in the rheumatoid synovial fluid [203]. Increased 
levels of ACE can lead to increased locally-generated angio-
tensin II levels, which subsequently act on specific AT1 re-
ceptors present on the synovial microvessels and synovial 
stroma in the rheumatoid synovium [200] and modulate 
synovial perfusion [209]. The overall vasopressor effect of 
increased angiotensin II levels may lead to episodes of tissue 
hypoxia, which when followed by reperfusion may lead to 
formation of free radicals (ROS), well known mediators of 
cell damage in RA [210]. Further involvement of angiotensin 
II could be as a result of its ability to act as activator of the 
pro-inflammatory transcription factors NF-kB [211] and ac-
tivator protein (AP-1) leading to up-regulation of TNF-a and 
IL-6 gene expression in macrophages [212, 213]; of chemoat-
tractants for monocuclear cells, neutrophils, T and B lym-
phocytes to the synovium [214, 215]; and of growth factors 
regulating cellular growth, matrix synthesis, fibroblast pro-
liferation, angiogenesis, and fibrosis [214-218], all of which 
may promote and exacerbate chronic inflammatory arthritis 
[219] (Fig. 4). 
 However, increased ACE may also exert anti-inflamma- 
tory properties by inactivating bradykinin and substance P, 
both of which have been previously demonstrated to have 
pro-inflammatory effects in the inflamed joints [220]. In 
theory, ARBs may be preferential to ACE-I for patients with 
arthritis. ACE-I possess two potentially disadvantageous 
properties: they increase levels of bradykinin and substance 
P, both of which are pro-inflammatory, and their effect on 
reducing angiotensin II levels is limited by the presence of 
non-ACE dependent pathways (e.g. chymase) [221]. Since 
chymase is found in mast cells [222] and the latter are abun-
dant in rheumatoid synovium [223], it seems likely that non-
ACE-dependent angiotensin II production would be en-
hanced in this environment. This raises the possibility that 
AT1 receptor blockade may present a novel and more effec-
tive therapeutic target than ACE-I in the treatment of joint 
inflammation. In line with this, a recent study [224] has 
shown that ARBs suppressed the development of severe ar-
thritis and joint destruction in the collagen-induced-arthritis 
model in mice, via attenuation of Th1 responses. Olmesar-
tan, an ARB, inhibits the angiotensin II-induced NF-kB tran-
scriptional activation [54], providing a possible explanation 
for these findings. Similar observations have been made in 
the collagen-induced arthritis mouse model, in a study show-
ing that prophylactic or therapeutic treatment regimes with 
quinapril or candesartan reduced the severity of arthritis 
[225]. In parallel human in vitro experiments, ACE inhibition 
suppressed lipopolysaccharide-stimulated production of 
TNF- by monocytes, an effect which is probably mediated 
by the documented ability of ACE-I to reduce NF-kB activa-
tion [169]. The latter suggests that autocrine production of 
angiotensin II is important in promoting human monocyte 
responses to other pro-inflammatory stimuli. Recently, it has 
also been shown that losartan at a dose of 15 mg/kg could 
inhibit both acute (carrageenan/kaolin) and chronic (Fre-
und’s complete adjuvant) arthritis models in rats by 50% 
[209]. This dose is much higher to that used therapeutically 
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in humans (1.5mg/kg), but it is possible that it may be toler-
ated by humans since ultra-high doses of irbesartan (900mg/ 
day) were found to be safe in patients with type 2 diabetes 
mellitus [226]. 
ANTI-OBESITY DRUGS 
 Excess adiposity - especially abdominal - is one of the 
components of the MetS and a significant and independent 
predictor of future cardiovascular events [227]. Depending 
on the definition used, it is measured either as body mass 
index (BMI) or waist circumference [228]. However, adipos-
ity can be much more accurately assessed using body com-
position analysis based on bioelectrical impedance, hydro-
static weighing, dual-energy x-ray absorptiometry, total body 
nitrogen, 40K whole body counting, and urinary creatinine 
excretion thickness of partial subcutaneous fat, near-infrared 
rays, or ultrasound [229-234]. 
 Adipose tissue, initially considered simply an energy 
reservoir, is now recognised as a metabolically active tissue. 
It secretes a number of bioactive proteins called adipokines 
or adipocytokines some of which, e.g.TNF and IL-6, are 
implicated in local and systemic inflammation. These adipo-
cytokines have also been implicated in insulin resistance and 
endothelial dysfunction, both major contributors to the de-
velopment of CVD [235]. 
 Consequently, the treatment of obesity is a cornerstone in 
the attempt to reduce CVD. Currently, lifestyle changes (i.e. 
diet and exercise) are considered to be the most effective 
means to reduce excess adiposity [236] but their uptake by 
the population at large does not appear to be sufficient to 
address the magnitude of the epidemic of obesity. Therefore 
pharmacological approaches are being developed, and some 
of them seem to have an additive effect to lifestyle modifica-
tion, in terms of both weight loss and weight maintenance 
thereafter [236]. To date, three anti-obesity agents are avail-
able: Sibutramine, Orlistat and Rimonabant. Sibutramine is a 
centrally acting serotonin-norepinephrine reuptake inhibitor, 
which acts by inhibiting the reuptake of norepinephrine, se-
rotonin and dopamine, thereby inducing satiety [237]. Orlistat 
is a pancreatic lipase inhibitor which reduces fat absorption 
from the intestine through inhibition of the hydrolysis of 
dietary fat into absorbable free fatty acids and monoacylgly- 
cerols [237]. Rimonabant is a cannabinoid type 1 receptor 
antagonist, which has been shown to reduce food intake via 
inhibition of the endocannabinoid system, which is known to 
play a role in the central and peripheral regulation of body 
weight and energy balance [238]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The activated renin-angiotensin axis in the inflamed joint. 
Synovial fluid ACE levels are universally increased in RA patients. Elevated ACE activity has been demonstrated in synovial tissue, particu-
larly endothelial cells, monocytes and fibroblast-like stromal cells. Increased levels of ACE can lead to increased locally generated angio-
tensin II levels, which subsequently act on specific AT1 receptors present on the synovial microvessels and synovial stroma in the rheuma-
toid synovium and modulate synovial perfusion. Angiotensin II also activates of the pro-inflammatory transcription factors nuclear factor 
kappa B (NF-kB) and activator protein-1 leading to (i) up-regulation of TNF-a and IL-6 gene expression in macrophages, (ii) production of 
chemoattractants for monocuclear cells, neutrophils, T and B lymphocytes in the synovium and (iii) production of growth factors regulating 
cellular growth, matrix synthesis, fibroblast proliferation, angiogenesis, and fibrosis. 
AT: angiotensin, ACE: angiotensin converting enzyme, TNF: tumor necrosis factor, IL: interleukin, TNF-: tumor necrosis alpha, IL: inter-
leukin. 
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 The results from two studies, investigating the effects of 
sibutramine-induced weight loss on inflammation, are con-
flicting [239,240]. Both administered sibutramine to obese 
individuals for a period of six months. One study found no 
effect of the treatment on adiponectin levels or CRP [239], 
whereas the other [240] detected significantly increased adi-
ponectin levels and decreased CRP following treatment. The 
inconsistency between the two studies may lie in the magni-
tude of weight loss. Participants in the first study lost only 
2% of their initial body weight. However, according to the 
findings of the latter study [240], a reduction of body weight 
greater than >5% is necessary for significant changes in adi-
pocytokines to be seen. 
 The effects of weight-loss following Orlistat treatment on 
inflammation have been assessed in four studies [240-243]. 
Obese individuals were treated with Orlistat for six [240, 241, 
243] or 12 [242] months. Irrespective of treatment duration, 
significant reductions in CRP [241-243], IL-6 [241,243], 
TNFa [241] and significant increases in adiponectin and 
leptin [242] were observed. However, one of the studies 
[240] was unable to trace statistically significant changes in 
the measured variables; yet, in that study, a trend towards 
increased adiponectin and decreased CRP following treat-
ment was observed. Most likely, this is explained by the lim-
ited weight loss (i.e. <5% reduction in body weight) the par-
ticipants experienced. 
 To date, there is no study in humans assessing the effects 
of Rimonabant on inflammation. However, there is evidence 
that administration of the drug over a 12 month period (in 
combination with diet) resulted in significant increases in 
serum adiponectin levels, irrespective of weight loss, sug-
gesting the possibility of a direct impact of Rimonabant on 
inflammation [16]. This is further supported by two studies 
that investigated the anti-inflammatory effects of Rimona-
bant on rats [244,245]. The first [244] was conducted on lean 
and diet-induced obese rats with arthritis (induced by com-
plete Freund's adjuvant). Results indicated that administra-
tion of Rimonabant reduced the global arthritic score and 
joint width in obese rats and also reduced thermal hyperalge-
sia and mechanical allodynia (i.e. pain) in both lean and 
obese rats, with a greater effect in the latter. The second 
[245] assessed the effects of Rimonabant on Escherichia coli 
lipopolysaccharide-induced plasma TNF release. Results 
again indicated a favourable effect of the drug on inflamma-
tion as it inhibited overproduction of TNF. The studies con-
cluded that Rimonabant could potentially reduce pain as well 
as disease severity in inflammatory diseases [244, 245]. 
 In RA adiposity has probably increased significance. Pro-
inflammatory cytokines, such as IL-1 and IL-6, and TNF 
are clearly implicated in the pathogenesis and progression of 
the disease [246, 247], and although the extent to which the 
adipose tissue produces these cytokines is still under intense 
investigation, it is widely accepted that inflammatory cyto-
kine levels increase with increased body fat [7]. 
 Almost two thirds of RA patients suffer from a condition 
termed rheumatoid cachexia, which is characterised by mus-
cle wasting in the presence of stable total body weight [248]. 
As a result, RA patients present with significantly increased 
levels of body fat compared to healthy individuals of the 
same BMI [8]. This fact, coupled with the association of 
adiposity with cytokine production, lead to speculations that 
reductions in body fat of RA patients may positively affect 
RA disease activity, but direct evidence for this is currently 
lacking. 
CONCLUSION 
 All three classes of drugs discussed in this review offer 
the promise of additive beneficial effects to conventional 
CVD risk factor reduction in patients with RA, through their 
anti-inflammatory, immunomodulatory potential, which may 
be useful both for control of cardiovascular comorbidity and 
rheumatoid disease modification (Fig. 5). This needs to be 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Common beneficial effects of statins and ACE-I/ARBs. 
ACE-I: angiotensin converting enzyme inhibitors, ARBs: angiotensin II type 1 receptor blockers. 
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tested in prospective RCTs designed specifically for the pur-
pose. 
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Objectives: To assess whether body mass index (BMI) and body fat (BF) differ between rheumatoid arthritis
(RA) patients, patients with non-inflammatory arthritis (osteoarthritis, OA) and healthy individuals, and
whether disease specific measures of adiposity are required to accurately reflect BF in these groups.
Methods: 641 individuals were assessed for BMI (kg/m2) and BF (bioelectrical impedance). Of them, 299
(174 RA, 43 OA and 82 healthy controls (HC)) formed the observation group and 342 (all RA) the validation
group. RA disease characteristics were collected.
Results: ANOVA revealed significant differences between disease groups for BMI (p,0.05) and BF
(p,0.001). ANCOVA showed that age accounted for the differences in BMI (F1,294 = 5.10, p,0.05); age
(F1,293 = 22.43, p,0.001), sex (F1,293 = 380.90, p,0.001) and disease (F2, 293 = 18.7, p,0.001)
accounted for the differences in BF. For a given BF, patients with RA exhibited BMI levels reduced by
1.83 kg/m2 (p,0.001) compared to HC; there were no significant differences between OA and HC. A
predictive model for BF was developed (R2 = 0.769, p,0.001) and validated using limits of agreement
Analysis against measured BF in the validation group (95%LIMAG = 6.17; CV = 8.94).
Conclusions: In individuals with RA, BMI cut-off points should be reduced by 2 kg/m2 (that is, to 23 kg/m2
for overweight and 28 kg/m2 for obesity). The equation developed can be used to accurately predict BF from
BMI in RA patients. These findings may be important in the context of the cardiovascular comorbidity of RA.
E
xcess body fat (BF) is a prominent health hazard1
significantly contributing to the development of cardio-
vascular disease (CVD).2 About two-thirds of patients who
have had a myocardial infarction (MI) exhibit increased body
weight.3 Obesity increases the risk of coronary heart disease
(CHD) through a number of different pathophysiological
pathways, including insulin resistance, type 2 diabetes,
hypertension and dyslipidaemia.4 5
Assessments for overweight or obesity include the calculation
of body mass index6 (BMI, in kg/m2) or more accurate
estimations of relative adiposity (BF percentage) through a
number of techniques (for example, skinfold thickness,
hydrostatic weighing and bioelectrical impedance).7 BF estima-
tions require sophisticated equipment and trained personnel,
whereas BMI is easy to obtain and is widely used in the routine
clinical setting.
In the general population, BMI of ,25 kg/m2, 25–30 kg/m2
and .30 kg/m2 indicate healthy, overweight, and obese
individuals and associate with low, medium and high CVD
risk, respectively.8 9 However, BMI is only a proxy of body fat,6
and over recent years its validity has been questioned.3 7 10–13
Overweight as defined by BMI of .25 kg/m2, has poor
specificity in detecting excess body fat in healthy men and
women of all ages6 as well as in patients with coronary heart
disease.3 In specific subpopulations, such as people of Indian-
Asian race,10 women11–13 and large size athletes,7 new BMI cut-
off points have been suggested that optimally reflect BF and
may better predict CVD risk.
The weakness of BMI is that it does not distinguish between
lean body mass and fat mass. Consequently people of similar
stature and weight, but different muscle content, will have the
same BMI but different BF levels. This tends to be more evident
in individuals with low BMI levels.6 Such limitations of the BMI
may explain the better cardiovascular outcomes observed in
overweight and mildly obese patients with established CHD
compared to their normal weight counterparts, who may have
proportionately more BF.3 Therefore, although it is well
established that CHD risk increases with advancing BMI levels,9
global cut-off points may be misleading for several populations.
Central obesity poses a great risk for CVD.13 15 Regional fat
distribution, as measured by waist to hip ratio, has been
proposed as a more accurate predictor of CHD risk than
BMI.14 15 Indeed, it has been suggested that obesity should be
redefined based on waist to hip ratio instead of BMI, since
waist to hip ratio is significantly associated with MI risk in
most ethnic groups.16 However, its predictive strength can be
negatively affected by sex and overall body weight,17 in a way
that pear-shaped or obese individuals might have optimal waist
to hip ratio but increased overall body weight. More research is
necessary to identify the optimal definition of obesity as a
predictor for CHD in the general population and specific
subgroups.18
Patients with rheumatoid arthritis (RA) have an increased
risk for CHD events.19 RA is a chronic inflammatory disease
which affects predominantly synovial joints, causing pain,
swelling, stiffness and eventually irreversible damage and
deformity, all of which may lead to significant reduction in
physical activity. RA associates with increased mortality
particularly from CHD,19 most probably because of accelerated
atherogenesis secondary to the metabolic and vascular effects
of systemic inflammation.20 Nearly two-thirds of all individuals
with RA experience involuntary loss of fat-free mass and
progressively increased fat mass in the presence of stable or
even slightly decreased weight, a condition referred to as
Abbreviations: ANCOVA, analysis of co-variance; ANOVA, analysis of
variance; BF, body fat; BMI, body mass index; CHD, coronary heart
disease; CVD, cardiovascular disease; DAS, disease activity score; HC,
healthy controls; MI, myocardial infarction; LIMAG, limits of agreement;
OA, osteoarthritis; RA, rheumatoid arthritis
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rheumatoid cachexia.21 The exact mechanisms causing rheu-
matoid cachexia remain undetermined, but muscle loss due to
systemic inflammation and reduced physical activity may both
contribute.22
We hypothesised that for a given BMI, RA patients exhibit
significantly higher proportions of fat mass than healthy
individuals, or even than patients with movement restriction
due to a non-inflammatory arthritis, such as osteoarthritis
(OA). The possible consequences of this, in the context of the
increased CVD mortality in RA, are obvious. In the present
study we aimed to investigate whether BMI and BF differ
according to arthritic disease (OA vs RA) and within RA according
to disease state (for example, active vs inactive, early vs
established disease). We also developed and validated RA specific
BMI cut-off levels and algorithms to calculate BF from BMI.
METHODS
Participants
Consecutive patients attending routine rheumatology or ortho-
paedic outpatient clinics at the Dudley Group of Hospitals NHS
Trust, UK, and healthy controls (hospital and university staff)
were invited to participate. The study had local research ethics
committee approval by the Dudley ethics committee, and all
volunteers provided informed consent. The observation group
(n = 299) included 174 volunteers with RA (1987 revised
American Rheumatism Association criteria23), 43 with OA of
the hip25 or knee,26 and 82 healthy controls (individuals who by
self report did not have any known clinical conditions and were
taking no medication). The validation group (n = 342) con-
sisted of RA patients only. Demographic and disease character-
istics from all subjects appear in table 1.
Assessments
All volunteers were subjected to the same data collection
procedures overseen by the same trained investigators.
Specifically, standing height was measured to the nearest
0.5 cm on a Seca 214 Road Rod portable stadiometer. Body
composition was assessed by bioelectrical impedance, using a
Tanita BC-418 MA Segmental Body Composition Analyzer,
which incorporates eight tactile electrodes (Tanita Corporation,
Table 1 Demographic and disease characteristics of all volunteers (mean (SD))
Observation group Validation group
Male (n = 110) Female (n = 189) Male Female
RA OA HC RA OA HC RA RA
Number 56 15 39 118 28 43 99 243
Age 60.6 (11.8)** 56.7 (13.3)* 45.1 (13.3) 59.6 (12.2)**  52.8 (12.5)* 46.8 (11.5) 62.1 (11.6) 61.7 (11.9)
Height 173.6 (7)* 171.3 (6.7)* 177.3 (6.7) 159.1 (6.5)** 161 (5) 163.6 (6.9) 174 (6.8) 160.4 (6.7)
Weight 83.6 (13.3) 78.4 (14.8) 80.9 (11.4) 68.6 (15) 70.8 (16.5) 68.1 (16.3) 82.7 (15.8) 70.2 (14.4)
BMI 27.7 (4.3)* 26.8 (4.7) 25.7 (3) 26.9 (5.7) 27.2 (5.7) 25.4 (5.5) 27.3 (4.4) 27.3 (5.3)
BF 28.7 (7.7)** 24.8 (7.9)* 19.2 (5.2) 38.3 (7.3)**  35.2 (8.5) 32.1 (8.2) 27 (6.4) 38.3 (7.1)
Trunkal fat 30.5 (8)** 26.6 (8.9)* 21.4 (6) 35.7 (8.6)**  31.6 (9.6) 29.1 (8.7) 27.4 (7.7) 1 35.4 (8.1)
DAS28 4.2 (1.2) 4.3 (1.4) 4.1 (1.4) 4.3 (1.4)
ESR (mm in
1st hour)
23.2 (18.5) 26 (22.1) 25.3 (21.5) 30 (26.3)
CRP 15.6 (15) 15.8 (14.9) 16.8 (18.6) 17.6 (23.6)
Disease
duration
11.4 (10.2) 11.3 (9.9) 12.5 (11) 13.2 (11)
RA, rheumatoid arthritis; OA, osteoarthritis; HC, healthy controls; BMI, body mass index; BF, body fat; DAS28, disease activity score-28; ESR, erythrocyte sedimentation
rate; CRP, C-reactive protein.
One way ANOVA: *Significant difference compared to HC (p,0.05).
**Significant difference compared to HC (p,0.001).
Significant difference compared to OA (p,0.05).
1Significant difference compared to experimental RA group (p,0.001).
Table 2 BMI and BF of RA patients (observation group) according to categorisation based on their disease characteristics
Disease characteristics Categories
BMI BF
Male Female Male Female
DAS28 (DAS28 score) Remission (,2.6) 27.2 (3.46) 27.2 (5.6) 26.5 (7.6) 39.5 (6.7)
Mild (2.7–3.2) 28 (4.3) 27.3 (4.6) 28 (6) 39.3 (6.6)
Moderate (3.3–5.1) 27.8 (4.5) 27 (5.3) 27.4 (6.8) 37.3 (7.7)
High (.5.1) 25.3 (5.5) 27.3 (5.5) 26.1 (5.6) 37.7 (7.2)
ESR (mm in 1st hour) Normal* 27.9 (4.4) 26.9 (4.8) 27.1 (7.2) 38.3 (6.3)
High 26.4 (4.6) 27.6 (6.1) 26.7 (5.9) 37.6 (8.9)
CRP (mg/l) Low (,3) 26.5 (2.4) 28.3 (6.2) 25.9 (5.4) 38.5 (8.7)
Normal (3–8) 27.8 (4.7) 26.5 (4.7) 26.7 (8) 37.6 (6.6)
High (.8) 26.9 (4.6) 27.6 (5.7) 27.3 (5.8) 38.3 (7.9)
Disease duration (years) Early (,3) 26.4 (5) 26.1 (5) 26.4 (7.9) 37.9 (8.3)
Established (3–10) 28.8 (4.1) 27.8 (5.7) 27.8 (6.3) 38.2 (7.5)
Longstanding (.10) 26.8 (4.4) 27.1 (5.1) 27.7 (5.7) 38.8 (6.7)
Rheumatoid factor Positive 26.6 (3.6) 27.2 (5.7) 25.1 (6.7) 38.3 (7.3)
Negative 27.5 (5) 27.1 (5.1) 27.7 (6.4) 37.9 (7.3)
Corticosteroid administration Yes 27.1 (4.4) 27.3 (5.3) 26.2 (6) 38.1 (7.4)
No 24.5 (4.9) 26.7 (5.3) 27.8 (7.3) 37.7 (7)
DAS28, disease activity score-28; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
For all differences between groups: p.0.05.
*Normal ESR: ,50 years: male ,15, female ,20.
.50 years: male ,20, female ,30.
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Tokyo, Japan). This apparatus measures total body mass and
assesses body composition in terms of percentage body fat, fat
mass, fat free mass and total body water, as well as fat
distribution in different body segments (abdominal and
peripheral fat) and has a standard error of ,3.26 After initial
manual entry of their demographic details, participants stood
bare footed on the analyser and held the handgrips provided
until the apparatus printed the results. BMI (kg/m2) was
calculated on the basis of measured height and weight. In RA
patients, contemporary serological inflammation and clinical
disease activity were assessed by the erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP) (using routine laboratory
procedures) and the disease activity score-28 (DAS28).27
Disease duration was recorded from review of the patients’
hospital notes.
Data management and analysis
Data were inserted in a purpose designed spreadsheet
(Microsoft Excel 2003) and audited for accuracy weekly. They
were exported for analysis to the Statistical Package for Social
Sciences version 11.0 (SPSS Inc, Chicago, IL, USA). Preliminary
evaluation of the variables using a Kolmogorov-Smirnov test of
normality revealed that none of them required logarithmic
transformation to reach normality. Means (SD) were calculated
for all variables.
The method of analysis was to define either BMI or BF as the
dependent variable and then to incorporate all other known
parameters thought to influence these measures of adiposity as
either factors in an ANOVA or factors with covariates in an
ANCOVA. Factors included sex and disease status (RA, OA and
HC) while age, disease activity and duration, and serological
inflammation were entered as continuous covariates. The initial
ANCOVA analysis incorporated all these factors and covariates,
but only those found to be significant were subsequently
retained and reported in the prediction equation model below.
Within the RA population of the observation group, correla-
tions of disease activity (DAS28, ESR, CRP) and disease
duration with BMI and BF were obtained for each sex. RA
patients were also subgrouped according to their clinical
disease activity (DAS remission ,2.6, mild 2.7–3.2, moderate
3.3–5.1, high .5.127), serological inflammation (ESR28 and
CRP29), disease duration (early ,3 years, established 3–
10 years, longstanding .10 years), rheumatoid factor positivity
(ever), or corticosteroid administration (yes/no ever): differ-
ences between these subgroups in relation to BMI and BF were
assessed using ANCOVA (table 2). The level of significance was
set at p,0.05.
The external validity of the predictive model was tested with
the limits of agreement (LIMAG) method
30 against BF of the
validation group. The limits of agreement were obtained as
follows:
(1) We calculated the mean (d) and the standard deviation (s)
of the differences that indicate the level of bias and the
random variation between the two measures of BF (that is,
the predicted BF and measured BF of the validation group,
respectively).
(2) Provided the differences are normally distributed, the 95%
limits of agreement are given by: d ¡ (1.966s).
Bland and Altman30 argue that, provided that differences
within these limits are not clinically important, the two
measurement methods can be used interchangeably.
RESULTS
Observation group
Within the RA population of the observation group, no
significant correlations were found between DAS28, ESR,
CRP, disease duration and BMI or BF. Similarly, when RA
patients were grouped according to these variables as well as
rheumatoid factor positivity and corticosteroid use, no sig-
nificant differences for BMI and BF were observed (p.0.05 in
all cases, see table 2).
Between the different disease groups, one way ANOVA
revealed significant differences in BMI (p,0.05) and BF
(p,0.001; table 1): RA males had higher BMI and BF
(including trunkal fat) than HC males, and RA females had
higher BF than HC females, even though their BMI did not
differ significantly. ANCOVA revealed that BMI differences
between the groups were mainly the result of the significant
effect of the covariate age (F1,294 = 5.10, p ,0.05) and not
because of disease (F2,294 = 1.00, p .0.05), sex (F1,294 = 0.59, p
.0.05) or their interactions.
ANCOVA also revealed that RA and OA patients exhibited
lower BMI levels than their HC for a given BF. However,
differences were only significant for the RA patients
(RA:21.826 kg/m2 (p,0.001); OA: 20.352 kg/m2 (p.0.05)).
BMI was significantly (p,0.001) predicted by age, disease, sex
and BF (R2 = 0.58).
When BF was adopted as the dependent variable, ANCOVA
identified significant differences between disease groups
(F2,293 = 18.70, p,0.001) and sex (F1,293 = 380.90, p,0.001)
together with a significant covariate, age (F1,293 = 22.43,
p,0.001). The contribution of BMI as a covariate in this
analysis was also significant (F1,293 = 370.74, p,0.001). For a
given BMI, RA patients exhibited significantly increased levels
of BF (4.273, p,0.001) compared to healthy controls. The
difference for OA patients was non-significant (1.648, p.0.05).
The variation of BF was predicted by age, gender, BMI, and
disease type (R2 = 0.769, p,0.001). This was only very slightly
improved (for RA) by the addition of RA disease duration
(F1,293 = 0.340, p.0.05) in the equation (from 76.9% to 77.1%),
so we did not include this variable in the final model. The
predictive model obtained from this analysis is:
N BF = disease status + sex 2 0.719 + 0.1086age + 1.0596
BMI
– Disease status: RA = 4.273, OA = 1.648, HC = 0.
– Sex: male =211.294, female = 0.
Figure 1 Agreement between predicted and measured fat in patients with
RA. Body fat was measured by bioelectrical impedance using a Tanita BC-
418 MA Segmental Body Composition Analyzer. Predicted fat was
assessed using the formula: BF = 4.273 + sex 2 0.719 + 0.1086 age +
1.059 6 BMI. 95% limits of agreement were 6.17 with a coefficient of
variation of 8.9.
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Validation group
To establish external validity of our predictive model, we
assessed its agreement with the measured BF in 342 patients
with RA. Preliminary analyses for LIMAG revealed no hetero-
scedasticity, thus the LIMAG can be reported as absolute
measurements.30 Our analyses suggested that the bias of our
prediction is 0.4 (that is, our model overpredicts BF by 0.4) with
a standard error of 3.2 (95% LIMAG = 6.17, coefficient of
variation = 8.9; fig 1). The difference is statistically significant
(t = 2.3, p,0.05), but the coefficient variation (CV = 8.9) is
within acceptable limits.
RA specific BMI cut-off levels
The fact that patients with RA exhibited increased BF values for
a given BMI compared to HC suggested that BMI cut-off points
in the RA population would be more appropriate if they were
reduced by approximately 2 kg/m2 (to 23 kg/m2 and 28 kg/m2
for overweight and obesity, respectively). We therefore com-
pared the proportions of subjects in each group that would be
correctly classified as overweight or obese using the widely
accepted BMI cut-offs of 25 kg/m2 and 30 kg/m2 vs the
proposed (for RA) 23 kg/m2 and 28 kg/m2 vs the age and sex
specific cut-off points of measured BF. This analysis showed
that 9% of male and 15% of female RA patients would be
misclassified as of normal weight based on traditional BMI cut-
offs. Such misclassification was not a problem either for OA or
HC, where if anything, BMI overestimated BF. Application of
the proposed RA specific BMI cut-offs of 23 kg/m2 and 28 kg/
m2 corrected this misclassification (fig 2A). A modified, RA
specific BMI chart for the classification of patients with RA into
underweight, normal, overweight and obese categories was
developed and is provided in figure 2B.
DISCUSSION
The validity of BMI as an acceptable measure of overweight or
obesity, and as an accurate reflection of body fat (BF) content,
has been repeatedly questioned and the need for population
specific BMI cut-off points has been highlighted.7 10–13 Ideally,
individualised assessment of BF should be pursued in the
clinical setting, as BF percentage is a more reliable measure of
fatness than BMI, at least in the general population.31 Indeed,
our data indicate that only 58% of the variance in BMI can be
predicted, as opposed to 77% in BF. BF in vivo can be
determined via a number of methods such as underwater
weighing, dual energy x ray absorptiometry, total body water,
total body nitrogen, 40K whole body counting and urinary
creatinine excretion.32–34 BF can also be estimated from the
thickness of partial subcutaneous fat, near infrared rays and
ultrasound.35 However, none of these methods can be practi-
cally used in the routine clinical setting as they require
sophisticated apparatus and specialised personnel.33
In recent years, a bioelectrical impedance method for the
estimation of BF in different populations has become popular
and widely recommended, as it is reliable, objective, practical,
relatively inexpensive and does not require highly trained
personnel.32 33 The validity of this method has been confirmed
in various studies.32 36–39 Devices with eight tactile electrodes
using single frequency electrical current, similar to the one used
in this study, generate highly reproducible measurements of
total BF and segmental fat distribution.40 Their correlation with
the ‘‘gold standards’’ of dual energy x ray absorptiometry and
hydrostatic weighing is 0.90 and 0.80, respectively, with a
standard error of around 3.0, producing a coefficient of
variation of ,10%.33 This suggests that bioelectrical impedance
measurements (especially when using eight electrodes) are
valid and suitable for body composition studies.32 39 40 Patients
Figure 2 (A) Classification of male (top) and female (bottom) participants
into obese, overweight, normal and underweight groups according to
currently accepted BMI cut-off points (BMI), body fat content (BF) and RA
specific BMI cut-off points (RA-BMI). Accepting BF as the most accurate
assessment of body fatness, currently accepted BMI cut-off points
misclassify a significant proportion of both males and females with RA
(notice the difference in the respective bars). This misclassification is
corrected when the proposed RA specific BMI cut-off points are applied.
RA, patients with rheumatoid arthritis; OA, patients with osteoarthritis; HC,
healthy controls; BMI, classification according to existing body mass index
(BMI) cut-off points of 25 kg/m2 for overweight and 30 kg/m2 for obesity;
BF, classification according to age and sex specific cut-off points for body
fat percentage; RA-BMI, classification according to the proposed RA
specific BMI cut-off points of 23 kg/m2 for overweight and 28 kg/m2 for
obesity. (B) BMI chart developed specifically for patients with RA. Values
were calculated using the formula: BMI = weight (in kg)/height2 (in metres)
for the rheumatoid arthritis specific BMI levels identified in the present study
(23 kg/m2 for overweight, 28 kg/m2 for obesity). The generally accepted
lower threshold for normal BMI (18.5 kg/m2) was not altered.
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are usually happy to undergo such a measurement because of
its simplicity and similarity to normal weighing.
In the absence of the necessary equipment or expertise, the
predictive model presented here can be used to easily calculate
BF of RA patients from BMI. The cross validation of this
predictive model in patients with RA is reassuring. Even though
there was a statistically significant difference between the
measured and the predicted BF, closer examination of the
means indicates that this difference is at a level of less than
0.5% of BF with a coefficient of variation of ,10%. The
statistical significance of such a small difference can be
attributed to the very large number of the validation group
and is clinically not significant. However, the parts of the
equation referring to OA patients and healthy individuals need
further prospective validation in sufficiently large samples of
the relevant populations.
BMI remains the most commonly used indicator of body
fatness in the clinical setting, and the cut-off points of 25 kg/m2
and 30 kg/m2 (for overweight and obesity, respectively) used
for the general population are also routinely applied in RA
patients. This study shows that application of these BMI cut-off
points misclassified 9% of male and 15% of female RA patients
in terms of actual body fatness. For a given BMI, RA patients
exhibited an average 4.3% increase in BF compared to healthy
controls. In contrast, for the same level of BF, RA patients had
BMI values almost 2 kg/m2 lower than those of healthy
controls. We propose that BMI cut-off points in the RA
population should be lowered to 23 kg/m2 (from 25 kg/m2)
for overweight, and 28 kg/m2 (from 30 kg/m2) for obesity. The
lowest limit for normal BMI (that is, 18.5 kg/m2) should
remain unaltered, as low BMI levels have been related to
increased cardiovascular risk in patients with RA.41 42 We also
provide a chart for the classification of RA patients in normal,
overweight and obese categories according to these BMI cut-
offs, for use in the routine clinical setting (fig 2B).
The most likely explanation for the BMI and BF differences
observed in RA is rheumatoid cachexia associated with the
chronic inflammatory response, given that such differences
were not as prominent in OA. RA patients experience
accelerated involuntary loss of fat-free mass, predominantly
in the skeletal muscle, in excess of what is normally expected as
a result of the ageing process.43 Although the underlying
mechanisms for rheumatoid cachexia remain unknown,
possible contributing factors include the overproduction of
inflammatory cytokines such as tumour necrosis factor a and
interleukin 1b.43 44 Our subanalyses within the RA population
revealed that neither BMI nor BF were associated with current
clinical or serological disease activity, seropositivity for rheu-
matoid factor (which tends to associate with more severe
disease) or corticosteroid administration. This is not totally
surprising as disease activity may vary within small periods of
time, depending on medication and the disease itself, whereas
changes in body composition are longer term processes. On the
other hand, disease duration appeared to be of some
importance. It is possible that most alterations in body
composition of RA patients occur in the first few years of the
disease, as it has previously been reported,21 irrespective of
disease characteristics or medical treatment.
The results of the present study are reminiscent of the
observations made for Asian populations, which have signifi-
cantly higher CVD risk than white people: BF in Asians has
been found to be 3–5% higher than that of white people with
similar BMI, whereas BMI was 3–4 kg/m2 lower than that of
white people with similar BF.32 Differences in body build (trunk
to leg length ratio and slenderness) and in muscularity have
been suggested as possible explanations for these discrepancies.
As a result, new cut-off points for Asian populations have been
set at 23 kg/m2 and 27 kg/m2 for overweight and obesity,
respectively,10 and have been shown to be more sensitive in
identifying Asians at increased risk for CVD.45
In our participants, lowered BMI cut-off points would reflect
an average reduction of 5–6 kg, or 8%, in the ideal weight (the
weight one should have in order to be below the BMI cut-off for
overweight). Such reductions in body weight are likely to lead
to physiological benefits in the cardiovascular system: in the
general population, even a 5% reduction of body weight is
known to favourably affect most classic CVD risk factors.46 47
The reduced BMI cut-off points for RA suggested here may be
of significance both for the management of individual patients
and for further research into the cardiovascular morbidity and
mortality of RA. In the clinical arena, the reduction of these
thresholds would identify an additional 10–15% of people with
RA as overweight or obese, and may trigger closer scrutiny for
other CVD risk factors and appropriate intervention, if
necessary. Moreover, obesity, defined by the BMI, is one of
the WHO criteria for the metabolic syndrome.46 Aggressive
identification and reduction of classic CVD risk factors in
patients with RA is an obvious strategy for reducing the
increased cardiovascular mortality of this disease.19 From the
research perspective, the new thresholds may trigger re-analysis
of previously published cohorts or further analysis of prospec-
tive cohorts as to the importance of body fat as a predictor of
CVD in RA and its association with other individual risk factors.
We conclude that, in the clinical setting, body fatness of RA
patients should be evaluated based on the BMI cut-off points of
23 kg/m2 for overweight and 28 kg/m2 for obesity. In the
absence of specialised equipment, if necessary, BF of patients
with RA can be estimated from BMI using the equation
provided.
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Abstract Obesity is characterised by low-grade inflamma-
tion and could potentially affect disease activity and severity
in patients with rheumatoid arthritis (RA). Body mass index
(BMI), body fat (BF), erythrocyte sedimentation rate, C-
reactive protein, disease activity score 28, physical function
(health assessment questionnaire) and presence of erosions
and joint surgery were assessed in 294 (female=219)
volunteers with established RA [age 63.3 (56.2–69.6); disease
duration 13 (7–20) years]. Smoking status, rheumatoid factor
and anti-cyclic citrullinated peptide positivity were also
assessed. BMI and BF independently associated with disease
characteristics. Compared to normal-weight patients, under-
weight and obese had higher C-reactive protein (p=0.046)
and physical dysfunction (p=0.034). BMI or BF did not
associate with presence of erosions or joint surgery. In
patients with established RA, both very low and very high
BMI and BF associate independently with increased disease
activity and physical dysfunction; however, this does not
seem to associate with presence of erosions or joint surgery.
Further longitudinal studies are required to address this
apparent dissociation.
Keywords Body weight . Bodymass index . Obesity .
Percentage body fat . Rheumatoid arthritis outcome
Introduction
Rheumatoid arthritis (RA) is the commonest inflammatory
arthritis [1, 2]. It affects predominantly the synovial joints,
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which are infiltrated by chronic inflammatory cells produc-
ing cytokines such as tumour necrosis factor-α (TNF-α)
and interleukin (IL)-1 [1]. Permanent joint damage and
functional decline usually ensue [3], so the efforts of the
scientific community have focused on symptom control and
limitation of joint damage [4].
An indirect effect of RA is alteration in body composi-
tion. Almost two thirds of RA patients suffer from a
condition termed rheumatoid cachexia, which is character-
ised by muscle wasting in the presence of stable total body
weight [5]. As a result, RA patients present with signifi-
cantly increased levels of body fat compared to healthy
individuals of the same body mass index (BMI) [6].
Adipose tissue, initially considered to be simply an
energy reservoir, is now recognised as a metabolically
active tissue. It secretes a number of bioactive proteins
called adipokines or adipocytokines, including TNF-α and
IL-6 [7]. This could potentially result in more active disease
in obese RA patients. However, studies in patients with
early RA, of up to 3 years duration, surprisingly suggest
that obesity may protect against joint damage [8–10]. In
contrast, studies in unselected (for disease duration) RA
patients suggest that obesity leads to worse quality of life [11],
indicating that its potential protective effects in early RA are
diminished or reversed later on in the course of the disease.
The present study aimed to add information in the field by
assessing the associations of body weight and body fat with
RA characteristics in patients with well-established disease.
Materials and methods
Participants
Consecutive patients with RA (1987 revised American
College of Rheumatology criteria [12]) of more than
3 years duration since symptom onset, attending routine
rheumatology clinics at the Dudley Group of Hospitals
NHS Trust, UK, were invited to participate. The study had
Local Research Ethics Committee approval, and all
volunteers provided informed consent conforming to the
declaration of Helsinki. A total of 294 (male=75, female=
219) volunteers were assessed, reflecting the classical male-
to-female ratio (i.e. 1:3) of RA [13]. Their demographic and
disease characteristics appear in Table 1.
Assessments
All volunteers were subjected to the same data collection
procedures overseen by the same trained personnel.
Specifically, standing height was measured to the nearest
0.5 cm on a Seca 214 Road Rod portable stadiometer (Seca
GmbH & Co. Kg., Hamburg, Germany). Body weight and
composition were assessed using a Tanita BC-418 MA
Segmental Body Composition Analyser (Tanita Corporation,
Tokyo, Japan). After initial manual entry of their demo-
graphic details, participants stood bare-footed on the
analyser and held the handgrips provided until the apparatus
printed the results. This apparatus measures total body mass
and assesses body composition in terms of percentage body
fat (BF), fat mass, fat-free mass and total body water, as well
as fat distribution in different body segments (abdominal and
peripheral fat) and has a standard error of <3 [13, 14]. Body
mass index (BMI in kilogramme per square metre) was
calculated on the basis of measured height and weight.
Waist circumference was measured to the closest 0.5 cm
using a Seca 200 Circumference measuring tape (Seca
GmbH & Co. Kg., Hamburg, Germany).
Positivity for rheumatoid factor (RF) and anti-cyclic
citrullinated peptide (anti-CCP) antibodies was assessed in
serum using enzyme-linked immunosorbent assay micro-
plate techniques (DIASTAT™, Axis-Shield Diagnostics
Ltd., Dundee, UK). For RF, patients with a concentration
of >20 units per millilitre were considered positive; for anti-
CCP, patients with a concentration of >5 units per millilitre
were considered positive.
Erythrocyte sedimentation rate (ESR) was measured using
a Starrsed compact device (Mechatronics BV, Netherlands). A
total of 10 ml of undiluted blood, anti-coagulated with EDTA,
was inserted in a vertical tube. The sedimentation (in
millimetres) of the red blood cells within 1 h gives the value
Table 1 Demographic and disease characteristics of all volunteers
[median (interquartile range) or percentage of positives]
Male Female
N 75 219
Age (years) 62.1 (54.2–69.7) 62.1 (55–68.1)
Height (cm) 173.0 (168–178) 160 (155.5–164)
Weight (kg) 83.6 (74.3–93.6) 70 (60.9–80.7)
BMI (kg/m2) 27.6 (25.8–30.3) 26.9 (24.1–31.3)
BF (%) 28.8 (24.1–31.7) 38.9 (34.5–43.2)
ESR (mm/h) 18.5 (6.8–31) 21 (10–36)
CRP (mg/L) 12 (6–22.3) 8.0 (5–20)
DAS28 4 (3.3–4.9) 4.1 (3.3–5.1)
HAQ 1.4 (0.5–2) 1.6 (0.9–2.3)
Presence of erosions (%) 72.8 60.9
Knee surgery (%) 6.7 8.7
Hip surgery (%) 5.3 5.5
Wrist/hand surgery (%) 10.7 9.1
Elbow surgery (%) 1.3 2.3
Shoulder surgery (%) 2.7 1.6
Neck surgery (%) 4 2.7
Any surgery (%) 30.7 29.9
Disease duration (years) 14.5 (7.8–20) 12 (7–22)
N number, BMI body mass index, BF body fat percentage, ESR
erythrocyte sedimentation rate, CRP C-reactive protein, DAS28
disease activity score 28, HAQ health assessment questionnaire
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of ESR. C-reactive protein (CRP) was measured in blood
serum with a Vitros® 5.1 FS chemistry system (Johnson and
Johnson Inc., Langhorne, PA, USA).
Clinical disease activity and physical function were
assessed by the Disease Activity Score-28 (DAS28) [15]
and the Anglicised version of the Stanford Health Assessment
Questionnaire (HAQ) [16], respectively. HAQ, a surrogate of
cumulative disease activity [17], served as the primary
outcome measure of the present study. X-rays of hands and
wrists were independently assessed by two rheumatologists
for presence of erosions; in case of disagreement (nine in
total), X-rays were jointly reviewed and a consensus opinion
reached. Information on disease duration, smoking status and
previous joint surgery (presence or absence) were obtained
from patient interview and confirmed by reviewing the
patients’ hospital notes.
Data management and analyses
Data were inserted in a purpose-designed spreadsheet
(Microsoft Excel 2003) and audited for accuracy weekly.
They were exported for analysis to The Statistical Package
for Social Sciences version 15.0 (SPSS Inc. Chicago, IL,
USA). The Kolmogorov–Smirnov test of normality was
used to assess dispersion of the variables.
Spearman’s correlations were used to assess the association
of weight, BMI and BF with disease activity and physical
function (i.e. ESR, CRP, DAS28, HAQ). These associations
were subsequently adjusted for age, gender, smoking status,
RF and anti-CCP positivity and disease duration using
multivariable analyses.
Thereafter, binary logistic models, with backward elim-
ination of statistically insignificant variables, were used to
test the associations of weight, BMI and BF with the
presence of erosions and joint surgery. For joint surgery,
independent examination of the association for each joint
area (i.e. neck, shoulder, elbow, hand and wrist, hip, knee,
ankle and forefoot) was pursued. The total number of joint
operations was calculated and its association with BMI and
BF was tested using multinomial regression. Results were
standardised for age, gender, smoking status, RF and anti-
CCP positivity and disease duration.
Finally, participants were categorised according to RA-
specific BMI [6] into four distinct subgroups (i.e. under-
weight, normal weight, over-weight and obese). Analysis of
variance (ANOVA) was used to assess differences between
groups for disease activity and physical function (i.e. ESR,
CRP, DAS28, HAQ). Analysis of covariance was used to
assess the independence of these associations from age,
gender, smoking status, RF and anti-CCP positivity and
disease duration. BMI groups were also subjected to a
cross-tabulation with presence of erosions and total number
of operations and chi-squared analyses were performed.
Dispersion of data is reported as median (interquartile
range) due to their not-normal distribution pattern. Results
of the logistic models are reported as odds ratio with 95%
confidence intervals (OR, 95% CI). Statistical significance
was set at p<0.05.
Results
Weight correlated significantly only with CRP (r=0.161,
p=0.002). BMI correlated significantly with ESR
(r=0.145, p=0.012), CRP (r=0.178, p=0.002) and HAQ
(r=0.117, p=0.044). Similarly, BF correlated significantly
with ESR (r=0.168, p=0.005) and HAQ (r=0.179,
p=0.003). After adjustment for age, gender, smoking status,
RF and anti-CCP positivity and disease duration, the
association of weight with CRP was lost. BMI retained its
association only with ESR (F1, 290=7.567; p=0.006)
and HAQ (F1, 290=4.059; p=0.045) whereas BF was found
to associate with ESR (F1, 290=5.767; p=0.017), CRP
(F1, 290=4.162; p=0.042) and HAQ (F1, 290=7.726;
p=0.006). The association of BF with DAS28 was
borderline non-significant (F1, 290=3.888; p=0.055).
Binary logistic regression showed no association of
either weight, BMI or BF with the presence of erosions.
Subsequently, the same analyses revealed an inverse
association of BMI with neck surgery (OR=0.781, 95%
CI 0.637–0.958; p=0.018) and a positive association of BF
with total knee replacement (OR=1.146, 95% CI 1.094–
1.201; p=0.046), but no other associations were found.
Multinomial regression models showed no association of
either BMI or BF with the total number of operated joints.
Following patient grouping according to BMI into
underweight, normal weight, over-weight and obese,
ANOVA demonstrated significant differences in CRP
(p=0.046) and HAQ (p=0.034) between the groups:
patients who were either underweight or obese had
significantly worse CRP and HAQ than those who had
normal weight, in an almost U-shaped mode (Fig. 1). A
similar trend was seen with ESR and DAS28 also, but the
differences were not significant (p=0.095 and p=0.063,
respectively; Fig. 1). Chi-squared analyses failed to identify
any differences between BMI subgroups for either the
presence of joint erosions or total number of operations.
Discussion
This study aimed to identify possible associations between
weight, BMI and/or body fat with RA activity and severity
in patients with established disease of more than 3 years
duration. Weight did not associate with any of the studied
variables. However, BMI significantly associated with ESR
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and HAQ; BF also associated with ESR, CRP and HAQ.
These associations appear to be U-shaped, as both low and
high BMI and BF associate with unfavourable disease
activity and physical function. The differences between
weight, BMI and BF in the observed associations might be
explained by their varying ability to assess actual adiposity.
Weight is a very generic measure that allows for large errors
in the estimation of adiposity. BMI also has an inherent
inability to distinguish between fat and fat-free body mass
[18], which makes it a less accurate marker of adiposity
than BF [19], particularly in conditions such as RA, which
are characterised by significant alterations of body compo-
sition [6]. We were unable to find any associations of either
weight, BMI or BF with the presence of erosions in
radiographs of the hands and wrists. BMI was inversely
associated with neck surgery, while BF associated positively
with total knee replacement, but their overall influence on
the total number of operated joints was not significant.
The present study has several potential limitations. Themain
one is its cross-sectional nature: the associations found are
interesting and can serve for hypothesis generation, but they do
not provide definitive evidence for causality or directionality,
which can only be addressed in long-term prospective studies.
The presence of erosions was assessed only qualitatively in
radiographs of the hands and wrists: this does not allow
quantitative analysis as all methods for quantification of
erosions require X-rays from several different joints. Thus,
patients with erosive disease were grouped together irrespec-
tive of the extent of erosive damage, and severity of joint
damage could only be inferred by joint surgery. However, we
have included these measures only as simple indications and
we do not draw any of our major conclusions from them.
Finally, body composition was assessed by bioelectrical
impedance. This method has been validated [20–24] and is
thought to be suitable for body composition studies in diverse
populations [23–26], correlates well with the “gold standards”
of dual-energy X-ray absorptiometry and hydrostatic weigh-
ing [24] and is widely used in RA research [6, 25, 27–30], but
it has not actually been specifically validated in the RA
population. On the other hand, even though a priori power
calculations were not performed due to limited literature on
the subject, retrospective power calculations, with HAQ as
primary outcome, indicate that the size of the cohort gives a
>0.99 power to our observations. Also the prospective
collection of data in a standardised systematic manner
minimised missing values and selection bias.
Overall, the associations of adiposity with RA disease
characteristics found in this study are intriguing, in that
Fig. 1 Disease activity and physical function among BMI categories. Asterisks, significant difference compared to normal weight (p<0.05). ESR
erythrocyte sedimentation rate; CRP C-reactive protein; DAS disease activity score 28; HAQ health assessment questionnaire
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some of them are relatively easy to explain, while others
seem counterintuitive. Pro-inflammatory cytokines, such as
IL-1, IL-6 and TNFα, are clearly implicated in the
pathogenesis and progression of RA [2, 31]. IL-6 stimulates
liver production of CRP [32], a marker of inflammation and
a measure of RA disease activity, and induces further
release of IL-1 and TNF-α [33], which, amongst many
other functions, can activate the transcription factor nuclear
factor-kappa beta [34]; this is over-expressed in the
inflamed synovium [35] and plays a central role in the
initiation and progression of the chronic inflammation of
RA [36]. The extent to which adipose tissue directly
produces or indirectly induces the production of cytokines
is still under intense investigation, but it is widely accepted
that pro-inflammatory cytokine levels (such as IL-1, IL-6
and TNF-α) increase and anti-inflammatory cytokine levels
(such as adiponectin, IL-1 receptor antagonist and IL-10)
decrease with increasing adiposity [37]. We did not directly
assess cytokine levels in this study, but this mechanism
would be a good explanation for the higher disease activity
(in terms of ESR, CRP or DAS28) and physical dysfunc-
tion (as reflected in the HAQ) observed in participants with
increased BMI or BF.
This mechanism, however, does not explain the worse
disease profile observed in underweight patients with very
low BMI, which is in-line with evidence from other studies
showing increased mortality levels among underweight RA
patients [38]. In these patients, significantly reduced BMI is
likely to be the result of highly active disease over many
years [5] rather than vice versa, and it is interesting that low
BMI appeared to associate with more neck surgery, which
usually occurs in severe, uncontrolled and long-standing
RA. The cross-sectional design of the present study and the
relatively small number of underweight patients limit our
ability to draw any definitive conclusions.
Counterintuitively, we were unable to demonstrate
consistent associations between adiposity with the presence
of erosions or joint surgery, despite the association of over-
weight and obesity with higher ESR, CRP and HAQ.
Within the aforementioned limitations of the study, a
possible explanation for this is the previously reported
protective effect of BMI against joint damage in early RA
[8–10]. The protective effect seems to occur mainly in RF-
and/or anti-CCP-positive patients [8, 10], to be present
before the diagnosis of the disease, with over-weight or
obese RA patients exhibiting less joint damage than their
normal-weight counterparts at the time of diagnosis [8] and
to continue during the first few years of the disease, with
joint damage progressing less rapidly in obese than in
normal-weight RA patients [8–10]. It is not entirely clear
whether this is solely an effect of increased weight, for
example, through increased mechanical loading stimulating
bone synthesis [39], or also a reflection of joint damage at
the time of first diagnosis. Our data suggest that although
the protective effect of increased BMI may be less
pronounced in established disease, it would still appear
that obese patients with established RA do not exhibit
increased levels of joint destruction, despite higher levels of
systemic inflammation. A partial uncoupling between the
acute-phase response and joint damage in RA has previously
been suggested [40] and this may also be an explanation. In
addition to this, it would be interesting to speculate an
uncoupling between the effects of body weight (mainly
reflected in weight) and adiposity (mainly reflected in BF):
it is possible that the protective effects of body weight (i.e.
increased mechanical loading of the bones) continue
throughout the disease, whereas the deleterious effects of
adiposity (i.e. increased inflammatory load) only “kick in”
later, once a critical amount of fat has accumulated through
the body composition changes occurring in RA.
In conclusion and within the limitations of this cross-
sectional study, in established RA, both reduced and
increased adiposity seem to be related to greater disease
activity and physical dysfunction but not to more joint
damage. These observations are independent from several
potential confounders including RF and anti-CCP positivity.
Further longitudinal studies are required to address this
apparent dissociation.
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ABSTRACT
Objectives: To assess the association of body mass
index (BMI) with modifiable cardiovascular disease (CVD)
risk factors in patients with rheumatoid arthritis (RA).
Methods: BMI, disease activity, selected CVD risk factors
and CVD medication were assessed in 378 (276 women)
patients with RA. Patients exceeding accepted thresholds
in >3 CVD risk factors were classified as having the
metabolic syndrome (MetS).
Results: BMI independently associated with hypertension
(OR = 1.28 (95% CI = 1.22 to 1.34); p = 0.001), high-
density lipoprotein (OR = 1.10 (95% CI = 1.06 to 1.15);
p = 0.025), insulin resistance (OR = 1.13 (95% CI = 1.08
to 1.18); p = 0.000) and MetS (OR = 1.15 (95%
CI = 1.08 to 1.21); p = 0.000). In multivariable analyses,
BMI had the strongest associations with CVD risk factors
(F1–354 = 8.663, p = 0.000), and this was followed by
lipid-lowering treatment (F1–354 = 7.651, p = 0.000), age
(F1–354 = 7.541, p = 0.000), antihypertensive treatment
(F1–354 = 4.997, p = 0.000) and gender (F1–354 = 4.707,
p = 0.000). Prevalence of hypertension (p = 0.004),
insulin resistance (p = 0.005) and MetS (p = 0.000) was
significantly different between patients with RA who were
normal, overweight and obese, and BMI differed
significantly according to the number of risk factors
present (p = 0.000).
Conclusions: Increasing BMI associates with increased
CVD risk independently of many confounders. RA-specific
BMI cut-off points better identify patients with RA at
increased CVD risk. Weight-loss regimens should be
developed and applied in order to reduce CVD in patients
with RA.
Rheumatoid arthritis (RA) associates with
increased risk for cardiovascular disease (CVD).1
This is most likely a combination of genetic
predisposition,2 modifiable CVD risk factors and
the inflammatory burden of the disease.3 Patients
with RA have a significantly higher body fat
content compared with healthy individuals of the
same height and weight.4 This led to the develop-
ment of RA-specific body mass index (BMI)
thresholds for overweight and obesity that better
identify patients with RA with increased body fat,4
and possibly CVD risk.
In the general population, obesity is a major
contributor to dyslipidaemia, hypertension and
insulin resistance5 and the underlying cause of
the metabolic syndrome (MetS).5 The associations
between obesity and CVD risk factors or the MetS
in RA have not been extensively investigated.
Obesity in this population is usually considered a
confounder, against which data should be standar-
dised, but not as the possible underlying cause for
several CVD risk factors. The aim of this study was
to quantify the associations of BMI with classical
CVD risk factors in a large sample of patients with
RA.
METHODS
Participants
The study had ethical approval and all volunteers
provided informed consent. A total of 400 (289
women) consecutive patients with RA were
assessed; of these, none had uncontrolled thyroid
disease, but 22 were excluded due to cancer. The
analyses from the remaining 378 (276 women)
patients are reported: their characteristics appear in
table 1.
Assessments
Standing height, weight, BMI (kg/m2) and waist
circumference were measured. CVD risk factors
(blood pressure (BP), lipids) were assessed, smoking
status noted and the Framingham 10-year CVD
event probability was calculated. The Homeostasis
Model Assessment of insulin resistance (HOMA)
and the Quantitative Insulin sensitivity Check
Index (QUICKI),were used to determine insulin
resistance (IR). The NCEP ATP III criteria5 were
used to identify patients with the MetS.
Erythrocyte sedimentation rate, C-reactive protein,
disease activity score (using 28 joint counts)
(DAS28) and the Stanford Health Assessment
Questionnaire (HAQ) were also assessed.
Data analysis
The Statistical Package for Social Sciences version
15.0 was used (SPSS Inc. Chicago, Illinois, USA).
Dispersion of the variables was assessed using the
Kolmogorov–Smirnov test. Spearman’s correla-
tions explored the associations of CVD risk factors
and 10-year CVD event probability with BMI.
Results were standardised for gender, age, smoking
status, RA characteristics and CVD medication
using univariable analyses. Multivariable analyses
were used to asses the overall association of each of
the possible confounders with the CVD risk factors
and the 10-year CVD event probability.
Following grouping according to RA-specific
BMI4 in those who were underweight, normal
weight, overweight and obese, analysis of variance
(ANOVA) was used to assess differences in BP, lipids
and IR between groups. Analysis of co-variance
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(ANCOVA) was then used to standardise for the same possible
confounders as above. x2 analyses were used to identify
differences in the prevalence of each risk factor or the MetS
between BMI groups. Binary logistic models were used to test the
independence of these associations from the same possible
confounders.
Finally, patients were grouped according to the total number
of risk factors they had. ANOVA was used to assess differences
in BMI among these latter groups and ANCOVA to adjust for
the same possible confounders. Data are reported as median
(interquartile range). Statistical significance was set to p,0.05.
RESULTS
Body mass index and cardiovascular disease risk factors
BMI correlated significantly with systolic BP (r = 0.240,
p = 0.000), high-density lipoprotein (r =2183, p = 0.000),
HOMA (r = 0.302, p = 0.000) and QUICKI (r =20.300,
p = 0.000). BMI also correlated with erythrocyte sedimentation
rate (r = 0.128, p = 0.011), C-reactive protein (r = 0.155,
p = 0.002) and HAQ (r = 0.133, p = 0.009); therefore, results
were standardised for these parameters as well as for gender,
age, smoking and CVD medication. BMI retained its association
with systolic BP (F1–354 = 23,372, p = 0.000), high-density
lipoprotein (F1–354 = 10.439, p = 0.001), HOMA (F1–
354 = 11.311, p = 0.001) and QUICKI (F1–354 = 34.678,
p = 0.000) and also associated with diastolic BP (F1–
354 = 7,593, p = 0.006), triglycerides (F1–354 = 4.496, p = 0.035)
and 10-year CVD event probability (F1–354 = 5.857, p = 0.016).
Different multivariate models, using BP, lipids and IR as
dependent variables, gender and smoking status as factors and
BMI, age, RA characteristics and CVD medication as covariates
indicated that the variance observed in all CVD risk factors was
more closely associated with BMI (F1–354 = 8.663, p = 0.000),
followed by lipid-lowering treatment (F1–354 = 7.651, p = 0.000),
age (F1–354 = 7.541, p = 0.000), antihypertensive treatment (F1–
354 = 4.997, p = 0.000) and male gender (F1–354 = 4.707,
p = 0.000).
ANCOVA, with corrections for gender, age, smoking, RA
characteristics and usage of CVD medication, showed signifi-
cant differences between BMI subgroups (underweight, normal
weight, overweight and obese) for systolic BP (F1–354 = 14.707,
p = 0.000), diastolic BP (F1–354 = 6.457, p = 0.011), triglycerides
(F1–354 = 4.700, p = 0.031), high-density lipoprotein (F1–
354 = 7.545, p = 006), HOMA (F1–354 = 9.720, p = 0.002),
QUICKI (F1–354 = 30.332, p = 0.000) and 10-year CVD event
probability (F1–354 = 3.981, p = 0.046).
Body mass index subgroups and the prevalence of
cardiovascular disease risk factors
Cross-tabulation of BMI subgroups with presence or absence of
each risk factor or the MetS demonstrated significant differ-
ences between groups for the prevalence of hypertension
(p = 0.004), insulin resistance (p = 0.005) and the MetS
(p = 0.000) (fig 1). The binary logistic models indicated that
BMI associated with hypertension (OR = 1.28, 95% CI = 1.22 to
1.34; p = 0.001), high-density lipoprotein (OR = 1.10, 95% CI:
1.06 to 1.15; p = 0.025), IR (OR = 1.13, 95% CI = 1.08 to 1.18;
p = 0.000) and the MetS (OR = 1.15, 95% CI: 1.08 to 1.21;
p = 0.000) independently of confounding factors.
Following grouping for the total number of risk factors
present, ANOVA showed significant differences in BMI
between groups (p = 0.000; table 1), while ANCOVA revealed
that this association was independent of gender, age, smoking,
RA characteristics and use of CVD medication (p = 0.000).
DISCUSSION
These results suggest an almost linear relationship between BMI
and CVD risk in this patient group, with the risk profile
worsening as BMI increases, in a pattern similar to that
described in the general population.5 These associations were
independent of multiple confounders, and if anything, they
became stronger following inclusion of CVD medication in the
models. It must be emphasised that these are all cross-sectional
associations, and they do not provide definitive evidence for
causality or directionality: longitudinal studies are required
for this.
There is no reason to suggest that the mechanisms by which
obesity increases CVD risk in RA are different from those in the
general population. Excess adipose tissue releases non-esterified
fatty acids in the circulation, which overload the liver and
Table 1 Demographic and disease characteristics of volunteers
(median (interquartile range))
Male Female
N 102 276
Age 63.5 (13.6) 63 (14.8)
Height 173.0 (9.8) 160.0 (8.0)
Weight 83.3 (19.7) 70.0 (19.9)
BMI 27.6 (5.5) 26.7 (7.2)
DAS28 4.0 (1.8) 4.2 (1.9)
HAQ 1.2 (1.8) 1.6 (1.5)
ESR 19.0 (30.0) 21.0 (28.0)
CRP 10.0 (15.0) 8.0 (13.0)
Disease duration 9.0 (15.0) 10.0 (15.0)
BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score (using
28 joint counts); ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire.
Figure 1 Mean (95% confidence interval of the mean) for body mass
index (BMI) of participants according to risk factor grouping. Differences
between groups in BMI are significant (p = 0.000). Risk factors include:
hypertension, high triglycerides, low high-density-lipoprotein, insulin
resistance and waist circumference.
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muscles with lipids and increase lipolysis, while reducing
glucose utilisation. Circulating glucose stimulates insulin
production, leading to insulin resistance.6 Endothelial function
is often impaired causing arterial stiffness and hypertension.7
Obesity may also increase CVD risk by reducing adiponectin,
activating the rennin–angiotensin–aldosterone system, and
increasing sympathetic activity and renal sodium reabsorption.6
However, as we did not measure any of these parameters we
can only postulate about their contribution to our observations.
Recent studies in RA have shown no relation8 or even a
‘‘paradoxical’’ protective effect of obesity against CVD,9
although no potential mechanisms were described. In our
study, lipid-lowering and antihypertensive drugs strongly
associated with CVD risk factors; their inclusion in the models
strengthened the association of BMI with all risk factors
assessed. Such drugs, known to improve CVD risk and reduce
mortality, are more frequently prescribed in obese than in non-
obese individuals.10 Thus their inclusion in the analyses of
studies investigating CVD risk and outcome in RA is of
paramount importance.
In the present study, neither disease characteristics nor
smoking affected the associations of BMI with CVD risk. This
finding is similar to our previous observations indicating that
alterations in body composition of patients with RA occur in
the early years of the disease4 or even prior to it. This could be
the case for some CVD risk factors as ‘‘the risk of coronary heart
disease in RA patients precedes the ACR criteria-based diagnosis
of RA’’.11 Similarly, smoking appears to confer less CVD risk in
RA than in the general population.3 Most likely, this is the result
of the smoking-induced weight-loss we recently described in
RA,12 which may counteract the known negative effects of
smoking on risk factors. However, disease characteristics and
smoking were treated solely as possible confounders, thus their
direct associations with CVD risk in RA cannot be assessed in
this study.
An important finding of the present study is the BMI level at
which CVD risk increases. Patients with one risk factor had a
median BMI of,25 kg/m2, whereas those with MetS,30 kg/m2
and by applying general BMI thresholds would be classified as
normal weight and overweight respectively; however, based on
RA-specific BMI thresholds they would be classified as overweight
or obese. This could be important in routine clinical practice,
where such classifications may be used to target patients at
increased risk for screening, early identification and management
of risk factors.
In the general population, weight loss can reverse the adverse
effects of obesity. However, in a population with significant
muscle wasting, such as RA, the type of weight-loss interven-
tion has to be carefully considered. Among existing weight-loss
regimens, exercise and especially resistance training, is the only
one proven to increase muscle mass in the general population13
and may be applied in patients with RA without aggravating
their disease.14 Moreover, exercise is known to further reduce
CVD risk irrespective of weight loss.15 Research focusing on
weight-loss interventions and their effects on CVD in RA are
necessary.
Within its limitations, this study shows that increasing BMI
in patients with RA associates with increased CVD risk. The use
of RA-specific BMI thresholds better identifies patients with RA
at increased CVD risk. Weight-loss regimens specific for patients
with RA need to be developed and evaluated.
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Abstract
Introduction Rheumatoid arthritis (RA) is associated with
altered metabolism leading to muscle wasting. In the general
population, cigarette smoking is known to affect body
composition by reducing fat and inhibiting muscle synthesis.
Even though smoking has been implicated in the
pathophysiology and progression of RA, its possible effects on
body composition of such patients have not been studied. This
cross-sectional study aimed to identify potential associations of
smoking with body weight and composition of RA patients.
Methods A total of 392 patients (290 females) with RA were
assessed for body mass index (BMI), body fat (BF), fat-free
mass (FFM), and waist circumference. Erythrocyte
sedimentation rate, C-reactive protein, Disease Activity Score-
28, and Health Assessment Questionnaire score were used to
assess disease activity and severity. Smoking habit (current
smoker, ex-smoker, or never-smoker) and intensity (pack-years)
were also noted.
Results Current smokers had a significantly lower BMI
compared with ex-smokers (mean difference: male -2.6, 95%
confidence interval [CI]: -3.5 to -1.7; female: -2.6, 95% CI: -4.8
to -0.5) and never-smokers (mean difference: male -1.8, 95%
CI: -3 to -0.6; female: -1.4, 95% CI: -2.4 to -0.4). Similarly, the
BF of current smokers was lower compared with that of ex-
smokers (mean difference: male: -4.3, 95% CI: -7.5 to -1.2;
female: -3.4, 95% CI: -6.4 to -0.4) and never-smokers (mean
difference: male: -3.3, 95% CI: -6.3 to -0.4; female: -2.1, 95%
CI: -4 to -0.2). FFM did not differ between groups. Finally,
current smokers had a significantly smaller waist circumference
compared with ex-smokers only (mean difference: male: -6.2,
95% CI: -10.4 to -1.9; female: -7.8, 95% CI: -13.5 to -2.1).
Following adjustments for age, disease duration, and HAQ
score, smoking remained a significant predictor for BMI (P <
0.001), BF (P < 0.05), and waist circumference (P < 0.05).
Pack-years were inversely correlated with BF (r = -0.46; P <
0.001), and heavy smokers exhibited a significantly lower FFM
(P < 0.05) compared with all other participants.
Conclusion Within the limitations of a cross-sectional study, it
appears that cigarette smoking associates with reduced BMI
and BF in patients with RA and heavy smoking associates with
lower muscle mass. Smoking cessation appears to associate
with increased BMI, BF, and waist circumference in these
patients. These results should be confirmed in prospective
studies. Given the numerous adverse effects of smoking on
general health and RA, patients should be actively advised
against it. However, smoking cessation regimes in RA may need
to include more general lifestyle counselling, particularly about
weight control.Page 1 of 7
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Rheumatoid arthritis (RA), the commonest inflammatory arthri-
tis, is associated with altered metabolism [1]. Compared with
healthy controls, RA patients exhibit elevated resting energy
expenditure (REE) and enhanced muscle catabolism [2]. Such
changes may lead to rheumatoid cachexia (that is, involuntary
loss of fat-free mass [FFM] with a proportional increase of
body fat [BF]) in the presence of stable body weight [3,4].
Body composition changes, particularly BF increase, may
remain largely undetected by traditional assessments such as
the body mass index (BMI) [5]. Increased BF, together with
reduced levels of physical activity due to joint inflammation and
damage [3,6], is associated with several comorbidities, includ-
ing cardiovascular disease [7,8] as well as increased mortality
[3].
Cigarette smoking is an important risk factor for several dis-
eases [9]. It is also known to decrease body weight in healthy
individuals by reducing appetite and increasing REE [10]. In
contrast, smoking cessation may associate with significant
weight increase, which constitutes a major deterrent to smok-
ing control [11].
We have recently demonstrated that smoking further
increases REE in RA [12] and this could potentially augment
rheumatoid cachexia in these patients. Given the RA-related
alterations in body composition and the comorbidity associ-
ated with them, the examination of potential contributors to
muscle wasting, such as smoking, is important. The aim of this
cross-sectional study was to detect potential associations
between smoking and body weight, body composition, and
rheumatoid cachexia in RA patients.
Materials and methods
Participants
Consecutive patients attending routine rheumatology clinics at
the Dudley Group of Hospitals NHS Trust, UK, were invited to
participate. All applicable institutional and governmental regu-
lations concerning the ethical use of human volunteers were
followed during this research. The study had local research
ethics committee and research and development directorate
approvals, and all volunteers provided informed consent. A
total of 400 volunteers (108 males and 292 females) with RA
(1987 revised American College of Rheumatology criteria
[13]) were assessed. Of them, 8 (6 males) were excluded from
the analyses due to missing data for body composition. Data
from the remaining 392 (median age: 63.1 [55.5 to 69.6]
years; median disease duration: 10 [4 to 18] years) were ana-
lysed.
Assessments
All volunteers were subjected to the same data collection pro-
cedures overseen by the same trained investigators. Standing
height was measured to the nearest 0.5 cm on a Seca 214
Road Rod portable stadiometer (Seca gmbh & co. kg., Ham-
burg, Germany). Body weight and composition (that is, BF and
FFM) were assessed using a Tanita BC- 418 MA Segmental
Body Composition Analyzer (Tanita Corporation, Tokyo,
Japan). After initial manual entry of their demographic details,
participants stood barefooted on the analyzer and held the
handgrips provided until the apparatus printed the results. BMI
was calculated on the basis of measured height and weight in
kilograms per square metre. Waist circumference was also
measured. Contemporary disease activity was assessed by
the erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and the Disease Activity Score-28 (DAS28) [14]. The
Anglicised version of the 40-item Stanford Health Assessment
Questionnaire (HAQ) [15] was used to measure physical dys-
function as a proxy of disease severity. Patients' self-reported
smoking status and intensity (that is, pack-years) were noted.
Data management and analyses
Data were analysed using the Statistical Package for Social
Sciences version 15.0 (SPSS Inc., Chicago, IL, USA). A pre-
liminary evaluation of the variables using a Kolmogorov-Smir-
nov test of normality revealed that none of them required
transformation to reach normality. Mean ± standard deviation
was calculated for all variables. Differences in BMI, BF, and
FFM between smoking groups are presented as mean differ-
ences with 95% confidence intervals (CIs).
According to their smoking status, patients were grouped into
never-smokers, current smokers, and ex-smokers. Analysis of
variance (ANOVA) assessed differences in demographic char-
acteristics, BMI, and body composition between groups for
each gender. Analysis of covariance (ANCOVA) was
employed to determine whether the differences observed
were attributed to smoking status or other confounding factors
(for example, gender, age, and disease characteristics).
In the current smoker and ex-smoker groups, further associa-
tions between pack-years with BMI and body composition
were examined. Thereafter, patients in these groups were
divided into quartiles according to pack-years. ANOVA was
employed to assess differences in the measured variables
between these subgroups. ANCOVA was used to correct for
any confounding factors.
Thereafter, patients were grouped according to (a) RA-spe-
cific BMI [5] and (b) gender-specific BF [16] thresholds into
underweight, normal weight, overweight, and obese. Subse-
quently, they were grouped based on gender-specific cut-offPage 2 of 7
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FFM into low or normal FFM groups [18]. Chi-square analyses
were employed to assess differences between smoking
groups in the prevalence of overweight, obesity, high risk, and
low FFM. For all tests, the level of significance was set at a P
value of less than 0.05.
Results
Table 1 illustrates means ± standard deviations and the
ANOVA results for all studied parameters. Current smokers
had a significantly lower BMI than ex-smokers (mean differ-
ence: male -2.6, 95% CI: -3.5 to -1.7; female: -2.6, 95% CI: -
4.8 to -0.5) and never-smokers (mean difference: male -1.8,
95% CI: -3 to -0.6; female: -1.4, 95% CI: -2.4 to -0.4). Current
smokers also had a significantly lower BF compared with ex-
smokers (mean difference: male: -4.3, 95% CI: -7.5 to -1.2;
female: -3.4, 95% CI: -6.4 to -0.4) and never-smokers (mean
difference: male: -3.3, 95% CI: -6.3 to -0.4; female: -2.1, 95%
CI: -4 to -0.2). FFM did not differ between these groups (mean
difference: current smokers versus ex-smokers, male: -4.6,
95% CI: -10.7 to 1.6; female: -1.2; 95% CI: -3.8 to 1.4; cur-
rent smokers versus never-smokers, male: -2.7, 95% CI: -9.2
to 3.9; female: 0.1, 95% CI: -2.4 to 2.4). Current smokers had
a significantly smaller waist circumference than ex-smokers
(mean difference: male: -6.2, 95% CI: -10.4 to -1.9; female: -
7.8, 95% CI: -13.5 to -2.1) but not never-smokers (mean dif-
ference: male: -2.9, 95% CI: -10.6 to 4.9; female: -3.9, 95%
CI: -9.2 to 1.5). Also, ex-smokers had a larger waist circumfer-
ence than never-smokers but the difference was significant for
males only (mean difference: male: 3.3, 95% CI: 0.4 to 6.3;
female: 3.9, 95% CI: -0.4 to 8.1).
In ANCOVA with gender and smoking as factors and age,
DAS28, HAQ score, and disease duration as covariates,
smoking was a significant and independent predictor for BMI
(F2,387 = 8; P < 0.001), BF (F2,387 = 4.4; P < 0.05), and waist
circumference (F2,387 = 7.9; P < 0.001). Smoking also
emerged as a significant predictor of FFM (F2,387 = 5.1; P <
0.05), but inclusion of BMI as a covariate eliminated the effect
of smoking on FFM (P > 0.05).
There was a significant negative correlation between pack-
years and BF (r = -0.46; P < 0.001) in the current smoker and
the ex-smoker groups. This remained significant after adjust-
ment for gender, age, DAS28, HAQ score, and disease dura-
tion (F1,389 = 4.8; P < 0.05). Following pack-year grouping into
quartiles (pack-group), ANOVA did not reveal any differences
for BMI or body composition among the current and ex-smoker
pack-groups. However, an ANCOVA model with gender and
pack-group as factors and age and weight as covariates (fol-
lowing stepwise elimination of ESR, CRP, DAS28, HAQ
score, and disease duration) revealed a significant effect of
pack-group on FFM (F3,217 = 2.7; P < 0.05), with heavy smok-
ers exhibiting the lowest values. Mean (95% CI) values of this
variable in the pack-year subgroups appear in Figure 1.
Following BMI and BF grouping, chi-square analyses showed
significant differences (P < 0.05) in the prevalence of over-
Table 1
Measured variables of participants classified as current smokers (CS), ex-smokers (XS), and never-smokers (NS)
Gender Male (n = 102) Female (n = 290)
Smoking status CS XS NS CS XS NS
Number 20 50 32 49 97 144
Age, years 58.8 ± 8.1a 65.2 ± 9.9b 58.8 ± 15 57.4 ± 13.3a 64.1 ± 11.2b 60.7 ± 11.8
Height, cm 171.3 ± 7.1 174.3 ± 6.9 172.7 ± 7.7 160.9 ± 6.9 160.8 ± 6.8 159.5 ± 6.8
Weight, kg 76 ± 12.9b, c 85.8 ± 13.6 84.1 ± 14.8 67.5 ± 14.2a 74.8 ± 15.2 69.9 ± 13.6
Body mass index, kg/m2 25.8 ± 3.3b, c 28.4 ± 3.8 27.6 ± 4.6 26.1 ± 5.5a, b 28.6 ± 5.4 27.5 ± 5
Body fat, percentage 24.5 ± 6.4c, d 28.8 ± 6.8 27.8 ± 5.6 35.9 ± 7a, b 39.2 ± 6.5 38.1 ± 6.7
Fat-free mass, kg 57.2 ± 9.4 61.7 ± 7.7 59.8 ± 10.3 42.5 ± 4.8 43.7 ± 6.1 42.5 ± 6.1
Waist circumference, cm 100 ± 7.9c 106.2 ± 10.8b 102.9 ± 9.3 90.8 ± 12.8a 98.6 ± 13 94.7 ± 12.7
ESR, mm/hour 26.5 ± 20.5 22.8 ± 21.3 20.7 ± 19.7 30.5 ± 26 34.3 ± 32.7b 25.5 ± 19.8
C-reactive protein, mg/L 13.3 ± 9.4 16.1 ± 20.4 16 ± 24.3 21.9 ± 23.2b 21.4 ± 32.7b 11.9 ± 12.5
DAS28 4 ± 0.9 4.1 ± 1.5 3.9 ± 1.6 4.5 ± 1.5 4.3 ± 1.5 4.1 ± 1.2
HAQ score 0.9 ± 0.8 1.4 ± 1 1.1 ± 0.9 1.5 ± 0.9 1.5 ± 0.9 1.5 ± 0.9
Disease duration, years 8.6 ± 7.8 11.9 ± 10.6 14.6 ± 12.7 11.4 ± 9.8 13.5 ± 10.8 13.5 ± 11.1
Values are presented as mean ± standard deviation. aSignificant difference compared with XS (P < 0.05). bSignificant difference compared with 
NS (P < 0.05). cSignificant difference compared with XS (P < 0.001). dSignificant difference compared with NS (P < 0.001). DAS28, Disease 
Activity Score-28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire.Page 3 of 7
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more prevalent in ex-smokers (50%) followed by never-smok-
ers (39%) and current smokers (30%). Similarly, ex-smokers
had a significantly (P < 0.05) higher prevalence of increased
waist circumference (69%) compared with never-smokers
(60%) and current smokers (49%). However, FFM did not dif-
fer between groups (P > 0.05) (Figure 2).
Discussion
To our knowledge, this is the first study to identify significant
associations between smoking, body weight, and body com-
position of RA patients: current smokers had a significantly
lower BMI and BF compared with never-smokers. Both BMI
and BF were significantly increased in ex-smokers, whereas
very heavy smoking appeared to associate with reduced FFM.
The study has several potential limitations. These are all cross-
sectional associations, and although they can serve for
hypothesis generation, they do not provide definitive evidence
for causality or directionality: longitudinal studies are required
for this. In addition, body composition was assessed by bioe-
lectrical impedance. This method has been validated [19-23]
and is thought to be suitable for body composition studies in
diverse populations [22-25], correlates well with the 'gold
standards' of dual-energy x-ray absorptiometry and hydrostatic
weighing [23], and is widely used in RA research
[5,12,24,26,27], but it has not actually been specifically vali-
dated in the RA population. Finally, although self-report of
smoking, especially smoking history, is generally reliable, both
under- and over-reporting can occur [28]. This is unlikely to
have influenced the primary findings of this study (that is, the
differences between current, ex-, and non-smokers), while any
misreporting in pack-years may have been smoothed by the
large number of participants. It is difficult to assess any other
selection bias: the prevalence of current, ex-, and non-smokers
among the participants of this study was similar to that
reported for local general population subjects of similar age
[29], although it was different from an RA cohort established
more than 10 years ago [30].
Our observations for BMI are consistent with those in the gen-
eral population. Both male and female smokers tend to have
decreased BMI compared with their non-smoking counter-
parts [10,31]. In contrast, significant BMI increases have been
noted after smoking cessation [11]. Smokers have increased
levels of leptin [32], which regulates food intake and fat depo-
sition [33], and reduced hypothalamic neuropeptide Y [34],
which regulates appetite [35]. Smoking-induced increases in
the levels of epinephrine, norepinephrine, and thyroid hor-
mones lead to increased energy expenditure at rest [36,37]
and during light physical activity [38-40]. However, these
effects are short-lived: after smoking cessation, leptin
decreases to levels below those expected for non-smokers of
similar weight [32] and resting energy expenditure (REE)
returns to normal [41].
In patients with RA, smoking has been shown to elevate REE
[12]; however, no data are available on other potential contrib-
utors to smoking-related weight loss or smoking cessation-
Figure 1
Fat-free mass for males (a) and females (b) according to pack-year grouping. Data are presented as means with 95% confidence intervals. Pack-
year groups: 1, 1 to 9 pack-years; 2, 10 to 19 pack-years; 3, 20 to 34 pack-years; 4, greater than 35 pack-years. Asterisk indicates significant differ-
ence compared with group 1 (P < 0.05).Page 4 of 7
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Available online http://arthritis-research.com/content/10/3/R59related weight gain for this population. Although we did not
assess energy intake and expenditure or related regulators
(such as leptin), it is likely that the mechanisms behind the
reduced body weight of current smokers and the increased
body weight of ex-smokers with RA are similar to those
described for the general population.
Interestingly, the lower BMI of current smokers in the present
study seems to be due to decreased BF rather than FFM. A
possible mechanism by which smoking may affect fat metabo-
lism is through a reduction in neuropeptide Y. This molecule
not only stimulates food intake, but also promotes white fat
lipid storage and decreases brown fat thermogenesis [35], so
its inhibition through smoking would be expected to have the
opposite effects. Additionally, smoking results in decreased
adipose tissue lipoprotein lipase activity [42], which diverts fat
storage away from adipose tissue and toward utilization by
muscle [43], possibly leading to the decreased BF of smokers
[42,44]. In the present study, the inverse association between
smoking and BF appeared to be dose-dependent: increasing
pack-years associated with reducing BF levels. Smoking ces-
sation is thought to result in a reversal of the mechanisms
described above, leading to increases in BF [42] and, most
importantly, abdominal fat [45]. Indeed, among these RA
patients, ex-smokers seemed to be the most 'unhealthy' group
in terms of body weight and composition as they exhibited the
highest BMI, BF, and waist circumference values.
In predominantly healthy people who are from the general pop-
ulation and who do not have wasting muscle disease, smoking
of any intensity has been implicated in muscle wasting [10] by
impairing the process of muscle protein synthesis [46]. In con-
trast, in the present study, only very heavy smoking appeared
to associate with a reduction in FFM. It is possible that the
effect of smoking on muscle is of less significance than the
muscle loss associated with RA itself, as part of rheumatoid
cachexia. This hypothesis is supported by the finding that
increased duration of smoking (that is, pack-years) associated
with lower FFM in both current and ex-smokers, which sug-
gests the existence of a threshold below which smoking does
Figure 2
Prevalence of overweight and obesity, increased waist circumference, and low fat-free mass in smoking groups. (a) Prevalence of overweight and 
obesity based on rheumatoid arthritis (RA)-specific body mass index for current, ex-, and never-smokers. (b) Prevalence of overweight and obesity 
based on body fat for current, ex-, and never-smokers. (c) Prevalence of high risk based on waist circumference for current, ex-, and never-smokers. 
(d) Prevalence of low fat-free mass for current, ex-, and never-smokers. Chi-square analyses identified significant defences among smoking groups 
for prevalence of (a) overweight and obesity based on body mass index (P < 0.05), (b) overweight and obesity based on body fat (P < 0.05), and 
(c) increased waist circumference (P < 0.05). Prevalence of low fat-free mass did not differ between groups (P > 0.05).Page 5 of 7
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study of the impact of smoking intensity (and cessation) on the
body composition of patients with RA may throw more light on
the mechanistic basis of these observations.
Overall, this study suggests that, in RA, smoking associates
with reduced body mass and fatness without inducing further
muscle loss, except in very heavy smokers; in contrast, smok-
ing cessation associates with increased body mass and fat-
ness. This should not be interpreted as favouring what is a very
unhealthy habit. Smoking cessation, even if it occurs in mid-
life, reduces most of the later risk of death from tobacco [47].
However, smoking cessation is known to result in body weight
increase, and this may affect some people's decision to stop
smoking [11,44,45]. Therefore, any smoking cessation regime
should be underpinned by more generalised lifestyle counsel-
ling, including advice on exercise and weight management.
This is emphasized by the fact that, based on recently
described RA-specific BMI [5], BF [16], and waist circumfer-
ence thresholds [48], ex-smokers have the highest prevalence
of obesity – both total and abdominal. FFM did not differ
between groups and the prevalence of low FFM was compa-
rable to that expected in age- and gender-matched healthy
individuals [18].
Conclusion
Within the limitations of this study, it is concluded that RA
smokers have a lower BMI and BF than RA non-smokers, while
heavy smokers also have a reduced FFM. A history of smoking
cessation appears to associate with increases in BMI, BF, and
waist circumference. Nevertheless, given the numerous
adverse effects of smoking on health, smokers with RA should
be actively advised against it, but smoking cessation programs
should include wider lifestyle counselling for weight control,
also focusing on increased physical activity and a healthy diet.
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